OA17147A - Microrna compounds and methods for modulating MIR-21 activity - Google Patents
Microrna compounds and methods for modulating MIR-21 activity Download PDFInfo
- Publication number
- OA17147A OA17147A OA1201400479 OA17147A OA 17147 A OA17147 A OA 17147A OA 1201400479 OA1201400479 OA 1201400479 OA 17147 A OA17147 A OA 17147A
- Authority
- OA
- OAPI
- Prior art keywords
- nucleoside
- certain embodiments
- modified oligonucleotide
- cet
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 304
- 230000000694 effects Effects 0.000 title abstract description 59
- 229920001239 microRNA Polymers 0.000 title description 115
- 230000000051 modifying Effects 0.000 title description 19
- 239000002777 nucleoside Substances 0.000 claims abstract description 711
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 380
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 132
- 230000004761 fibrosis Effects 0.000 claims abstract description 132
- 201000011510 cancer Diseases 0.000 claims abstract description 75
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 67
- 201000010099 disease Diseases 0.000 claims abstract description 63
- 239000003112 inhibitor Substances 0.000 claims abstract description 32
- 229920000272 Oligonucleotide Polymers 0.000 claims description 318
- 125000003835 nucleoside group Chemical group 0.000 claims description 170
- -1 bicyclic nucleoside Chemical class 0.000 claims description 124
- 230000000295 complement Effects 0.000 claims description 91
- 239000005549 deoxyribonucleoside Substances 0.000 claims description 53
- 210000003734 Kidney Anatomy 0.000 claims description 50
- 210000004185 Liver Anatomy 0.000 claims description 39
- 238000002560 therapeutic procedure Methods 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 206010022114 Injury Diseases 0.000 claims description 23
- 230000001684 chronic Effects 0.000 claims description 23
- 201000007270 liver cancer Diseases 0.000 claims description 21
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 17
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 14
- 230000000747 cardiac effect Effects 0.000 claims description 14
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 14
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 11
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims description 11
- 230000001154 acute Effects 0.000 claims description 11
- 206010001843 Alport's syndrome Diseases 0.000 claims description 10
- 101710038499 COL4A5 Proteins 0.000 claims description 10
- 102100009791 COL4A5 Human genes 0.000 claims description 10
- 229940104302 Cytosine Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000001093 anti-cancer Effects 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 241000083551 Ena Species 0.000 claims description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 7
- 108009000252 Lung fibrosis Proteins 0.000 claims description 6
- 210000003491 Skin Anatomy 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 206010067125 Liver injury Diseases 0.000 claims description 5
- 229940121363 anti-inflammatory agents Drugs 0.000 claims description 5
- 201000005216 brain cancer Diseases 0.000 claims description 5
- 230000002489 hematologic Effects 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 201000004044 liver cirrhosis Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 229920001499 Heparinoid Polymers 0.000 claims description 4
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 4
- 229960002474 Hydralazine Drugs 0.000 claims description 4
- 229960000201 Isosorbide Dinitrate Drugs 0.000 claims description 4
- MOYKHGMNXAOIAT-JGWLITMVSA-N Isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 4
- 206010023424 Kidney infection Diseases 0.000 claims description 4
- 210000000952 Spleen Anatomy 0.000 claims description 4
- 231100000012 chronic liver injury Toxicity 0.000 claims description 4
- 239000002554 heparinoid Substances 0.000 claims description 4
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010017758 Gastric cancer Diseases 0.000 claims description 3
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims description 3
- 208000006454 Hepatitis Diseases 0.000 claims description 3
- 208000010159 IGA Glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- 231100000852 glomerular disease Toxicity 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 3
- 231100000855 membranous nephropathy Toxicity 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000000261 vasodilator Effects 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 2
- 108020001621 Natriuretic Peptides Proteins 0.000 claims description 2
- 102000004571 Natriuretic peptide Human genes 0.000 claims description 2
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 239000000692 natriuretic peptide Substances 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 51
- 230000004048 modification Effects 0.000 abstract description 38
- 238000006011 modification reaction Methods 0.000 abstract description 38
- 239000000203 mixture Substances 0.000 abstract description 35
- 230000002159 abnormal effect Effects 0.000 abstract description 11
- 230000003389 potentiating Effects 0.000 abstract description 5
- 235000000346 sugar Nutrition 0.000 description 101
- 210000004027 cells Anatomy 0.000 description 91
- 239000002679 microRNA Substances 0.000 description 75
- 210000004369 Blood Anatomy 0.000 description 56
- 239000008280 blood Substances 0.000 description 56
- 239000008194 pharmaceutical composition Substances 0.000 description 53
- 108010035532 Collagen Proteins 0.000 description 52
- 102000008186 Collagen Human genes 0.000 description 52
- 229920001436 collagen Polymers 0.000 description 52
- 229960005188 collagen Drugs 0.000 description 52
- 238000000034 method Methods 0.000 description 43
- 206010028980 Neoplasm Diseases 0.000 description 42
- 150000007523 nucleic acids Chemical class 0.000 description 36
- 108020004707 nucleic acids Proteins 0.000 description 35
- 239000008177 pharmaceutical agent Substances 0.000 description 35
- 210000001519 tissues Anatomy 0.000 description 32
- 210000002700 Urine Anatomy 0.000 description 27
- 230000004083 survival Effects 0.000 description 27
- 108020004999 Messenger RNA Proteins 0.000 description 26
- 102100001249 ALB Human genes 0.000 description 25
- 101710027066 ALB Proteins 0.000 description 25
- 229940050528 albumin Drugs 0.000 description 25
- 125000002619 bicyclic group Chemical group 0.000 description 24
- 238000000338 in vitro Methods 0.000 description 23
- 229920002106 messenger RNA Polymers 0.000 description 23
- 210000000056 organs Anatomy 0.000 description 23
- 230000002829 reduced Effects 0.000 description 22
- 230000003907 kidney function Effects 0.000 description 21
- 230000001105 regulatory Effects 0.000 description 21
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 19
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 208000009304 Acute Kidney Injury Diseases 0.000 description 17
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 17
- 206010038436 Renal failure acute Diseases 0.000 description 17
- 206010063837 Reperfusion injury Diseases 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 108020004388 MicroRNAs Proteins 0.000 description 16
- 230000000875 corresponding Effects 0.000 description 16
- 210000002950 fibroblast Anatomy 0.000 description 16
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 16
- 206010001580 Albuminuria Diseases 0.000 description 15
- 206010027476 Metastasis Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 230000003908 liver function Effects 0.000 description 14
- 230000002485 urinary Effects 0.000 description 14
- 210000004072 Lung Anatomy 0.000 description 13
- 238000004166 bioassay Methods 0.000 description 13
- 125000003843 furanosyl group Chemical group 0.000 description 13
- 101710038979 SBXA1 Proteins 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 229940002612 prodrugs Drugs 0.000 description 12
- 208000001083 Kidney Disease Diseases 0.000 description 11
- 201000001474 proteinuria Diseases 0.000 description 11
- 101700080605 NUC1 Proteins 0.000 description 10
- 201000010915 glioblastoma multiforme Diseases 0.000 description 10
- 150000002632 lipids Chemical group 0.000 description 10
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 101700006494 nucA Proteins 0.000 description 10
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 201000009673 liver disease Diseases 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 8
- 108060001084 Luciferase family Proteins 0.000 description 8
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 230000004217 heart function Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 230000002685 pulmonary Effects 0.000 description 8
- 200000000019 wound Diseases 0.000 description 8
- 206010038444 Renal failure chronic Diseases 0.000 description 7
- 108020004417 Untranslated RNA Proteins 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 201000000522 chronic kidney disease Diseases 0.000 description 7
- 238000002591 computed tomography Methods 0.000 description 7
- 239000006184 cosolvent Substances 0.000 description 7
- 230000001934 delay Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229920001894 non-coding RNA Polymers 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 231100000486 side effect Toxicity 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 229960004397 Cyclophosphamide Drugs 0.000 description 6
- 102100015239 F2 Human genes 0.000 description 6
- 208000006750 Hematuria Diseases 0.000 description 6
- 210000001165 Lymph Nodes Anatomy 0.000 description 6
- 230000036650 Metabolic stability Effects 0.000 description 6
- 206010061289 Metastatic neoplasm Diseases 0.000 description 6
- 229940039716 Prothrombin Drugs 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 6
- 108010063628 acarboxyprothrombin Proteins 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 125000004429 atoms Chemical group 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 201000009030 carcinoma Diseases 0.000 description 6
- 231100000304 hepatotoxicity Toxicity 0.000 description 6
- 230000002503 metabolic Effects 0.000 description 6
- 230000001394 metastastic Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 102100008450 AFP Human genes 0.000 description 5
- 108010082126 Alanine Transaminase Proteins 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 206010007541 Cardiac disease Diseases 0.000 description 5
- 229940109239 Creatinine Drugs 0.000 description 5
- 102100010966 GPT Human genes 0.000 description 5
- 102000013519 Lipocalin-2 Human genes 0.000 description 5
- 108010051335 Lipocalin-2 Proteins 0.000 description 5
- 208000009856 Lung Disease Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 5
- 230000002730 additional Effects 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 201000010238 heart disease Diseases 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 4
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 4
- 206010049460 Abasia Diseases 0.000 description 4
- 108010005144 Bevacizumab Proteins 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- 208000005846 Cardiomyopathy Diseases 0.000 description 4
- 230000037250 Clearance Effects 0.000 description 4
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 4
- 210000002808 Connective Tissue Anatomy 0.000 description 4
- 101710037135 GAPC2 Proteins 0.000 description 4
- 101710037116 GAPC3 Proteins 0.000 description 4
- 101710025049 GAPDG Proteins 0.000 description 4
- 101710008404 GAPDH Proteins 0.000 description 4
- 102100006425 GAPDH Human genes 0.000 description 4
- 101710010461 Gapdh1 Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 210000002216 Heart Anatomy 0.000 description 4
- 206010053317 Hydrophobia Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- 101710025050 MK0970 Proteins 0.000 description 4
- 206010029260 Neuroblastoma Diseases 0.000 description 4
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 description 4
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 210000003932 Urinary Bladder Anatomy 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 230000003432 anti-folate Effects 0.000 description 4
- 230000000692 anti-sense Effects 0.000 description 4
- 229960000397 bevacizumab Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 201000008031 cardiomyopathy Diseases 0.000 description 4
- 101710025091 cbbGC Proteins 0.000 description 4
- 230000033077 cellular process Effects 0.000 description 4
- 230000035512 clearance Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 210000004748 cultured cells Anatomy 0.000 description 4
- 201000010046 dilated cardiomyopathy Diseases 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 231100000317 environmental toxin Toxicity 0.000 description 4
- 238000010228 ex vivo assay Methods 0.000 description 4
- 239000004052 folic acid antagonist Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 101710025070 gapdh-2 Proteins 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000024924 glomerular filtration Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 108091007165 microRNA precursor Proteins 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002342 ribonucleoside Substances 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000087 stabilizing Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 208000009956 Adenocarcinoma Diseases 0.000 description 3
- 102000008873 Angiotensin II receptor Human genes 0.000 description 3
- 108050000824 Angiotensin II receptor Proteins 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- 230000035639 Blood Levels Effects 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000008581 Brain Disease Diseases 0.000 description 3
- 229960004562 Carboplatin Drugs 0.000 description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 3
- 102000012192 Cystatin C Human genes 0.000 description 3
- 108010061642 Cystatin C Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229960004679 Doxorubicin Drugs 0.000 description 3
- 101700008821 EXO Proteins 0.000 description 3
- 101700083023 EXRN Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010014623 Encephalopathy Diseases 0.000 description 3
- 206010014625 Encephalopathy Diseases 0.000 description 3
- 229960005420 Etoposide Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960002949 Fluorouracil Drugs 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 210000000585 Glomerular Basement Membrane Anatomy 0.000 description 3
- 206010061989 Glomerulosclerosis Diseases 0.000 description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
- 229960001101 Ifosfamide Drugs 0.000 description 3
- 206010022095 Injection site reaction Diseases 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
- 206010027525 Microalbuminuria Diseases 0.000 description 3
- 229960004857 Mitomycin Drugs 0.000 description 3
- 208000010125 Myocardial Infarction Diseases 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- URBXHNSZZLMBOT-UHFFFAOYSA-N N-[9-(4-fluoro-3,5,6-trihydroxyoxan-2-yl)purin-6-yl]benzamide Chemical compound OC1C(F)C(O)C(O)OC1N1C2=NC=NC(NC(=O)C=3C=CC=CC=3)=C2N=C1 URBXHNSZZLMBOT-UHFFFAOYSA-N 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical group ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010061481 Renal injury Diseases 0.000 description 3
- 102100004994 SPART Human genes 0.000 description 3
- 101700080258 SPART Proteins 0.000 description 3
- 206010050207 Skin fibrosis Diseases 0.000 description 3
- 229940113082 Thymine Drugs 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 201000003397 Troyer syndrome Diseases 0.000 description 3
- 230000036488 Urinary output Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000003111 delayed Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 230000029578 entry into host Effects 0.000 description 3
- 230000001747 exhibiting Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000003463 hyperproliferative Effects 0.000 description 3
- 230000001771 impaired Effects 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- 200000000010 kidney injury Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 230000003278 mimic Effects 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- 230000001737 promoting Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000001340 slower Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 201000010874 syndrome Diseases 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- 229960005486 vaccines Drugs 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 2
- XYVLZAYJHCECPN-UHFFFAOYSA-L 6-aminohexyl phosphate Chemical compound NCCCCCCOP([O-])([O-])=O XYVLZAYJHCECPN-UHFFFAOYSA-L 0.000 description 2
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 2
- 229960003896 Aminopterin Drugs 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 229950006323 Angiotensin ii Drugs 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 2
- 210000001367 Arteries Anatomy 0.000 description 2
- 206010003658 Atrial fibrillation Diseases 0.000 description 2
- 210000002469 Basement Membrane Anatomy 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- 102100020540 CCN2 Human genes 0.000 description 2
- 102100016705 COL18A1 Human genes 0.000 description 2
- 101710038497 COL4A3 Proteins 0.000 description 2
- 229960004015 Calcitonin Drugs 0.000 description 2
- 102400000113 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N Candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- WNRZHQBJSXRYJK-UHFFFAOYSA-N Carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010022830 Cetuximab Proteins 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 Chlorambucil Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 108020004461 Double-Stranded RNA Proteins 0.000 description 2
- 108010043428 EC 2.1.2.1 Proteins 0.000 description 2
- 102000015082 EC 2.1.2.2 Human genes 0.000 description 2
- 108010064209 EC 2.1.2.2 Proteins 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- 229960001904 EPIRUBICIN Drugs 0.000 description 2
- 229960000873 Enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N Enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 210000000981 Epithelium Anatomy 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N Eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- 229960001433 Erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 210000002744 Extracellular Matrix Anatomy 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 102000037290 Folate transporters Human genes 0.000 description 2
- 108091006698 Folate transporters Proteins 0.000 description 2
- 229950005309 Fostamatinib Drugs 0.000 description 2
- GKDRMWXFWHEQQT-UHFFFAOYSA-N Fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 2
- 208000002672 Hepatitis B Diseases 0.000 description 2
- 206010020243 Hodgkin's disease Diseases 0.000 description 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 101700046422 IFNA Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II dizwitterion Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229940028435 Intralipid Drugs 0.000 description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N Irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
- 102100013180 KDR Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N Lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 208000009721 Leukemia, Monocytic, Acute Diseases 0.000 description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 229960002394 Lisinopril Drugs 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 229960004773 Losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N Losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- 229960004961 Mechlorethamine Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 229950007856 Mofetil Drugs 0.000 description 2
- 239000005462 Mubritinib Substances 0.000 description 2
- 229950002212 Mubritinib Drugs 0.000 description 2
- ZTFBIUXIQYRUNT-MDWZMJQESA-N Mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 2
- 206010028640 Myopathy Diseases 0.000 description 2
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 2
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 2
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 2
- 206010073131 Oligoastrocytoma Diseases 0.000 description 2
- 239000005480 Olmesartan Substances 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 102000024367 PPAR alpha Human genes 0.000 description 2
- 108010028924 PPAR alpha Proteins 0.000 description 2
- 108010061219 Panitumumab Proteins 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229940066842 Petrolatum Drugs 0.000 description 2
- TZMSYXZUNZXBOL-UHFFFAOYSA-N Phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229950008882 Polysorbate Drugs 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229940097325 Prolactin Drugs 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N Quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
- 229960003401 Ramipril Drugs 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N Ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 206010038038 Rectal cancer Diseases 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- SGOOQMRIPALTEL-UHFFFAOYSA-N Roquinimex Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 2
- 102000019394 Serine hydroxymethyltransferase Human genes 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
- 229960005314 Suramin Drugs 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N Telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229960003433 Thalidomide Drugs 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 102000005497 Thymidylate Synthase Human genes 0.000 description 2
- 108010067449 Thymidylate Synthase Proteins 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 231100000765 Toxin Toxicity 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 108010010691 Trastuzumab Proteins 0.000 description 2
- 229940035893 Uracil Drugs 0.000 description 2
- 108091007928 VEGF receptors Proteins 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N Valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- 210000003462 Veins Anatomy 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 230000001476 alcoholic Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960000932 candesartan Drugs 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000003205 diastolic Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002091 elastography Methods 0.000 description 2
- 229960004563 eprosartan Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000000630 fibrocyte Anatomy 0.000 description 2
- 230000003176 fibrotic Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 125000001072 heteroaryl group Chemical class 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000002601 intratumoral Effects 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 238000009588 inulin clearance Methods 0.000 description 2
- 229960002198 irbesartan Drugs 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 229960003784 lenvatinib Drugs 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
- 229940121386 matrix metalloproteinase inhibitors Drugs 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical group CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 2
- 201000009251 multiple myeloma Diseases 0.000 description 2
- 201000010770 muscular disease Diseases 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 230000000414 obstructive Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960005117 olmesartan Drugs 0.000 description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 229960003407 pegaptanib Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 230000000644 propagated Effects 0.000 description 2
- 229960001455 quinapril Drugs 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960003522 roquinimex Drugs 0.000 description 2
- 239000001296 salvia officinalis l. Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 102000002938 thrombospondin family Human genes 0.000 description 2
- 108060008245 thrombospondin family Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 108020003112 toxins Proteins 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 201000007423 tubular adenocarcinoma Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 2
- 201000002327 urinary tract obstruction Diseases 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000002747 voluntary Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- FGODUFHTWYYOOB-UHFFFAOYSA-L 1,3-diaminopropan-2-yl phosphate Chemical compound NCC(CN)OP([O-])([O-])=O FGODUFHTWYYOOB-UHFFFAOYSA-L 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- FDZGOVDEFRJXFT-UHFFFAOYSA-N 2-(3-aminopropyl)-7H-purin-6-amine Chemical compound NCCCC1=NC(N)=C2NC=NC2=N1 FDZGOVDEFRJXFT-UHFFFAOYSA-N 0.000 description 1
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 2-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-Methoxyestradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-UHFFFAOYSA-N 3,4,5-trihydroxypentanal Chemical compound OCC(O)C(O)CC=O ASJSAQIRZKANQN-UHFFFAOYSA-N 0.000 description 1
- KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 description 1
- HYCSHFLKPSMPGO-UHFFFAOYSA-L 3-hydroxypropyl phosphate Chemical compound OCCCOP([O-])([O-])=O HYCSHFLKPSMPGO-UHFFFAOYSA-L 0.000 description 1
- LZINOQJQXIEBNN-UHFFFAOYSA-N 4-hydroxybutyl dihydrogen phosphate Chemical compound OCCCCOP(O)(O)=O LZINOQJQXIEBNN-UHFFFAOYSA-N 0.000 description 1
- OFNXOACBUMGOPC-HZYVHMACSA-N 5'-hydroxystreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](CO)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O OFNXOACBUMGOPC-HZYVHMACSA-N 0.000 description 1
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-Hydroxymethylcytosine Chemical group NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1H-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1H-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940070021 ANABOLIC STEROIDS Drugs 0.000 description 1
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N Acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 206010001627 Alcoholic liver disease Diseases 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 108009000283 Allograft Rejection Proteins 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N Aminocaproic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N Anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 206010054793 Arterial fibrosis Diseases 0.000 description 1
- 229910017259 AsTe Inorganic materials 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 229960002747 Betacarotene Drugs 0.000 description 1
- 210000000013 Bile Ducts Anatomy 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 108010082834 Brain Natriuretic Peptide Proteins 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 1
- 101700026049 CCN2 Proteins 0.000 description 1
- 101710038504 COL4A4 Proteins 0.000 description 1
- 229940039231 CONTRAST MEDIA Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 206010000032 Cardiac conduction disease Diseases 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010046973 Cardiac valve disease Diseases 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N Carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 208000009863 Chronic Kidney Failure Diseases 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N Coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- 101700062901 DPP Proteins 0.000 description 1
- 101700039720 DPP4 Proteins 0.000 description 1
- 102100012353 DPP4 Human genes 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 1
- 206010061835 Diabetic nephropathy Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N Digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine hydrobromide Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101700039191 EGFR Proteins 0.000 description 1
- 229940068998 EGG YOLK PHOSPHOLIPIDS Drugs 0.000 description 1
- 240000001267 Echinacea angustifolia Species 0.000 description 1
- 206010014663 Endocardial fibroelastosis Diseases 0.000 description 1
- 229940095399 Enema Drugs 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N Eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 229940011871 Estrogens Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 102000013165 Exonucleases Human genes 0.000 description 1
- 108060002716 Exonucleases Proteins 0.000 description 1
- 210000001508 Eye Anatomy 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 229940014144 Folate Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N Furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 Furosemide Drugs 0.000 description 1
- 229910005900 GeTe Inorganic materials 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 229940025770 Heparinoids Drugs 0.000 description 1
- 108009000423 Hepatitis B infection Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 102100008764 IGBP1 Human genes 0.000 description 1
- 101700077226 IGBP1 Proteins 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 210000004969 Inflammatory Cells Anatomy 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 231100000601 Intoxication Toxicity 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229940039717 Lanolin Drugs 0.000 description 1
- 102000019298 Lipocalins Human genes 0.000 description 1
- 108050006654 Lipocalins Proteins 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100011960 MIR7-3HG Human genes 0.000 description 1
- 101710008473 MIR7-3HG Proteins 0.000 description 1
- 229940035363 MUSCLE RELAXANTS Drugs 0.000 description 1
- 210000001132 Macrophages, Alveolar Anatomy 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N Milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 206010027723 Mitral valvular disease Diseases 0.000 description 1
- 229940083876 Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 231100000637 Nephrotoxin Toxicity 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N Nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 208000009344 Penetrating Wounds Diseases 0.000 description 1
- FCCNSUIJIOOXEZ-SJYYZXOBSA-N Pentosan Polysulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@@H](OS(O)(=O)=O)[C@H](O)CO[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](O)OC1 FCCNSUIJIOOXEZ-SJYYZXOBSA-N 0.000 description 1
- 229940043138 Pentosan Polysulfate Drugs 0.000 description 1
- 208000008494 Pericarditis Diseases 0.000 description 1
- 240000005158 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- RDOWQLZANAYVLL-UHFFFAOYSA-N Phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical compound C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 108010045040 Phosphoribosylaminoimidazolecarboxamide Formyltransferase Proteins 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 210000000557 Podocytes Anatomy 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229940071643 Prefilled Syringe Drugs 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 229940100486 RICE STARCH Drugs 0.000 description 1
- 102100008510 RNF167 Human genes 0.000 description 1
- 101710030956 RNF167 Proteins 0.000 description 1
- 108010062724 Ranibizumab Proteins 0.000 description 1
- 229960003876 Ranibizumab Drugs 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 229920001914 Ribonucleotide Polymers 0.000 description 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229960000553 Somatostatin Drugs 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 229920000401 Three prime untranslated region Polymers 0.000 description 1
- 229940036555 Thyroid hormones Drugs 0.000 description 1
- 101700075175 Timp Proteins 0.000 description 1
- 241000159241 Toxicodendron Species 0.000 description 1
- 241000871311 Toxicodendron vernix Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 210000000626 Ureter Anatomy 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 208000009982 Ventricular Dysfunction Diseases 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 229940100445 WHEAT STARCH Drugs 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000001800 adrenalinergic Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 230000001139 anti-pruritic Effects 0.000 description 1
- 230000000417 anti-transforming Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000001746 atrial Effects 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N benzazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- OENHQHLEOONYIE-VYAWBVGESA-N beta-Carotene Natural products CC=1CCCC(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-VYAWBVGESA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 229940058933 biguanide antimalarials Drugs 0.000 description 1
- 229940090145 biguanide blood glucose lower drugs Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000013080 embryo development ending in birth or egg hatching Effects 0.000 description 1
- 230000013144 embryo development ending in seed dormancy Effects 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 231100000573 exposure to toxins Toxicity 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000003352 fibrogenic Effects 0.000 description 1
- 201000004098 fibrolamellar carcinoma Diseases 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 230000000893 fibroproliferative Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulators Drugs 0.000 description 1
- 230000003308 immunostimulating Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 230000001926 lymphatic Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003253 miRNA assay Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000001617 migratory Effects 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000651 myofibroblasts Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000011260 negative regulation of cellular process Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 231100001035 ocular change Toxicity 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 230000002206 pro-fibrotic Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- FAUKQZGBHAOERC-UHFFFAOYSA-N pyridin-2-amine;1H-pyridin-2-one Chemical compound NC1=CC=CC=N1.O=C1C=CC=CN1 FAUKQZGBHAOERC-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000023276 regulation of development, heterochronic Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 230000000862 serotonergic Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Abstract
Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.
Description
MICRORNA COMPOUNDS AND METIIODS FOR MODULATING MIR-21 ACTIVITY
FIELD OF INVENTION
Provided herein are methods and compositions for the modulation of miR-21 activity.
DESCRIPTION OF RELATED ART
MicroRNAs (microRNAs), also known as “mature microRNA” are small (approximately 18-24 nucléotides in length), non-coding RNA molécules encoded in the génomes of plants and animais. In certain instances, highly conserved, endogenously expressed microRNAs regulate the expression of genes by binding to the 3'-untranslated régions (3'-UTR) ofspécifie mRNAs. More than 1000 different 10 microRNAs hâve been identified in plants and animais. Certain mature microRNAs appear to originate from long endogenous primary microRNA transcripts (also known as pri-microRNAs, pri-mirs, pri-miRs or pri-pre-microRNAs) that are often hundreds of nucléotides in length (Lee, et al., EMBO J., 2002, 21(17), 4663-4670).
Functional analyses of microRNAs hâve revealed that these small non-coding RNAs contribute 15 to different physiological processes in animais, including developmental timing, organogenesis, différentiation, patteming, embryogenesis, growth control and programmed cell death. Examples of particular processes in which microRNAs participatc include stem cell différentiation, neurogenesis, angiogenesis, hematopoiesis, and exocytosis (reviewed by Alvarez-Garcia and Miska, Development, 2005,132,4653-4662).
SUMMARYOF INVENTION
Provided herein are compounds comprising a modified oligonucleotide, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 and wherein the modified oligonucleotide has a nucleosidc pattem described herein.
Provided herein are methods for inhibiting the activity of miR-21 comprising contacting a cell 25 with a compound described herein. In certain embodiments, the cell is in vivo. In certain embodiments, the cell is in vitro.
Provided herein are methods for treating a disease associated with miR-21 comprising administering to a subject having a disease associated with miR-21 a compound described herein. In certain embodiments, the subject is a human. In certain embodiments, the subject is a canine.
The compounds described herein are provided for use in therapy.
Provided herein are compounds comprising a modified oligonucleotide consisting of 8 to 22 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosidcs of the following nucleoside pattern ΙΠ in the 5* to 3’ orientation:
(R)x-Nb-Nq-N<3-Nb-(Nq-Nq-Nq-Nb)j-Ny-Nz wherein each R is a non-bicyclic nucleoside; X is from 1 to 4; each NB is a bicyclic nucleoside; each N41 is a non-bicyclic nucleoside; NY is a modified nucleoside or an unmodified nucleoside; and each Nz is a modified nucleoside.
Provided herein arc compounds comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosîdes, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosîdes of the following nucleoside pattern IV in the 5* to 3* orientation:
NM-NB-NQ-NQ-NB-(NO-N<5-N<,-NB)3-NY-NZ wherein NM is a modified nucleoside that is not a bicyclic nucleoside; each NB is a bicyclic nucleoside; each is a non-bicyclic nucleoside; NY is a modified nucleoside or an unmodified nucleoside; and Nz is a modified nucleoside.
Provided herein arc compounds comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosîdes, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1 ) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosîdes of the following nucleoside pattern V in the 5’ to 3’ orientation:
NM-NB-(N<Î-N<Î-NB-NB)4-NZ wherein NM is a modified nucleoside that is not a bicyclic nucleoside; each NB is a bicyclic nucleoside; each N45 is a non-bicyclic nucleoside; and Nz is a modified nucleoside.
Provided herein are compounds comprising a modified oligonucleotide consisting of 8 to 15 linked nucleosîdes, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1), and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosidcs of the following nucleoside pattern VI in the 5’ to 3* orientation:
NQ-NB-NB-NQ-(NB-NB-N<Î-N<Î)2-NB-N<Î-NB wherein each N43 is a non-bicyclic nucleoside; and each NB is a bicyclic nucleoside.
Provided herein arc compounds comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosîdes, wherein the nucleobase sequence of the modified oligonucleotide is complementary to mïR-21 (SEQ ID NO: 1), and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosîdes of the following nucleoside pattern VII in the 5’ to 3’ orientation: NM-(NB-NM-NM)2-NM-(NB-N<Î-N<Î-NQ)2-NB-NB-NZ wherein each NM is a modified nucleoside that is not a bicyclic nucleoside; each NB is a bicyclic nucleoside; each N^ is a non-bicyclic nucleoside; and Nz is a modified nucleoside.
In certain embodiments of any of the compounds provided herein, the modified oligonucleotide comprises at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17,at least 18,at least 19,at least 20, at least 21, or 22 contiguous nucleosîdes of nucleoside pattern
III. In certain embodiments of any of the compounds provided herein, the modified oligonucleotide comprises at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, or 19 contiguous nucleosides of nucleoside pattern IV, V, or VII. In certain embodiments of any of the compounds provided herein, the modified oligonucleotide comprises at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, or 15 contiguous nucleosides of nucleoside pattern VI. In certain embodiments of any of the compounds provided herein, the modified oligonucleotide consista of 8,9,10,11,12,13,14,15,16,17,18,19,20,21, or 22 linked nucleosides of nucleoside pattern III. In certain embodiments of any of the compounds provided herein, the modified oligonucleotide consista of 8,9,10,11, 12,13,14,15,16,17,18, or 19 linked nucleosides of nucleoside pattern IV, V, or VII. In certain embodiments of any of the compounds provided herein, the modified oligonucleotide consistsof 8,9,10,11,12,13,14, or 15 linked nucleosides of nucleoside pattern VI.
In certain embodiments of any of the compounds provided herein, the nucleobase sequence of the modified oligonucleotide is at least 90% complementary, is at least 95% complementary, or is 100% complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1),
In certain embodiments of any of the compounds provided herein, the nucleobase at position 1 of miR-21 is paired with the first nucleobase at the 3'-terminus of the modified oligonucleotide.
In certain embodiments of any of the compounds provided herein, each bicyclic nucleoside is independently selected from an LNA nucleoside, a cEt nucleoside, and an ENA nucleoside.
In certain embodiments of any of the compounds provided herein, each bicyclic nucleoside is a cEt nucleoside. In certain embodiments, the cEt nucleoside is an S-cEt nucleoside. In certain embodiments, the cEt nucleoside is an R-cEt nucleoside. In certain embodiments of any of the compounds provided herein, each bicyclic nucleoside is an LNA nucleoside.
In certain embodiments of any of the compounds provided herein, each bicyclic nucleoside comprises a non-methylated nucleobase.
In certain embodiments of any of the compounds provided herein, each non-bicyclic nucleoside is independently selected from a β-D-deoxyribonucleosidc, a β-D-ribonucleoside, 2'-O-methyl nucleoside, a 2’-O-methoxyethyl nucleoside, and a 2’-fluoronucleoside. Incertain embodiments of any of the compounds provided herein, each non-bicyclic nucleoside is independently selected from a β-Ddeoxyribonucleoside, and a 2'-O-mcthoxyethyl nucleoside. In certain embodiments of any of the compounds provided herein, each non-bicyclic nucleoside is a β-D-deoxyribonucleoside. In certain embodiments of any of the compounds provided herein, each non-bicyclic nucleoside is a 2’-Omethoxyethyl nucleoside.
In certain embodiments of any of the compounds provided herein, at least two non-bicyclic nucleosides comprise sugar moicties that are different from one another. In certain embodiments of any of the compounds provided herein, each non-bicyclic nucleoside has the same type of sugar moiety.
In certain embodiments of any ofthe compounds provided herein, no more than two non-bicyclic nucieosidcs are 2*-0-methoxyethyl nucleosides. In certain such embodiments, each other non-bicyclic nucleosîde is a β-D-deoxyribonucleoside.
In certain embodiments ofanyofthe compounds provided herein, the 5’-most and the 3*-most non-bicyclic nucleosides are 2’-0-methoxyethyl nucleosides and each other non-bicyclic nucleosîde is a β-D-deoxyribonucleoside. In certain embodiments of any of the compounds provided herein, two nonbicyclic nucleosides arc 2’-MOE nucleosides and each other non-bicyclic nuclcosidc is a fl-Ddeoxyribonucleosidc.
In certain embodiments of nucleosidc pattern ΠΙ, each nucleosîde of R is a 2*-0-methoxycthyl nucleosîde. In certain embodiments of nucleosidc pattern III, three nucleosides of R are 2’-Omethoxyethy! nucleosides and one nucleosîde of R is a β-D-deoxyribonucleosidc.
In certain embodiments of nucleosidc pattern III, each R is a 2’-0-methoxyethyl nucleosidc; X is l ; each NB is an S-cEt nucleosidc; each bP is a β-D-deoxyribonucleoside; NY is a β-Ddeoxyribonucleosidc; and Nz îs a 2’-0-mcthoxyethyl nucleosîde. In certain embodiments of nucleosîde pattern ΙΠ, each R is a 2’-0-methoxyethyl nucleosidc; X is l; each NB is an S-cEt nucleosîde; each bP is a β-D-deoxyribonucleoside; NY is a β-D-deoxyribonucleosidc; and Nz is an S-cEt nucleosidc. In certain embodiments of nucleosidc pattern ΙΠ, each R is a 2’-0-methoxyethyl nucleosidc; X is I; each NB is an S-cEt nucleosidc; each bP is a β-D-deoxyribonucleoside; NY is an S-cEt nucleosîde; and Nz is an S-cEt nucleosîde.
In certain embodiments of nucleosîde pattern IV, NM is a 2*-0-methoxyethyl nucleosîde; each N® is an S-cEt nucleosidc; each bP is a β-D-deoxyribonucleoside; NY is a β-D-deoxyribonucleoside; Nz is a 2’-O-methoxycthyl nucleosidc. In certain embodiments of nucleosîde pattern IV, NM is a 2’-Omethoxyethyl nucleosidc; each NBis an S-cEt nucleosîde; each bP is a β-D-dcoxyribonucleosidc; NY is a β-D-deoxyribonucleosidc; and Nz is an S-cEt nucleosîde. In certain embodiments of nucleosidc pattern IV, Nm is a 2’-0-methoxyethyl nucleosidc; each NB is an S-cEt nucleosidc; each bP is a β-Ddeoxyribonucleosidc; NY is an S-cEt nucleosîde; and N2 is an S-cEt nucleosîde. In certain embodiments of nucleosidc pattern IV, N” is a 2*-O-methoxycthyl nucleosidc; each NB is an S-cEt nucleosidc; each bP is independently selected from a β-D-deoxyribonucleoside and a 2*-0-methoxyethyl nucleosîde; NY is a β-D-deoxyribonucleosidc; and Nz is an S-cEt nucleosidc. In certain embodiments of nucleosîde pattern IV, the modified oligonucleotide has the structure:
AeCsAeTeCsAeGeTeCsTGAUsAAGCsTAs (SEQ ID NO: 3); or AeCsAeTeCsAeGeTeCsTGAUsAAGCsUsAs (SEQ ID NO: 3).
wherein nucleosides not followed by a subscript are β-D-deoxyribonucleosides; nucleosides followed by a subscript *‘E” are 2’-MOE nucleosides; and nucleosides followed by a subscript “S” are S-cEt nucleosides.
ln certain embodiments of nucleoside pattern V, NM is a 2’-0-methoxyethyl nucleoside; each NB is an S-cEt nucleoside; eachN*3 is a β-D-deoxyribonucleoside; and Nzis a 2’-0-methoxyethyl nucleoside.
In certain embodiments of nucleoside pattern V, the modified oligonucleotide has the structure:
AeCsATCsAsGTCsUsGAUsAsAGCsUsAe (SEQ ID NO: 3);
wherein nucleosides not followed by a subscript are β-D-deoxyribonucleosides; nucleosides followed by a subscript “E* are 2*-MOE nucleosides; and nucleosides followed by a subscript *’S” are S-cEt nucleosides.
In certain embodiments of nucleoside pattern VI, each N9 is a modified nucleoside that is not a bîcyclic nucleoside. In certain embodiments of nucleoside pattern VI, each is, independently, selected from a 2’-O-mcthoxycthyl nucleoside and a β-D-deoxyribonucleoside. In certain embodiments of nucleoside pattem VI, each N*3 is a 2’-0-methoxyethyl nucleoside. In certain embodiments of nucleoside pattem VI, each N*1 is a β-D-deoxyribonucleoside. In certain embodiments of nucleoside pattem VI, each N*3 is a 2’-O-methoxyethyl nucleoside; and each NB is an S-cEt nucleoside. ln certain embodiments of nucleoside pattem VI, each N0 is a β-D-deoxyribonucleoside nucleoside; and each NB is an S-cEt nucleoside. In any of the embodiments of nucleoside pattem VI, the modified oligonucleotide may hâve 0,1, or 2 mismatches with respect to the nucleobase sequence of miR-21. In certain such embodiments, the modified oligonucleotide has 0 mismatches with respect to the nucleobase sequence of miR-21. In certain embodiments, the modified oligonucleotide has 1 mismatch with respect to the nucleobase sequence ofmiR-21. ln certain embodiments, the modified oligonucleotide has 2 mismatches with respect to the nucleobase sequence ofmiR-21. ln certain embodiments ofnucleoside pattem VI, the modified oligonucleotide has the structure:
MîCeAsAsTeCsUsAeAeUsAsAeGeCsTeAs (SEQ ID NO: 7); wherein nucleosides followed by a subscript ME’ are 2’-MOE nucleosides; nucleosides followed by a subscript “S” are S-cEt nucleosides; and MeC is 5-methyl cytosine.
ln certain embodiments of nucleoside pattem VII, each NM is a 2’-0-methoxyethyl nucleoside; each Nb is an S-cEt nucleoside; each N9 is independently selected from a 2*-O-methyl nucleoside and a β-D-deoxyribonucleoside; and Nz is independently selected from an S-cEt nucleoside and a 2’-Omethoxycthyl nucleoside. In certain embodiments of nucleoside pattem VII, each NM is a 2’-Omethoxyethyl nucleoside; each NB is an S-cEt nucleoside; each N*3 is a β-D-deoxyribonucleosidc; and Nz is an S-cEt nucleoside. ln certain embodiments of nucleoside pattem VII, each NM is a 2’-Omethoxyethyl nucleoside; each N® is an S-cEt nucleoside; each N9 is independently selected from a 2’O-mcthyl nucleoside and a β-D-deoxyribonucleoside; and Nz is an S-cEt nucleoside. ln certain embodiments of nucleoside pattem VII, each NM is a 2’-0-methoxycthyl nucleoside; each NB is an S-cEt nucleoside; each N*3 is independently selected from a 2’-O-methyl nucleoside and a β-Ddeoxyribonucleoside; and Nz is 2’-0-methoxyethyl nucleoside. In certain embodiments of nucleoside pattem VII, the modified oligonucleotide has the structure:
AeCsAeTeCsAeGeTeCsTGAUsAAGCsUsAs (SEQ ID NO: 3).
In certain embodiments, a compound comprises a modified oligonucleotide consisting of 8 to 22 linked nucleosides, wherein the modified oligonucleotide comprises at least 8, at least 9, at least 10, at least 11,at least 12, at least 13, at least 14, at least 15,at least 16, at least 17,at least 18, orat least 19 contiguous nucleosides of a structure selected from the structures in Table 1. In certain embodiments, a compound comprises a modified oligonucleotide having a structure selected from the structures in Table 1.
In certain embodiments of any of the compounds provided herein, at least one intemucleosîde tinkage is a modified intemucleosîde linkage. In certain embodiments of any of the compounds provided herein, each intemucleosîde linkage is a modified intemucleosîde tinkage. In certain embodiments, the modified intemucleoside linkage is a phosphorothioate intemucleosîde tinkage.
In certain embodiments of any of the compounds provided herein, at least one nucleoside comprises a modified nuclcobase. In certain embodiments of any of the compounds provided herein, at least one cytosine is a 5-methyl cytosine. In certain embodiments of any ofthe compounds provided herein, each cytosine is a 5-methylcytosine. In certain embodiments of any ofthe compounds provided herein, the cytosine at position two of the modified oligonucleotide is a 5-methylcytosine.
In certain embodiments of any of the compounds provided herein, the modified oligonucleotide has the nuclcobase sequence of a sequence selected from SEQ ID NOs: 3 to 10, wherein each T in the sequence is independently selected from T and U.
In certain embodiments of any ofthe compounds provided herein, the modified oligonucleotide has 0,1,2, or 3 mismatches with respect to the nucleobase sequence of miR-21. In certain embodiments of any of the compounds provided herein, the modified oligonucleotide has 0,1, or 2 mismatches with respect to the nucleobase sequence of miR-21. In certain such embodiments, the modified oligonucleotide has 0 mismatches with respect to the nucleobase sequence of miR-21. In certain embodiments, the modified oligonucleotide has 1 mismatch with respect to the nucleobase sequence of miR-21. In certain embodiments, the modified oligonucleotide has 2 mismatches with respect to the nucleobase sequence of miR-21.
Provided herein are methods for Înhibiting the activity of mîR-21 comprising contacting a cell with a compound provided herein. In certain embodiments, the cell is in vivo. In certain embodiments, the cell is in vitro. In certain embodiments, the cell is a fibroblast cell, an épithélial cell, a stellate cell, a kératinocyte, or a fibrocyte. In certain embodiments, the cell is a hyperproliferative cell or a hypoxie cell. In certain embodiments, the fibroblast cell is a hyperproliferative fibroblast cell.
Provided herein are methods of inhibiting the activity of miR-21 comprising contacting a cell with with any of the compounds described herein. In certain embodiments, the cell is in vivo. In certain embodiments, the cell is in vitro. In certain embodiments, the cell is a fibroblast cell, a hyperproliferative cell, a kératinocyte, or a hypoxie cell.
Provided herein are methods for decreasing collagen expression in a cell comprising contacting a cell with a compound provided herein.
Provided herein are methods to treat, prevent, or delay the onset of a disease associated with miR-21, comprising administering to a subject having such a disease any of the compounds provided herein.
In certain embodiments, the disease is fibrosis. In certain embodiments the fibrosis is kidney fibrosis, lung fibrosis, liver fibrosis, cardiac fibrosis, skin fibrosis, age-related fibrosis, spleen fibrosis, scleroderma, and/or post-transplant fibrosis.
In certain embodiments, the fibrosis is kidney fibrosis and is présent in a subject having a disease or condition selected from glomerulosclerosis, tubulointerstitial fibrosis, IgA nephropathy, înterstitial fîbrosis/tubular atrophy; chronic kidney damage, chrome kidney disease,, glomerular disease, glomerulonephritis, diabètes mellitus, idiopathy focal segmentai glomerulosclerosis, membranous nephropathy, collapsing glomerulopathy, chronic récurrent kidney infection, chronic kidney disease following acute kidney injury (AKI), kidney damage following exposure to environmental toxin and/or naturel product, and end stage rénal disease. In certain embodiments, the kidney fibrosis results from acute or répétitive trauma to the kidney.
In certain embodiments, the fibrosis is liver fibrosis and is présent în a subject having a disease selected from chronic liver injury, hepatitis infection (such as hepatitis B infection and/or hcpatitis C infection), non-alcoholic steatohepatitis, alcoholic liver disease, liver damage following exposure to environmental toxin and/or naturel product, and cirrhosis.
In certain embodiments, the pulmonary fibrosis is idiopathic pulmonary fibrosis, or the subject has chronic obstructive pulmonary disease.
In certain embodiments, disease is an inflammatory disease.
Provided herein are methods of promoting wound healing in a subject comprising administering to a subject having an acute or chronic wound any of the compounds provided herein. In certain embodiments, the chronic wound is an acute or chronic surgical wound, a penetrating wound, an avulsion injury, a crushing injury, a shearing injury, a bum injury, a lacération, a bite wound, an arterial ulcer, a venous ulcer, a pressure ulcer, or a diabetic ulcer. In certain embodiments, the compound is administered topically to the wound.
Provided herein are methods to treat a fibroprolîferetive disorder in a subject comprising administering to the subject any of the compounds provided herein.
Any ofthe methods provided herein may comprise selecting a subject having elevated miR-21 expression in one or more tissues.
In certain embodiments, administering any of the compounds provided herein to a subject rcduces collagen expression.
In certain embodiments, a subject is in need of improved organ function, wherein the organ function is selected from cardiac function, pulmonary function, liver function, and kidney function. In certain embodiments, the administering of any of the compounds provided herein improves organ function in the subject, wherein the organ function is selected from cardiac function, pulmonary function, liver function, and kidney function.
Any of the methods provided herein comprises evaluating kidney function in a subject, which may include measuring blood urea nitrogen in the blood of the subject; measuring créatinine in the blood of the subject; measuring créatinine clearance in the subject; measuring proteinuria in the subject; measuring albumimereatinine ratio in the subject; measuring urinary output in the subject; measuring inulin clearance in the urine of the subject; measuring urinary osmolarity in the subject; measuring urinary osmolality in the subject; measuring hematuria in the subject; measuring cystatin C in the blood and/or urine of the subject; and/or measuring neutrophil gelatinase-associated lipocalin (NGAL) in the blood or urine of the subject.
Any of the methods provided herein may comprise evaluating liver function in a subject, which may include measuring alanine aminotransferase Ievels in the blood of the subject; measuring aspartate aminotransferase Ievels in the blood of the subject; measuring bilirubin Ievels in the blood of the subject; measuring albumin Ievels in the blood of the subject; measuring prothrombin time in the subject; measuring ascites in the subject; measuring encephalopathy in the subject; and/or measuring liver stiffness, for example, using transient elastography.
Any of the methods provided herein may comprise evaluating lung function in a subject, which may include measuring vital capacity in the subject; measuring forced vital capacity in the subject; measuring forced expiratory volume in one second in the subject; measuring peak expiratory flow rate in the subject; measuring forced expiratory flow in the subject; measuring maximal voluntary ventilation in the subject; determining the ratio of forced expiratory volume in one second to forced vital capacity in the subject; measuring ventilation/perfusion ratio in the subject; measuring nitrogen washout in the subject; and/or measuring absolute volume of air in one or more lungs of a subject.
Any of the methods provided herein may comprise evaluating cardiac function in a subject, which may include measuring cardiac output in the subject; measuring stroke volume in the subject; measuring mean systolic éjection rate in the subject; measuring systolic blood pressure in the subject; measuring left ventricular éjection fraction in the subject; determining stroke index in the subject; determining cardiac index in the subject; measuring left ventricular percent fractional shortening in the subject; measuring mean velocity of circumferential fiber shortening in the subject; measuring left ventricular inflow velocity pattern in the subject; measuring pulmonary venous flow velocity pattern in the subject; and/or measuring peak early diastolic velocity of the mitral annulus of the subject.
Any of the methods provided herein may comprise administering to a subject at least one therapeutic agent selected from an anti-inflammatory agent, an immunosuppressive agent, an anti· diabetic agent, digoxin, a vasodilator, an angiotensin II converting enzyme (ACE) inhibitors, an angiotensin II receptor blockers (ARB), a calcium channel blocker, an isosorbide dinitrate, a hydralazîne, a nitrate, a hydralazîne, a beta-blocker, a natriuretic peptides, a heparinoid, a connective tissue growth factor inhibitor, and a transforming growth factor inhibitor. In certain embodiments, the anti17147 inflammatory agent is a non-steroidal anti-inflammatory agent, wherein the non-steroidal antiinflammatory agent is optionally selected from ibuprofcn, a COX-l inhibitor and a COX-2 inhibitor. In certain embodiments, the immunosuppressive agent is selected from a corticosteroid, cyclophosphamide, and mycophcnolate mofetil. In certain embodiments, anti*inflammatory agent is a corticosteroid, wherein 5 the corticosteroid is optionally prednisone. In certain embodiments, the angiotensin Π converting enzyme (ACE) inhibitors is selected from captopril, enalapril, lisinopril, benazepril, quinapril, fosînopril, and ramipril. In certain embodiments, the angiotensin Π receptor blocker (ARB) is selected from candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, and eprosartan.
In certain embodiments, a disease is cancer. In certain embodiments, the cancer is liver cancer, 10 breast cancer, bladder cancer, prostate cancer, colon cancer, lung cancer, brain cancer, hematological cancer, pancreatic cancer, head and neck cancer, cancer of the longue, stomach cancer, skin cancer, thyroid cancer, neuroblastoma, esophageal cancer, mesothelioma, neuroblastoma, bone cancer, Iddney cancer, testicular cancer, rectal cancer, cervical cancer, or ovarian cancer. In certain embodiments, the liver cancer is hepatocellular carcinoma. In certain embodiments, the brain cancer is glioblastoma 15 multiforme, oligoastrocytoma, or oligodendrogliome. In certain embodiments, the glioblastoma multiforme is proneural glioblastoma multiforme, neural glioblastoma multiforme, classical glioblastoma multiforme, or mesenchymal glioblastoma multiforme. In certain embodiments, the hematological cancer is acute myelogenous leukemia, acute lymphocytic leukemia, acute monocytic leukemia, multiple myeloma, chronic lymphotic leukemia, chronic myeloid leukemia, hodgkïn’s lymphoma, or non20 hodgkin’s lymphoma. In certain embodiments, the skin cancer is melanoma. In certain embodiments, the kidney cancer is rénal cell carcinoma. In certain embodiments, the breast cancer is ductal cell carcinoma in situ, invasive ductal cell carcinoma, triple négative breast cancer, medullaiy carcinoma, tubular carcinoma, and mucinous carcinoma.
In certain embodiments, the methods provided herein comprise administering at least one additional anti-cancer therapy to the subject. In certain embodiments, the anti-cancer therapy is a DNA damaging agent, a prolifération inhibitor, an anti-folate, a growth factor receptor inhibitor, an antiangiogenic agent, a receptor tyrosine kinase inhibitor, a kinase inhibitor, a growth factor inhibitor, a cytotoxic agent, radiation therapy, or surgical résection of a tumor. In certain embodiments, the DNA damaging agent is 1,3-bis(2-chloroethyl) -1 -nitrosourea, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, daunonibicin, doxorubicin, epïrubïcin, etoposide, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan, mitomycin C, mitoxantrone, oxaliplatin, temozolomide, or topotecan. In certain embodiments, the anti-folate is méthotrexate, aminopterin, thymidylate synthase, serine hydroxymethyltransferase, folyilpolyglutamyl synthetase, g-glutamyl hydrolase, glycinamide-ribonucleotide transformylase, leucovorin, amino-imidazole-carboxamide35 ribonucleotide transformylase, 5-fluorouracil, or a folate transporter. In certain embodiments, the growth factor receptor inhibitor is erlotinib, or gefitinib. In certain embodiments, the angiogenesis inhibitor is bevacizumab, thalidomide, carboxyamidotriazole, TNP-470, CM 101, IFN-α, plate le t factor-4, suramin,
SU5416, thrombospondin, a VEGFR antagonist, cartilage-dcrived angiogenesis inhibitory factor, a matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tccogalan, tetrathiomolybdate, prolactin, or linomide. In certain embodiments, the kinase inhibitor is bevacizumab, BIBW 2992, cetuximab, imatïnib, trastuzumab, gefïtinib, ranibizumab, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, panitumumab, vandetanib, E7080, pazopanib, mubritinib, or fostamatinib.
In certain embodiments, the administering to a subject having cancer results în réduction of tumor size and/ or tumor number. In certain embodiments, the administering to a subject having cancer prevents or delays an incrcase in tumor size and/or tumor number. In certain embodiments, the administering to a subject having cancer prevents or slows metastatic progression. In certain embodiments, the administering to a subject having cancer extends o vera 11 survival time and/or progression-free survival of the subject. In certain embodiments, the methods provided herein comprise selecting a subject having elevated sérum alpha-fetoprotein and/or elevated sérum des-gammacarboxyprothrombin. In certain embodiments, the methods provided herein comprise reducing sérum alpha-fetoprotein and/or sérum des -gamma -carboxyprothrombin. In certain embodiments, the methods provided herein comprise selecting an animal having abnormal liver function.
In certain embodiments, a subject is a human. In certain embodiments, a subject is a canine.
In any of the methods provided herein, the compound is present as a pharmaceutical composition.
Any of the compounds provided herein may be for use in therapy. Any of the compounds provided herein may be for use in the treatment of fibrosis. Any of the compounds provided herein may be for use in promoting wound healing. Any of the compounds provided herein may be for use in treating cancer. Any of the compounds provided herein may bc for use in preventing and/or delaying the onset of metastasis.
Any of the compounds provided herein may be for use in treating cardiac disease.
Any of the compounds provided herein may be for use in the préparation of a médicament. Any of the compounds provided herein may be for use in the préparation of a médicament for treating fibrosis. Any of the compounds provided herein may be for use in the préparation of a médicament for promoting wound healing. Any of the compounds provided herein may be for use in the préparation of a médicament for treating cancer. Any of the compounds provided herein may be for use in the préparation of a médicament for preventing and/or delaying the onset of metastasis.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 shows the change in (A) collagen 1 Al and (B) collagen 3A1 expression in kidneys of
UUO model mice administered certain anti-miR-21 compounds, as described in Example 1.
Figure 2 shows the change in (A) collagen 1 Al and (B) collagen 3A1 expression in kidneys of
UUO model mice administered certain anti-miR-21 compounds, as described in Example 1.
Figure 3 shows the change in (A) collagen 1 Al and (B) collagen 3Al expression in kidneys of
UUO model mice administered certain anti-miR-21 compounds, as described in Exampie 2.
Figure 4 shows (A) the change in collagen 1 Al expression, (B) the change in collagen 3Al expression, and (C) the collagen area fraction in kidneys of unilatéral IRI model mice administered certain anti-miR-21 compounds, as described in Example 3.
Figure 5 shows (A) urinary albumin to creatînine ratio in kidneys of IR/Nx model mice administered compound 36328 or a control compound, (B) urinary albumin to creatînine ratio in kidneys of IR/Nx model mice administered compound 36284, and (C) urinary albumin to creatînine ratio in kidneys of IR/Nx model mice administered compound 25220, as described in Example 4.
Figure 6 shows (A) luciferase activity of anti-miR-21 compounds and (B) anti-proliferatïve effects of anti-miR-21 compounds in cultured cells, as described in Example 6.
Figure 7 shows the change in (A) collagen 1 Al and (B) collagen 3Al expression in kidneys of UUO model mice administered certain anti-miR-21 compounds, as described in Example 6.
DETAILED DESCRIPTION
Unless defined otherwise, ail technical and scientific terms used herein hâve the same meaning as is commonly understood by one of skill in the arts to which the invention belongs. Unless spécifie définitions are provided, the nomenclature utilized in connection with, and the procedures and techniques 20 of, analytical chemistry, synthetic organic chemistry, and médicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. In the event that there is a plurality of définitions for terms herein, those in this section prevail. Standard techniques may be used for chemical synthesis, chemical analysis, pharmaceutical préparation, formulation and delivery, and treatment of subjects. Certain such techniques and procedures may be found for example in “Carbohydrate Modifications in Antisense Research” Editcd by Sangvi and Cook, American Chemical Society, Washington D.C., 1994; and Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 18th édition, 1990; and which is hereby incorporated b y reference for any purpose. Where permitted, ail patents, patent applications, published applications and publications, GENBANK sequences, websites and other published materials referred to throughout the entirc disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. Where reference is made to a URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can change, but équivalent information can be found by searching the internet. Reference thereto évidences the availability and public dissémination of such information.
Before the présent compositions and methods are disclosed and described, it is to be understood
3S that the terminology used herein is for the purpose of describing particular embodiments only and is not intcnded to be timiting. It must be noted that, as used in the spécification and the appcnded claims, the singular forms “a,” “an” and “the include plural référents unless the context clearly dictâtes otherwise.
Définitions
S “Fibrosis” means the formation or development of excess fibrous connective tissue in an organ or tissue. In certain embodiments, fibrosis occurs as a reparativc or reactive process. In certain embodiments, fibrosis occurs in response to damage or injury. The term “fibrosis” is to bc understood as the formation or development of excess fibrous connective tissue in an organ or tissue as a reparativc or réactive process, as opposcd to a formation of fibrous tissue as a normal constituent of an organ or tissue.
“Alport Syndrome” means an inherited form of kidney disease in which an abnormal level of glomerular basement membrane (GBM) is produced, leading to interstitîal fibrosis, glomerular sclerosis and eventual loss of kidney function. The disease is also frequcntly characterized by hearing defects and ocular anomalies.
“Subject suspected of having” means a subject exhibiting one or more clinîcal indicators of a disease.
“Subject suspected of having fibrosis” means a subject exhibiting one or more clinîcal indicators of fibrosis.
“Fibroproliferative disorder” means a disorder characterized by excessive prolifération and/or activation of fibroblasts.
“Liver cancer” means a malignant tumor of the liver, either a primary cancer or metastasized cancer. In certain embodiments, liver cancer indudes, but is not limited to, cancer arising from hépatocytes, such as, for exampie, hepatomas and hepatoccllular carcinomas; fibrolamellar carcinoma; and cholangiocarcinomas (or bile duct cancer).
“Metastasis” means the process by which cancer spreads from the place at which it first arosc as a primary tumor to other locations in the body. The metastatic progression of a primary tumor reflects multiple stages, including dissociation from neighboring primary tumor cells, survival in the circulation, and growth in a secondary location.
“Ovcrall survivat time” means the time period for which a subject survives after diagnosis of or treatment for a disease. In certain embodiments, the disease is cancer. In some embodiments, overall 30 survival time is survival after diagnosis. In some embodiments, overall survivat time is survival after the start of treatment.
“Progression-frec survival” means the time period for which a subject having a disease survives, without the disease getting worse. In certain embodiments, progression-frec survival is assessed by staging or scoring the disease. In certain embodiments, progression-free survivat of a subject having liver cancer is assessed by evaluating tumor size, tumor number, and/or metastasis.
“Halts further progression” means to stop movement of a medical condition to an advanced state.
Slows further progression” means to reduce the rate at which a medical condition moves towards an advanced state.
“Impaired kidney function” means reduced kidney function, relative to normal kldney function.
“Dclay time to dialysis” means to maintain kidney function so that the need for dialysis treatment is delayed.
“Dclay time to rénal transplant” means to maintain kidney function so that the need for a kidney transplant is delayed.
“Improves kidney function” means to change kidney function toward normal limits. In certain embodiments, improved kidney function is measured by a réduction in blood urea nitrogen, a réduction in proteînuria, a réduction in albuminuria, etc.
“Improves life expectancy” means to lengthen the life of a subject by treating one or more symptoms of a disease in the subject.
“Hematuria” means the presence of red blood cells in the urine.
“Albuminuria” means the presence of excess albumin in the urine, and includes without limitation, normal albuminuria, high normal albuminuria, microalbuminuria and macroalbuminuria. Normally, the glomerular filtration permeability barri er, which is composed of podocyte, glomerular basement membrane and endothélia! cells, prevents sérum protein from leaking into urine. Albuminuria may reflect injury of glomerular permeability barrier. Albuminuria may bc calculated from a 24-hour urine sample, an ovemight urine sample or a spot-urine sample.
“High normal albuminuria” means elevated albuminuria characterized by (i) the excrétion of 15 to <30 mg of albumin into the urine per 24 hours and/or (H) an albumin/creatinînc ratio of 1.25 to <2.5 mg/mmol (or 10 to <20 mg/g) in males or 1.75 to <3.5 mg/mmol (or 15 to <30 mg/g) in fcmales.
“Microalbuminuria means elevated albuminuria characterized by (i) the excrétion of 30 to 300 mg of albumin into the urine per 24 hours and/or (ii) an albumin/creatinine ratio of 2.5 to <25 mg/mmol (or 20 to <200 mg/g) in males or 3.5 to <35 mg/mmol (or 30 to <300 mg/g) in fcmales.
“Macroalbuminuria” means elevated albuminuria characterized by the excrétion of more than 300 mg of albumin into the urine per 24 hours and/or (ii) an albumin/creatinine ratio of >25 mg/mmol (or >200 mg/g) in males or >35 mg/mmol (or >300 mg/g) in fcmales.
“Albumin/creatinine ratio” means the ratio of urine albumin (mg/dL) per urine créatinine (g/dL) and is expressed as mg/g. Albumin/creatinine ratio may be calculated from a spot-urine sample and may bc used as an estimatc of albumin excrétion over a 24 hour period.
“Estimated glomerular filtration rate (eGFR) or “Glomerular filtration rate (GFR) means a measurement of how well the kidneys are filtering créatinine, and is used as an estimate of how much blood passes through the glomeruli per minute. Normal results may range from 90-120 mL/min/1.73 m2.
Levels below 60 ml/min/1.73 m1 for 3 or more months may be an indicator chrome kidney disease.
Levels below 15 mL/min/1.73 m2 may bean indicator of kidney failure.
“Proteinuria” means the presence of an excess of sérum proteins. Proteinuria may be characterized by the excrétion of > 250 mg of protein into the urine per 24 hours and/or a urine protein to créatinine ratio of > 0.20 mg/mg. Sérum proteins elcvated in association with proteinuria include, without limitation, albumin.
“Blood urea nitrogen” or BUN” means a measure of the amount of nitrogen in the blood in the form ofurea. The liver produces urea in the urea cycle as a waste product ofthe digestion ofprotein, and the urea is removed from the blood by the lddneys. Normal human adult blood may contain between 7 to 21 mg of urea nitrogen per 100 ml (7-21 mg/dL) of blood. Measurement of blood urea nitrogen is used as an indicator of rénal health. If the kidneys are not able to remove urea from the blood normally, a subject’s BUN rises.
“End stage rénal disease (ESRD)” means the complété or almost complète failure of kidney function.
“Anti-miR” means an oligonucleotide having a nucleobase sequence complementary to a microRNA. In certain embodiments, an anti-miR is a modified oligonucleotide.
“Anti-miR-X” where “miR-X désignâtes a particular microRNA, means an oligonucleotide ' having a nucleobase sequence complementary to miR-X. In certain embodiments, an anti-miR-X is fiilly complementary to miR-X (i.e., 100% complementary). In certain embodiments, an anti-miR-X îs at least 80%, at least 85%, at least 90%, or at least 95% complementary to miR-X, In certain embodiments, an anti-miR-X is a modified oligonucleotide.
“miR-21” means the mature miRNA having the nucleobase sequence UAGCUUAUCAGACUGAUGUUGA (SEQ ID NO: 1).
“miR-21 stem-loop sequence” means the stem-loop sequence having the nucleobase sequence UGUCGGGUAGCUUAUCAGACUGAUGUUGACUGUUGAAUCUCAUGGCAACACCAGUCGAU GGGCUGUCUGACA (SEQ ID NO: 2).
“Target nucleic acid means a nucleic acid to which an oligomeric compound is designed to hybridize.
“Targeting means the process of design and sélection of nucleobase sequence that will hybridize to a target nucleic acid.
“Targeted to” means having a nucleobase sequence that will allow hybridization to a target nucleic acid.
“Target engagement” means the interaction of an oligonucleotide with the microRNA to which it is complementary, in a manner that changes the actîvity, expression or level of the microRNA. In certain embodiments, target engagement means an anti-miR interacting with the microRNA to which it is complementary, such that the actîvity of the microRNA is inhibited.
“Modulation means a perturbation of function, amount, or actîvity. In certain embodiments, modulation means an increase in function, amount, or actîvity. In certain embodiments, modulation means a decrease in function, amount, or actîvity.
“Expression” means any fonctions and steps by which a gene’s coded information is converted into structures présent and operating in a cell.
“5’ target site” means the nucleobase of a target nucleic acid which is complementary to the 3’most nucleobase of a particular oligonucleotide.
“3’ target site” means the nucleobase of a target nucleic acid which is complementary to the 5’most nucleobase of a particular oligonucleotide.
“Région” means a portion of linked nucleosides within a nucleic acid. In certain embodiments, an oligonucleotide has a nucleobase sequence that is complementary to a région of a target nucleic acid. For example, in certain such embodiments an oligonucleotide is complementary to a région of a microRNA stem-loop sequence. In certain such embodiments, an oligonucleotide is folly complementary to a région of a microRNA stem-loop sequence.
“Segment” means a smaller or sub-portion of a région.
“Nucleobase sequence” means the order of contiguous nucleobases in an oligomeric compound or nucleic acid, typically listed in a 5’ to 3’ orientation, independent of any sugar, linkage, and/or nucleobase modification.
“Contiguous nucleobases” means nucleobases immediately adjacent to each other in a nucleic acid.
“Nucleobase complementarity” means the ability of two nucleobases to pair non-covalently via hydrogen bonding.
“Complementary” means that one nucleic acid is capable of hybridizing to another nucleic acid or oligonucleotide. In certain embodiments, complementary refers to an oligonucleotide capable of hybridizing to a target nucleic acid, “Fully complementary” means each nucleobase of an oligonucleotide is capable of pairing with a nucleobase at each corresponding position in a target nucleic acid. In certain embodiments, an oligonucleotide is folly complementary to a microRNA, i.e. each nucleobase of the oligonucleotide is complementary to a nucleobase at a corresponding position in the microRNA. In certain embodiments, an oligonucleotide wherein each nucleobase has complementarity to a nucleobase within a région of a microRNA stem-loop sequence is folly complementary to the microRNA stem-loop sequence.
“Percent complementarity means the pcrcentage of nucleobases of an oligonucleotide that are complementary to an equal-length portion of a target nucleic acid. Percent complementarity is calculated by dividing the number of nucleobases of the oligonucleotide that are complementary to nucleobases at corresponding positions in the target nucleic acid by the total number of nucleobases in the oligonucleotide.
“Percent identity” means the number of nucleobases in a first nucleic acid that arc identical to nucleobases al corresponding positions in a second nucleic acid, divided by the total number of nucleobases in the first nucleic acid. In certain embodiments, the first nucleic acid is a microRNA and the second nucleic acid is a microRNA. In certain embodiments, the first nucleic acid is an oligonucleotide and the second nucleic acid is an oligonucleotide.
“Hybridize” means the annealing of complementary nucleic acids that occurs through nucleobase complementarity.
“Mismatch” means a nucleobase of a first nucleic acid that is not capable of Watson-Crick pairing with a nucleobase at a corresponding position of a second nucleic acid.
“Identical in the context of nucleobase sequences, means having the same nucleobase sequence, independent of sugar, linkage, and/or nucleobase modifications and independent of the methyl state of any pyrimidines présent.
“MicroRNA means an endogenous non-coding RNA between 18 and 25 nucleobases in length, which is the product of cleavage of a pre-microRNA by the enzyme Dicer. Exemples of mature microRNAs are found in the microRNA database known as miRBase (http://microma.sanger.ac.uk/). In certain embodiments, microRNA is abbreviated as “microRNA” or “miR.” “Pre-microRNA” or “pre-miR” means a non-coding RNA having a hairpin structure, which is the product of cleavage of a pri-miR by the double-stranded RNA-specific ribonucléase known as Drosha. “Stem-loop sequence” means an RNA having a hairpin structure and containing a mature microRNA sequence. Pre-microRNA sequences and stem-loop sequences may overlap. Examples of stem-loop sequences are found in the microRNA database known as miRBase (http://microma.sanger.ac.uk/).
“Pri-microRNA” or “pri-miR” means a non-coding RNA having a hairpin structure that is a substrate for the double-stranded RNA-specific ribonucléase Drosha.
“microRNA precursor” means a transcript that originates from a genomic DNA and that comprises a non-coding, structured RNA comprising one or more microRNA sequences. For exampie, in certain embodiments a microRNA precursor is a pre-microRNA. In certain embodiments, a microRNA
5 precursor is a pri-microRNA.
“microRNA-regulated transcript” means a transcript that is regulated by a microRNA. “Monocistronic transcript” means a microRNA precursor containing a single microRNA sequence.
“Polycistronic transcript” means a microRNA precursor containing two or more microRNA sequences.
“Seed sequence” means a nucleobase sequence comprising from 6 to 8 contiguous nucleobases of nucleobases 1 to 9 of the 5*-end of a mature microRNA sequence.
“Seed match sequence” means a nucleobase sequence that is complementary to a seed sequence, and is the same length as the seed sequence.
“Oligomeric compound” means a compound that comprises a plurality of linked monomeric subunits. Oligomeric compounds induded oligonucleotides.
“Oligonucleotide” means a compound comprising a plurality of linked nucleosides, each of which can be modified or unmodified, independent from one another.
“Naturaliy occurring intcmucleoside linkage” means a 3’ to 5’ phosphodîester linkage between nucleosides.
“Natural sugar means a sugar found in DNA (2’-H) or RNA (2’-OH).
“Intcmucleoside linkage” means a covalent linkage between adjacent nucleosides.
“Linked nucleosides” means nucleosides joined by a covalent linkage.
“Nucleobase” means a heterocyclic moiety capable of non-covalently pairing with another nucleobase.
“Nucleoside” means a nucleobase linked to a sugar moiety.
“Nucléotide” means a nucleoside having a phosphate group covalently linked to the sugar portion of a nucleoside.
Compound comprising a modified oligonucleotide consisting of’ a number of linked nucleosides means a compound that includes a modified oligonucleotide having the specified number of linked nucleosides. Thus, the compound may include additional substituents or conjugates. Unless otherwise indicated, the compound does not include any additional nucleosides beyond those of the modified oligonucleotide.
“Modified oligonucleotide” means an oligonucleotide having one or more modifications relative to a naturaliy occurring terminus, sugar, nucleobase, and/or intcmucleoside linkage. A modified oligonucleotide may comprise unmodified nucleosides.
“Single-stranded modified oligonucleotide means a modified oligonucleotide which is not hybridized to a complementary strand.
“Modified nucleoside” means a nucleoside having any change from a naturaliy occurring nucleoside. A modified nucleoside may hâve a modified sugar, and an unmodified nucleobase. A modified nucleoside may hâve a modified sugar and a modified nucleobase. A modified nucleoside may hâve a natural sugar and a modified nucleobase. In certain embodiments, a modified nucleoside is a bicyclic nucleoside. In certain embodiments, a modified nucleoside îs a non-bicyclic nucleoside.
“Modified intcmucleoside linkage” means any change from a naturaliy occurring intcmucleoside linkage.
“Phosphorothioate intcmucleoside linkage” means a linkage between nucleosides where one of the non-bridging atoms is a sulfur atom.
“Modified sugar moiety” means substitution and/or any change from a natural sugar.
“Unmodified nucleobase means the naturaliy occurring heterocyclic bases of RNA or DNA: the purine bases adenîne (A) and guanine (G), and the pyrimidine bases thymine (T), cytosïne (C) (including 5-methylcytosine), and uracil (U).
“5-methylcytosine” means a cytosïne comprising a methyl group attached to the 5 position.
“Non-methylated cytosine” means a cytosine that does not hâve a methyl group attached to the 5 position.
“Modified nucleobase” means any nucleobase that is not an unmodified nucleobase.
“Furanosyl” means a structure comprising a 5-membered ring consisting of four carbon atoms and one oxygen atom.
“Naturally occurring furanosyl” means a ribofuranosyl as found in naturally occurring RNA or a deoxyribofuranosyl as found in naturally occurring DNA.
“Sugar moiety*’ means a naturally occurring furanosyl or a modified sugar moiety.
“Modified sugar moiety” means a substituted sugar moiety or a sugar surrogate.
“Substituted sugar moiety*’ means a furanosyl that is not a naturally occurring furanosyl. Substituted sugar moieties include, but are not limited to sugar moieties comprising modifications at the 2’-position, the 5’-position and/or the 4’-position of a naturally occurring furanosyl. Certain substituted sugar moieties are bicyclic sugar moieties.
“Sugar surrogate means a structure that does not comprise a furanosyl and that is capable of replacing the naturally occurring furanosyl of a nucleoside, such that the resulting nucleoside is capable of (l) incorporation into an oligonucleotide and (2) hybridization to a complementary nucleoside. Such structures include relatively simple changes to the furanosyl, such as rings comprising a different number of atoms (e.g., 4,6, or 7-membered rings); replacement of the oxygen of the furanosyl with a non-oxygen atom (e.g., carbon, sulfur, or nitrogen); or both a change in the number of atoms and a replacement of the oxygen. Such structures may also comprise substitutions corresponding with those described for substituted sugar moieties (e.g., 6-membered carbocyclic bicyclic sugar surrogates optionally comprising additional substituents). Sugar surrogates also include more complex sugar replacements (e.g., the nonring Systems of peptide nucieic acid). Sugar surrogates include without limitation morpholinos, cyclohexenyls and cyclohexitols.
“2’-O-methyl sugar” or “2*-OMe sugar” means a sugar having a O-methyl modification at the 2’ position.
“2’-O-mcthoxyethyl sugar” or “2’-MOE sugar” means a sugar having a O-methoxyethyl modification at the 2' position.
“2’-O-fluoro” or “2’-F* means a sugar having a fluoro modification of the 2’ position.
“Bicyclic sugar moiety*’ means a modified sugar moiety comprising a 4 to 7 membered ring (including by not limited to a furanosyl) comprising a bridge connecting two atoms of the 4 to 7 membered ring to form a second ring, resulting in a bicyclic structure. In certain embodiments, the 4 to 7 membered ring is a sugar ring. In certain embodiments the 4 to 7 membered ring is a furanosyl. In certain such embodiments, the bridge connecte the 2*-carbon and the 4’-carbon of the furanosyl. Nonlimiting exemplary bicyclic sugar moieties include LNA, ENA, cEt, S-cEt, and R-cEt.
“Locked nucieic acid (LNA) sugar moiety means a substituted sugar moiety comprising a (CHj)-O bridge between the 4’ and 2’ furanose ring atoms.
“ENA sugar moiety” means a substituted sugar moiety comprising a (CHjÏj-O bridge between the 4’ and 2’ furanose ring atoms.
“Constrained ethyl (cEt) sugar moiety” means a substituted sugar moiety comprising a CH(CHj)O bridge between the 4’ and the 2' furanose ring atoms. In certain embodiments, the CH(CH3)-O bridge is constrained in the S orientation. In certain embodiments, the CH(CHj)-O is constrained in the R orientation.
“S-cEt sugar moiety” means a substituted sugar moiety comprising an S-constraîned CH(CHj)-O bridge between the 4* and the 2* furanose ring atoms.
“R-cEt sugar moiety” means a substituted sugar moiety comprising an R-constrained CH(CHî)-0 bridge between the 4' and the 2* furanose ring atoms.
“2’-O-mcthyl nucleoside” means a 2,-modified nucleoside having a 2’-O-methyl sugar modification.
“2’-O-methoxyethyl nucleoside” means a 2’-modified nucleoside having a 2’-O-methoxyethyl sugar modification. A 2’-O-methoxyethyl nucleoside may comprise a modified or unmodi fied nucleobase.
“2’-fluoro nucleoside” means a 2’-modified nucleoside having a 2’-fluoro sugar modification. A 2’-fluoro nucleoside may comprise a modified or unmodified nucleobase.
“Bicyclic nucleoside” means a 2’-modified nucleoside having a bicyclic sugar moiety. A bicyclic nucleoside may hâve a modified or unmodified nucleobase.
“cEt nucleoside” means a nucleoside comprising a cEt sugar moiety. A cEt nucleoside may comprise a modified or unmodified nucleobase.
“S-cEt nucleoside” means a nucleoside comprising an S-cEt sugar moiety.
“R-cEt nucleoside” means a nucleoside comprising an R-cEt sugar moiety.
“Non-bicyclic nucleoside” means a nucleoside that has a sugar other than a bicyclic sugar. In certain embodiments, a non-bicyclic nucleoside comprises a naturally occurring sugar. In certain embodiments, a non-bicyclic nucleoside comprises a modified sugar. In certain embodiments, a nonbicyclic nucleoside is a β-D-deoxyribonucleoside. In certain embodiments, a non-bicyclic nucleoside is a 2’-O-methoxyethyl nucleoside.
“β-D-deoxyribonucleoside” means a naturally occurring DNA nucleoside. “β-D-ribonucleoside” means a naturally occurring RNA nucleoside. “LNA nucleoside” means a nucleoside comprising a LNA sugar moiety.
“ENA nucleoside” means a nucleoside comprising an ENA sugar moiety.
“Motif’ means a pattern of modified and/or unmodified nucleobases, sugars, and/or intemucleoside linkages in an oligonucleotide. In certain embodiments, a motif is a nucleoside pattern.
“Nucleoside pattern” means a pattern of nucleoside modifications in a modified oligonucleotide or a région thereof. A nucleoside pattern is a motif that describes the arrangement of nucleoside modifications in an oligonucleotide.
“Fully modified oligonucleotide” means each nucleobase, each sugar, and/or each intemucleoside linkage is modified.
“Uniformly modified oligonucleotide” means each nucleobase, each sugar, and/or each intemucleoside linkage has the same modification throughout the modified oligonucleotide.
“Stabîlizing modification” means a modification to a nucleoside that provides enhanced stability to a modified oligonucleotide, in the presence of nucleases, relative to that provided by 2*dcoxynuclcosides linked by phosphodiester intemucleoside linkages. For example, in certain embodiments, a stabîlizing modification is a stabîlizing nucleoside modification. In certain embodiments, a stabîlizing modification is an intemucleoside linkage modification.
“Stabîlizing nucleoside means a nucleoside modified to provide enhanced nuclease stability to an oligonucleotide, relative to that provided by a 2’-dcoxynuclcoside. In one embodiment, a stabîlizing nucleoside is a 2’-modified nucleoside.
“Stabîlizing intemucleoside linkage means an intemucleoside linkage that provides improved nuclease stability to an oligonucleotide relative to that provided by a phosphodiester intemucleoside linkage. In one embodiment, a stabîlizing intemucleoside linkage is a phosphorothioate intemucleoside linkage.
“Subject” means a human or non-human animal selected for treatment or therapy. In certain embodiments, a non-human animal subject is a canine.
“Subject in need thereof’ means a subject that is identified as in need of a therapy or treatment.
“Subject suspected of having” means a subject exhibiting one or more clinical indicators of a disease.
“Administering” means providing a pharmaceuticai agent or composition to a subject, and includes, but is not limited to, administering by a medical professional and self-administering.
“Parentéral administration” means administration through injection or infusion.
Parentéral administration includes, but is not limited to, subcutancous administration, intravenous administration, and intramuscular administration.
“Subcutaneous administration” means administration just below the skin.
“Intravenous administration” means administration into a vein.
“Intracardial administration” means administration into the heart. In certain embodiments, intracardial administration occurs by way of a cathéter. In certain embodiments, intracardial administration occurs by way of open heart surgery.
“Pulmonary administration” means administration to the lungs.
“Administered concomitantly” refers to the co-administration of two or more agents in any manner in which the pharmacological effects of both are manifest in the patient at the same time.
Concomitant administration does not require that both agents be administered in a single pharmaceuticai composition, in the same dosage form, or by the same route of administration. The effects of both agents need not manifest themselves at the same time. The effects need only be overlapping for a period of time and need not be coextensive.
“Duration” means the period of time during which an activity or event continues. In certain embodiments, the duration of treatment is the period of time during which doses of a pharmaceutical agent or pharmaceutical composition are administered.
“Therapy” means a disease treatment method. In certain embodiments, therapy includes, but is not limited to, chemotherapy, radiation therapy, or administration of a pharmaceutical agent.
“Treatment” means the application of one or more spécifie procedures used for the cure or amelioration of a disease. In certain embodiments, the spécifie procedure is the administration of one or more pharmaceutical agents.
“Amelioration” means a lessening of severity of at least one indicator of a condition or disease. In certain embodiments, amelioration includes a delay or slowing in the progression of one or more indicators of a condition or disease. The severity of indicators may be determined by subjective or objective measures which are known to those skilled in the art.
”At risk for developing” means the state in which a subject is predisposed to developing a condition or disease. In certain embodiments, a subject at risk for developing a condition or disease exhibits one or more symptoms of the condition or disease, but does not exhibit a sufficient number of symptoms to be diagnosed with the condition or discase. In certain embodiments, a subject at risk for developing a condition or discase exhibits one or more symptoms of the condition or disease, but to a lesscr extent required to be diagnosed with the condition or disease.
“Prevent the onset of ’ means to prevent the development of a condition or disease in a subject who is at risk for developing the disease or condition. In certain embodiments, a subject at risk for developing the disease or condition reçoives treatment similar to the treatment received by a subject who already has the discase or condition.
“Delay the onset of’ means to delay the development of a condition or disease in a subject who is at risk for developing the disease or condition. In certain embodiments, a subject at risk for developing the disease or condition receives treatment similar to the treatment received by a subject who already has the disease or condition.
“Therapeutic agent” means a pharmaceutical agent used for the cure, amelioration or prévention of a disease.
“Dose” means a specified quantity of a pharmaceutical agent provided in a single administration. In certain embodiments, a dose may bc administered in two or more boluses, tablets, or injections. For example, in certain embodiments, where subcutaneous administration is desired, the desired dose requires a volume not easily accommodated by a single injection. In such embodiments, two or more injections may bc used to achîeve the desired dose. In certain embodiments, a dose may bc administered in two or more injections to minimize injection site réaction in an individual. In certain embodiments, a dose îs administered as a slow infusion.
“Dosage unit” means a form in which a pharmaceutical agent is provided. In certain embodiments, a dosage unit is a vial containing lyophilized oligonucleotide. In certain embodiments, a dosage unit is a vial containing reconstituted oligonucleotide.
“Therapeutically effective amount” refers to an amount of a pharmaceutical agent that provides a therapeutic benefit to an animal.
“Pharmaceutical composition” means a mixture of substances suitable for administering to an individual that includes a pharmaceutical agent. For example, a pharmaceutical composition may comprise a stérile aqueous solution.
“Pharmaceutical agent” means a substance that provides a therapeutic effect when administered to a subject.
“Active pharmaceutical ingrédient” means the substance in a pharmaceutical composition that provides a desired effect.
“Improved organ function means a change in organ function toward normal limits. In certain embodiments, organ function is assessed by measuring molécules found in a subject’s blood or urine. For example, in certain embodiments, improved liver function is measured by a réduction in blood liver transaminase levels. In certain embodiments, improved kidney function is measured by a réduction in blood urea nitrogen, a réduction in proteînuria, a réduction in albuminuria, etc.
“Acceptable safety profile” means a pattern of side effects that is within clinically acceptable limits.
“Side effect” means a physiological response attributable to a treatment other than desired effects. In certain embodiments, side effects inciude, without limitation, injection site reactions, liver function test abnormal ities, rénal function abnormalîties, liver toxicity, rénal toxicity, central nervous system abnormalities, and myopathies. Such side effects may be detected directly or indirectly. For example, increased aminotransferase levels in sérum may indicate liver toxicity or liver function abnormality. For example, increased bilirubin may indicate liver toxicity or liver function abnormality.
“Injection site reaction” means inflammation or abnormal redness of skin at a site of injection in an individual.
“Subject compliance” means adhérence to a recommended or prescribed therapy by a subject.
“Comply” means the adhérence with a recommended therapy by a subject.
“Recommended therapy” means a treatment recommended by a medical professional to treat, ameliorate, delay, or prevent a disease.
Overview miR-21 is a ubiquitously expressed microRNA that is lînked to a variety of cellular processes, including cell différentiation, prolifération, apoptosis and matrix turnover. Additionally, mîR-21 is associated with multiple diseases. miR-21 is frequently upregulated in cancer, and inhibition of miR-21 has demonstrated a réduction in tumor growth in several animal models of cancer. Inhibition of miR-21 in an animal model of cardiac hypertrophy demonstrated a rôle for miR-21 in hcart disease. A rôle in fibrosis has been demonstrated in animal models of cardiac fibrosis, kidney fibrosis, and lung fïbrosîs. A study of the inhibition of miR-21 in a tissue expiants model illustrated that the inhibition of miR-21 promotes wound healing. As such, inhibitors of miR-21 are useful in a variety of research and clinical settings.
To identify potent inhibitors of miR-21, a large number of anti-miR-21 compounds were dcsigned and synthesized. The compounds varied in length, and in the number, placement, and identity of bicyclic nucleosides and non-bicyclic nucleosides. An initial sériés of compounds was tested in an in vitro lucifcrase assay, which identified a subset of compounds as in vitro active compounds. These in vitro active compounds were then tested în in vivo assays to identify those compounds that are potent inhibitors of miR-21 in vivo. From the initial in vitro and in vivo screens, certain compounds were selected as the basis for the design ofadditional compounds. The experimentally observed corrélations between structure and activity (both in vitro and in vivo) were used to inform the design of these additional compounds, with further variations in length and sélection and arrangement of bicyclic and non-bicyclic nucleosides. The in vitro and in vivo screening assays were repeated for these additional compounds. Certain compounds were also tested for other properties, for example, susceptibility to exonuclease activity and vîscosity in solution. It was observed that the most active in vitro compounds were not ncccssarily the most active in vivo compounds, and further that some modcrately active in vitro compounds were hîghly active in vivo compounds.
Of nearly 300 compounds screened in vitro during this process, no more 145 were identified as active in the in vitro lucifcrase assay. Of these active in vitro compounds, a subset was identified as active in vivo. Through this itérative process of designing and screening compounds, it was observed that compounds having particular patterns of bicyclic and non-bicyclic modifications were potent inhibitors of miR-21 in vivo. As such, these compounds are useful for the modulation of cellular processes that are promoted by the activity of miR-21. Further, such compounds are useful for treating, preventing, and/or delaying the onset of diseascs associated with miR-21. Such diseases may be characterized by abnormally high expression of miR-21, relative to non-disease samples. Such diseascs include, but are not limited to, fibrosis, acute kidney injury, cardiac hypertrophy, myocardial infarction, and cancer. Additionally, the compositions and methods provided herein may be used to promote wound healing.
Certain Modified Oligonucleotides Targeted to miR-21
Provided herein are modified oligonucleotides having certain patterns of bicyclic and nonbicyclic nucleosides. Modified oligonucleotides having the patterns identified herein are effective inhibitors of miR-21 activity.
Each of the nucleoside patterns illustrated herein is shown in the 5’ to 3’ orientation.
In certain embodiments, provided herein are compounds comprising a modified oligonucleotide consistingof 8 to 22 linked nucleosides, wherein thenucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattem III in the 5* to 3* orientation:
(Κ)χ-Ν3-Νώ-Νώ-Νβ-(Νώ-Νώ-Νώ-Νβ)3-Νυ-Νζ wherein each R is a non-bicyclic nucleoside; X is from 1 to 4;
each Nb is a bicyclic nucleoside;
each is a non-bicyclic nucleoside;
NY îs a modified nucleoside or an unmodified nucleoside; and each Nz is a modified nucleoside.
In certain embodiments of nucleoside pattem ΠΙ, X is 1. In certain embodiments of nucleoside pattem III, X is 2. In certain embodiments of nucleoside pattem III, X is 3. In certain embodiments of nucleoside pattem ΠΙ, X is 4.
In certain embodiments, provided herein are compounds comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1 ) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattem IV in the 5’ to 3’ orientation:
NM-Na-NQ-N<î-NB-(N<ï-N<ï-N<î-NB)3-NY-Nz wherein NM is a modified nucleoside that is not a bicyclic nucleoside;
each NB is a bicyclic nucleoside;
each N^ is a non-bicyclic nucleoside;
NY îs a modified nucleoside or an unmodified nucleoside; and
Nz îs a modified nucleoside.
In certain embodiments, provided herein are compounds comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattem V in the 5’ to 3’ orientation:
NM-Na-(N<,-N<ï-NB-NB)4-Nz wherein NM is a modified nucleoside that is not a bicyclic nucleoside;
each Nb is a bicyclic nucleoside;
each bP is a non-bicyclic nucleoside; and
Nz is a modified nucleoside.
In certain embodiments, provided herein are compounds comprising a modified oligonucleotide consisting of 8 to 15 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide îs complementary to miR-21 (SEQ ID NO: 1), and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the foliowing nucleoside pattem VI in the 5’ to 3’ orientation:
N<Ï-NB-NB->1Q-<NB-NB-NQ-NQ)2-NB-NQ-NB wherein each N43 is a non-bicyclic nucleoside; and each Nb is a bicyclic nucleoside.
In certain embodiments, provided herein are compounds comprising a modified oligonucleotide consisting of 8 to 19 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 (SEQ ID NO: 1 ) and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the foliowing nucleoside pattem VII in the 5* to 3* orientation:
NM<NB-NM-NM)2-NM-{NB-NQ-NQ-NQ)2-NB-NB-NZ wherein each NM is a modified nucleoside that is not a bicyclic nucleoside;
each Nb is a bicyclic nucleoside;
each is a non-bicyclic nucleoside; and
Nz is a modified nucleoside.
The foliowing embodiments apply to any of the nucleoside patterns described herein, including nucleoside patterns ΙΠ to VII.
In certain embodiments, the modified oligonucleotide comprises at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, or 22 contiguous nucleosides of a nucleoside pattem described herein.
In certain embodiments of any of the nucleoside patterns described herein, the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to miR-21 (SEQ ID NO: 1). In certain embodiments of any of the nucleoside patterns described herein, the nucleobase sequence of the modified oligonucleotide is at least 95% complementary to miR-21 (SEQ ID NO: 1). In certain embodiments of any of the nucleoside patterns described herein, the nucleobase sequence of the modified oligonucleotide is 100% complementary to miR-21 (SEQ ID NO: 1).
In certain embodiments of any of the nucleoside patterns described herein, the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 such that position 1 of the microRNA is paired with the 3’-tenninal nucleobase of the oligonucleotide. For example:
5'-UAGCUUAUCAGACUGAÜGUUGA-3' (miR-21; SEQ ID NO: 1)
I I I I I I I I I I I I I I I I I I I
3'-ATCGAATAGTCTGACTACA-5' (an anti-miR-21; SEQ ID NO: 3);
5'-UAGCUUAUCAGACUGAUGUUGA-3'
I I I 11 I I I I I I I I I I I I I I I I I
3'-ATCGAATAGTCTGACTACAACT-5' (miR-21; SEQ ID NO: 1) (an anti-miR-21; SEQ ID NO: 4);
5'-UAGCUUAUCAGACUGAUGUUGA-3' (miR-21; SEQ ID NO: 1)
I I I I I I I I I I I I I I I
3'-ATCGAATAGTCTGAC-5' (an anti-miR-21; SEQ ID NO: 5) ;
5'-UAGCUUAUCAGACUGAUGUUGA-3' (miR-21; SEQ ID NO: 1)
I I I I I I I I I11IIIII
3'-ATCGAATAGTCTGACT-5* (an anti-miR-21; SEQ ID NO: 6) ;
5'-UAGCUUAUCAGACUGAUGUUGA-3' (miR-21; SEQ ID NO: 1)
I I I I I I I I I I I I I I I I I I
3'-ATCGAATAGTCTGACTAC-5' (an anti-miR-21; SEQ ID NO: 9);
In certain embodiments of any of the nucleoside patterns described herein, the nucleobase sequence of the modified oligonucleotide is complementary to miR-21 such that position 2 of the microRNA is paired with the 3’-terminal nucleobase of the oligonucleotide. For example:
5'-UAGCUUAUCAGACUGAUGUUGA-3' (miR-21; SEQ ID NO: 1)
I I I I I I I I I I I 1 I I I I I I
3'-TCGAATAGTCTGACTACA-5' (an anti-miR-21; SEQ ID NO: 10);
In certain embodiments of any of the nucleoside patterns described herein the nucleobase sequence of the modified oligonucleotide is complementary to miR-21, and has 1 to 3 mismatches with respect to the nucleobase sequence of miR-21. In certain embodiments, the modified oligonucleotide is complementary to miR-21, and has 1 mismatch with respect to the nucleobase sequence of miR-21. the modified oligonucleotide is complementary to miR-21, and has 2 mismatches with respect to the nucleobase sequence of miR-21. In certain embodiments, the modified oligonucleotide has the sequence of any one of SEQ ID NOs: 3 to 6,9, and 10, but with 1 or 2 nucleobase changes. For example:
5'-UAGCUUAUCAGACUGAUGUUGA-3* (miR-21; SEQ ID NO: 1)
I I I I I I I I III II
3'-ATCGAATAATCTAAC-5' (an anti-miR-21; SEQ ID NO: 7);
5'-UAGCUUAUCAGACUGAUGUUGA-3' (miR-21; SEQ ID NO: 1)
I I I I I I I I I I I I I I I I I I
3'-TTCGAATAGTCTGACTACA-5' (an anti-miR-21; SEQ ID NO: 8);
It is to be understood that, in SEQ ID NOs: 3 to 10, each “Τ’ in the sequence may independently be either a “T” nucleobase or a “LT* nucleobase, and that a compound having the sequence of any or SEQ
ID NOs: 3 to 10 may comprise ail T’s, ail U*s, or any combination of U’s and T’s. Thus, the presence of “T at various positions in SEQ ID NOs: 3 to 10 throughout the présent disclosure and in the accompanying sequence listing is not limiting with respect to whether that particular nucleobase îs a “T* or a U.
In certain embodiments of any of the nucleoside patterns described herein, each bicyclic nucleoside is independently selected from an LNA nucleoside, a cEt nucleoside, and an ENA nucleoside. In certain embodiments, the sugar moieties of at least two bicyclic nucleosides are different from one another. In certain embodiments, ail bicyclic nucleosides hâve the same sugar moieties as one another. In certain embodiments, each bicyclic nucleoside is a cEt nucleoside. In certain embodiments, each bicyclic nucleoside is an LNA nucleoside.
In certain embodiments of any of the nucleoside patterns described herein, a cEt nucleoside îs an S-cEt nucleoside. In certain embodiments of any of the nucleoside patterns described herein, a cEt nucleoside is an R-cEt nucleoside.
In certain embodiments of any of the nucleoside patterns described herein, each non-bicyclic nucleoside is independently selected from a β-D-deoxyribonucleoside, a β-D-ribonucleoside, a 2’-Omethyl nucleoside, a 2’-O-methoxy ethyl nucleoside, and a 2’-fluoronucleoside.
In certain embodiments of any of the nucleoside patterns described herein, each non-bicyclic nucleoside is independently selected from a β-D-deoxyribonucleoside, and a 2’-O-methoxyethyI nucleoside.
In certain embodiments of any of the nucleoside patterns described herein, at Ieast two nonbicyclic nucleosides comprise sugar moieties that are different from one another and are independently selected from a β-D-deoxyribonucleoside, a β-D-ribonucleosîde, a 2’-O-mcthyl nucleoside, a 2’-Omethoxyethyl nucleoside, and a 2’-fluoronucleoside.
In certain embodiments of any of the nucleoside patterns described herein, at Ieast two nonbicyclic nucleosides comprise sugar moieties that are different from one another and are independently selected from a β-D-deoxyribonucleoside and a 2’-O-methoxyethyI nucleoside.
In certain embodiments of any of the nucleoside patterns described herein, each non-bicyclic nucleoside is independently selected from a β-D-deoxyribonucleoside, a 2’-O-methyi nucleoside, and a 2’-0-methoxyethyl nucleoside.
In certain embodiments ofany ofthe nucleoside patterns described herein, each non-bicyclic nucleoside has the same type of sugar moiety and is selected from a β-D-deoxyribonucleoside, a β-Dribonucleoside, a 2’-O-methyI nucleoside, a 2’-O-methoxyethyl nucleoside, and a 2’-fluoronucleoside.
In certain embodiments of any of the nucleoside patterns described herein, each non-bicyclic nucleoside is a β-D-deoxyribonucleoside. In certain embodiments, each non-bicyclîc nucleoside îs a 2’O-methyl nucleoside.
In certain embodiments of any of the nucleoside patterns described herein, no more than 3 of the non-bicyclic nucleosides are 2’-0-methoxyethyl nucleosides. In certain embodiments, no more than 2 of the non-bicyclic nucleosides are 2’-O-methoxyethyI nucleosides. Incertain embodiments, no more than 1 of the non-bicyclic nucleosides is a 2’-0-methoxyethyI nucleoside.
In certain embodiments of any of the nucleoside patterns described herein, one non-bicyclic nucleoside is a 2’-M0E nucleoside and each other non-bicyclic nucleosides is a β-Ddeoxyribonucleoside. In certain embodiments, two non-bicyclic nucleosides arc 2’-O-mcthoxyethyl nucleosides and each other non-bicyclic nucleoside is a β-D-deoxyribonucleostde. In certain embodiments, three non-bicyclic nucleosides arc 2’-O-methoxycthyl nucleosides and each other nonbicyclic nucleoside is a β-D-deoxyribonucleoside.
In certain embodiments of any of the nucleoside patterns described herein, the 5’-most nonbicyclic nucleoside and the 3’-most non-bicyclic nucleoside are 2’-O-mcthoxyethyl nucleosides, and each other non-bicyclic nucleoside is a β-D-deoxyribonucleoside·
In certain embodiments of nucleoside pattern III, R is a modified nucleoside that is not a bicyclic nucleoside; and x is 1. In certain embodiments of nucleoside pattern III, R is a modified nucleoside that is not a bicyclic nucleoside; x is 1 ; and each N*1 is an unmodified nucleoside. In certain embodiments of nucleoside pattern III, R is a modified nucleoside that is not a bicyclic nucleoside; x is 1; each N*7 is an unmodified nucleoside; each N° is independently selected from an S-cEt nucleoside and an LNA nucleoside; and NY is selected from a β-D-deoxyribonucleoside, a 2’-O-methoxycthyl nucleoside, an ScEt nucleoside, and an LNA nucleoside. In certain embodiments of nucleoside pattern III, R is a modified nucleoside that is not a bicyclic nucleoside; x is 1; and each N^ is a β-D-deoxyribonucleoside. In certain embodiments of nucleoside pattern ΠΙ, R is a modified nucleoside that is not a bicyclic nucleoside; x is 1; each N^ is a β-D-deoxyribonucleoside; each NB is independently selected from an S20 cEt nucleoside and an LNA nucleoside; and NY is selected from a β-D-deoxyribonucleoside, a 2'-Omethoxycthyl nucleoside, an S-cEt nucleoside, and an LNA nucleoside. In certain embodiments of nucleoside pattern ΠΙ, R is a modified nucleoside that is not a bicyclic nucleoside; x is 1; each N^ is an unmodified nucleoside; each NBis an S-cEt nucleoside; and NY is selected from a β-Ddeoxyribonucleoside, a 2’-O-mcthoxyethyl nucleoside, and an S-cEt nucleoside. In certain embodiments of nucleoside pattern III, R is a modified nucleoside that is not a bicyclic nucleoside; x is 1 ; each N47 is a β-D-deoxyribonucleoside; each NB is an S-cEt nucleoside; and NY is selected from a β-Ddeoxyribonucleoside, a 2*-O-methoxyethyl nucleoside, and an S-cEt nucleoside. In certain embodiments, the modified oligonucleotide of pattern ΙΠ has a nucleobase sequence selected from SEQ ID NOs: 3 to 10, wherein each T in the sequence is independently selected from T and U.
In certain embodiments of nucleoside pattern IV, N” is a 2’-O-mcthoxyethyl nucleoside; each NB is independently selected from an S-cEt nucleoside and an LNA nucleoside; each N^ is independently selected from a β-D-deoxyribonucleoside and a 2’-O-mcthoxyethyl nucleoside; NY is selected from a 2’O-mcthoxyethyl nucleoside, an S-cEt nucleoside, an LNA nucleoside, and a β-D-deoxyribonucleoside;
and Nz is selected from a 2’-O-methoxycthyl nucleoside, an LNA nucleoside, and an S-cEt nucleoside.
In certain embodiments of nucleoside pattern IV, l^1 is a 2’-O-methoxyethyl nucleoside; each NB is an ScEt nucleoside; each N^ is independently selected from a β-D-deoxyribonucleosidc and a 2’-Omethoxycthyl nucleoside; NY is selected from a 2*-0-mcthoxycthyl nucleoside, an S-cEt nucleoside, and a β-D-deoxyribonucleoside; and Nz is selected from a 2’-O-methoxyethyl nucleoside and an S-cEt nucleoside. In certain embodiments of nucleoside pattern IV, NM is a 2*-O-methoxyethyl nucleoside; each NB is an S-cEt nucleoside; each N*1 is a β-D-deoxyribonucleoside; NY is an S-cEt nucleoside; and Nz is an S-cEt nucleoside. In certain embodiments, the modified oligonucleotide of pattern IV has a nucleobase sequence selected from SEQ ID NOs: 3 to 10, wherein each T in the sequence is independently selected from T and U.
In certain embodiments of nucleoside pattern V, NM is a 2’-0-mcthoxyethyl nucleoside; each NB is independently selected from an S-cEt nucleoside and an LNA nucleoside; each N*3 is independently selected from a β-D-deoxyribonucleoside and a 2’-0-methoxyethyl nucleoside; and Nz is selected from a 2’-0-mcthoxyethyl nucleoside, an LNA nucleoside, and an S-cEt nucleoside. In certain embodiments of nucleoside pattern V, NM is a 2’-O-methoxyethyl nucleoside; each NB is an S-cEt nucleoside; each N0 is a β-D-deoxyribonucleoside; and Nz is selected from a 2’-O-methoxyethyl nucleoside and an S-cEt nucleoside. In certain embodiments of nucleoside pattern V, NM is a 2’-0-methoxyethyl nucleoside; each Nb is an S-cEt nucleoside; each N*1 is a β-D-deoxyribonucleoside; and Nz is a 2’-0-methoxyethyl nucleoside. In certain embodiments, the modified oligonucleotide of pattern V has a nucleobase sequence selected from SEQ ID NOs: 3 to 10, wherein each T in the sequence is independently selected from T and U.
In certain embodiments of nucleoside pattern VI, each NB is an S-cEt nucleoside; and each N*1 is a 2’-O-methoxyethyl nucleoside. In certain embodiments of nucleoside pattern VI, each NB is an S-cEt nucleoside; and each N*1 is a β-D-deoxyribonucleoside. In certain embodiments, the modified oligonucleotide of pattern VI has a nucleobase sequence selected from SEQ ID NOs: 5 and 7, wherein each T in the sequence is independently selected from T and U.
In certain embodiments of nucleoside pattern VII, each NM is a 2’-0-methoxyethyl nucleoside; each NB is an S-cEt nucleoside; each N*1 is independently selected from a 2’-O-methyl nucleoside and a β-D-deoxyribonucleoside; and Nz is selected from an S-cEt nucleoside and a 2’-O-methoxyethyl nucleoside. In certain embodiments of nucleoside pattern VII, each NM is a 2’-O-methoxyethyl nucleoside; each NB is an S-cEt nucleoside; each N*1 is a β-D-deoxyribonucleoside; and Nz is an S-cEt nucleoside. In certain embodiments of nucleoside pattern VII, each NM is a 2’-0-methoxyethyl nucleoside; each NB is an S-cEt nucleoside; each N*1 is independently selected from a 2’-O-methyl nucleoside and a β-D-deoxyribonucleoside; and Nz is an S-cEt nucleoside. In certain embodiments of nucleoside pattern VII, each NM is a 2’-0-methoxyethyl nucleoside; each NB is an S-cEt nucleoside; each N*3 is independently selected from a 2*-O-methy! nucleoside and a β-D-deoxyribonucleosïde; and Nz is a 2’-O-methoxyethyl nucleoside. In certain embodiments, the modified oligonucleotide of pattern VII has a nucleobase sequence selected from SEQ ID NOs: 3 to 10, wherein each T in the sequence is independently selected from T and U.
In certain embodiments, a compound provided herein has at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, atl east 17, at least 18, or at least 19 contiguous nucleosides of a nucleobase sequence and modifications (i.e., a “structure”) as shown in Table 1. In certain embodiments, a compound provided herein has a structure selected from the structures în Table 1. Nucleosîde modifications are indicated as follows: nucleosides not followed by a subscript indicate β-D-deoxyribonucleosides; nucleosides followed by a subscript “E” indicate 2’-M0E 5 nucleosides; nucleosides followed by a subscript “M” indicate 2*-O-methyl nucleosides; nucleosides followed by a subscript “S” indicate S-cEt nucleosides. Each intemucleoside linkage is a phosphorothioate intemucleoside linkage. Superscript “Me” indicates a 5-mcthyl group on the base of the nucleosîde.
Table 1: Anti-mIR-21 compounds
Compound # | Sequence and Chemistry (5’ to 3*) | SEQ ID NO | Pattern |
25221 | AeCsATCsAGTCsTGAUsAAGCsUsAs | 3 | III, IV |
25220 | AECsATCsAsGTCsUsGAUsAsAGCsUsAE | 3 | v |
36328 | m‘Ce AsGsTeCsU sGe AeUs As AgG eCsT E As | 5 | VI |
36284 | MeCEAsAsTECsUsAEAEUsAsAEGECsTEAs | 7 | VI |
36232 | CAsGsTCsUsGAUsAsAGCsTAs | 5 | VI |
36039 | AeCsAeTeCsAeGeTeCsTGAUsAAGCsTAs | 3 | III, IV |
36730 | UsCAGsTCUsGsAUsAAsGCsUsAs | 6 | |
36731 | AeCsAeTeCsAeGeTeCsTGAUsAAGCsUsAs | 3 | III, IV, VII |
36842 | AëCsAeTeCsAeGeTeCsTGsAUsÀAsGCsUsAs | 3 | |
36843 | AeCsAeTeCsAeGeTeCsTGmAUsAAmGCsUsAs | 3 | III, IV, VII |
36844 | AeCsAeTeCsAeGeTeCsTGmAUsAAmGCsUsTe | 8 | III, IV, VII |
36845 | AeCsAeTeCsAeGeTeCsTGAmUsAmAGCsUsAs | 3 | III, IV, VII |
36846 | AeCs AeTeCs AeGeT eCsTG Am Us Am AGCsUgT E | 8 | III, IV, Vil |
36847 | AECsATCsAsGTCsUsGAUsAsAGCsUsTE | 8 | V |
36000 | AëCs ATCsAeGeT eCsTGAeUsAeAGCsUsAs | 3 | III, IV |
36001 | AeCs ATCsAGeTeCsTGAeUsAeAGCsUs As | 3 | III, IV |
36002 | AeCsATCsAGTeCsTGAeUsAeAGCsUsAs | 3 | III, IV |
36003 | AeCsATCsAGTCsTGAeUsAeAGCsUsAs | 3 | III, IV |
36004 | AeC$ AT EC$ AEGET eCsTG AeUsAeAGCs υ$τΕ | 8 | III, IV |
36005 | AeCsATCsAeGeTeCsTGAeUsAeAGCsUsTe | 8 | 111,1V |
36006 | AeCsATCsAGeTeCsTGAeUsAeAGCsUsTe | 8 | III, IV |
36007 | AeCsATCsAGTeCsTGAeUsAeAGCsUsTe | 8 | III, IV |
36008 | AeCsATCsAGTCsTGAeUsAeAGCsUsTe | 8 | III, IV |
36009 | AeCsAeTeCsAeGeTeCsTGAUsAAGCsUs | 10 | III, IV, VII |
36010 | AeCsAeTeCsAeGeTeCsTGAUsAmAGCsUs | 10 | III, IV, VII |
36011 | AeCsAeTeCsAeGeTeCsTGAmUsAAGCsUs | 10 | III, IV, VII |
36012 | CsAeTeCsAeGeTeCsTGAUsAAGCsUsAs | 9 | ΠΙ, IV, VII |
36016 | AeCsAeTeCsAeGeTCsTGAmUsAAGCsUsAs | 3 | III, IV |
36017 | AeCsAeTCsAeGeTCsTGAmUsAAGCsUsAs | 3 | III, IV |
36018 | AeCsAeTeCsAeGeTCsTGAUsAmAGCsUsAs | 3 | m,IV |
36019 | AeC$AeTCsAeGeTCsTGAU$AmAGCsUsAs | 3 | m,iv |
36020 | AeCsAeTeCsAeGeTeCsTGAmUsAmAGCsUmA$ | 3 | III, IV |
36021 | AeCsAeTeCsAeGeTeCsTGAmUsAAGCsUmAs | 3 | III, IV |
36022 | AeCsAeTeCsAeGeTCsTGAmUsAAGCsUmAs | 3 | 111,1V |
36023 | AeCsAeTCsAeGeTCsTGAmUsAAGCsUmAs | 3 | III, IV |
36024 | AeCs AeTeCs AeGeTeCsTGAUsAm AGCgU m As | 3 | III, IV |
36025 | AeCj AeT eCs AeGeTCsTG AUsAm AGCsUm As | 3 | III, IV |
36026 | AeCsAeTCsAeGeTCsTGAUsAmAGCsUmAs | 3 | III, IV |
36027 | AeCsAeTeCsAeGeTeCsTGAUsAAOCsUmAs | 3 | III, IV |
36028 | AeCsAeTeCsAeGeTCsTGAUsAAGCsUmAs | 3 | III, IV |
36029 | AeCsAeTCsAeGeTCsTGAUsAAGCsUmAs | 3 | III, IV |
36030 | AeCsAeTeCsAeGeTeCsTGAUsAAGCsUmTe | 8 | 111,1V |
36031 | AeCsAeTeCsAeGeTCsTGAUsAAGCsUmTe | 8 | 111, IV |
36032 | AeCsAeTCsAeGeTCsTGAUsAAGCsUmTe | 8 | III, IV |
36033 | AeCsATCsAsGTCsUsGAUsAmAGCsUsAs | 3 | |
36034 | AeCsATCsAsGTCsUmGAUsAmAGCsU$As | 3 | |
36035 | ÀeCs ATCsAmGTCsU mG AU$ Ay AGCsU$ A$ | 3 | 111,1V |
36040 | AeCsATCsAsGTCsTeGAUsAeAGCsUsAs | 3 | |
36041 | AeCsATCsAeGTCsTeGAUsAeAGCsUsAs | 3 | III, IV |
36045 | AeCsATeCsAeGeTeCsTGAmUsAmAGCsUsTe | 8 | III, IV |
36046 | AeCsATCsAeGeTeCsTGAmUsAmAGCsUsTe | 8 | III, IV |
36047 | AeCsATCsAGeTeCsTGAmUsAmAGCsUsTe | 8 | III, IV |
36048 | AeCsATCsAGTeCsTGAmUsAmAGCsUsTe | 8 | III, IV |
36049 | AeCsATCsAsGTCsUsGAUsAmAGCsUsTe | 8 | |
36050 | AeCsATCsAsGTCsUmGAUsAmAGCsUsTe | 8 | |
36051 | AeCsATCsAmGTCsUmGAUsAmAGCsUsTe | 8 | III, IV |
36055 | AeCsATCsAsGTCsUsGAUsAsAGCsUs | 10 | V |
36239 | AeCsATCsAsGTCsUsGAUsAeAGCsUsAs | 3 | |
36968 | AeCsAeTeCsAeGeTCsTGAUsAAGCsUsAs | 3 | III, IV |
36969 | AeCsAeTCsAeGeTCsTGAUsAAGCsUsAs | 3 | III, IV |
36970 | AeCsAeTeCsAeGeTeCsTGAUsAAGCsUsTe | 8 | III, IV, VII |
36971 | AeCsAeTeCsAeGeTCsTGAUsAAGCsUsTe | 8 | III, IV |
36972 | AeCsAeTCsAeGeTCsTGAUsAAGCsUsTe | 8 | III, IV |
36973 | AeCsATeCsAeGeTeCjTGAUsAAGCsUsAs | 3 | III, IV |
36974 | AeCsAeTCsAeGeTeCsTGAUsAAGCsU$As | 3 | III, IV |
36975 | AeCsAeTeCsAGeTeCsTGAUsAAGCsUsAs | 3 | III, IV |
36976 | AeCsAeTeCsAeGTeCsTGAUsAAGCsUsAs | 3 | III, IV |
36977 | AeCsATCsAeGeTeCsTGAUsAAGCsUsAs | 3 | III, IV |
36978 | AeCsAeTeCsAGTeCsTGAUsAAGCsUsAs | 3 | III, IV |
36979 | AeCs AeT eCs AeGTCsTGAU$ AAGCsU$Aj | 3 | III, IV |
36980 | AeC$ ATCsAGeT eCsTGAUs AAGCsUjAs | 3 | III, IV |
36981 | AeCsATCsAGTeCsTGAUsAAGCsUsAs | 3 | III, IV |
36982 | AeCjAeTeCsAeGeTeCsTGAUsAAGCsTeAs | 3 | III, IV, VII |
36984 | AeCsAeTeCsAeGeTeCsTGAUsAAGeCsUsAs | 3 | III, IV, VII |
36985 | AeCsAeTeCsAeGeTeCsTGAUsAAeGCsUsAs | 3 | III, IV, VII |
36986 | AeCs AeT eCs AeGeT eCsTG AUs Ae AGCsUs As | 3 | III, IV, VII |
36988 | AeCsAeTeCsAeGeTeCsTGAeUsAAGCsUsAs | 3 | III, IV, VII |
36989 | AeCsAeTeCsAeGeTeCsTGeAUsAAGCsUsAs | 3 | III, IV, VII |
36990 | AeCs AeTeCsAeGeTeCsTeG AUs AAGCsUsA$ | 3 | III, IV, VII |
36992 | AeCsAeTeCsAeGeTeCsTGAUsAmAGCsUsAs | 3 | III, IV, VII |
36993 | AeCs AeTeCs AeGeTeCsTG AmUs AAGCsU$As | 3 | ΠΙ, IV, VII |
36994 | AeCsATeCsAeGeTeCsTGAmUsAmAGCsUsAs | 3 | III, IV |
36995 | AeCsATCsAeGeT eCsTG AmUsAmAGCsUsAs | 3 | III, IV |
36996 | AeCsATCsAGeTeCsTGAmUsAmAGCsUsAs | 3 | III, IV |
36997 | AeCsATCsAGTeCsTGAmUsAmAGCsUsAs | 3 | III, IV |
36998 | AeCsATCsAGTCsTGAmUsAmAGCsU$As | 3 | III, IV |
36999 | AeCs ATeCs AeGeT eCsTG AeUs Ae AGCsU$As | 3 | III, IV |
In certain embodiments of any of the nucleoside patterns described herein, a modified oligonucleotide consista of 8, 9, 10, 11,12,13,14,15,16,17,18,19,20,21,or221inkednucleosides.In certain embodiments, the modified oligonucleotide comprises at least 8 linked nucleosides of a nucleoside pattern set forth în nucleoside pattern III. In certain embodiments, the modified oligonucleotide comprises at least 8 linked nucleosides of a nucleoside pattern set forth in nucleoside pattern IV. In certain embodiments, the modified oligonucleotide comprises at least 8 linked nucleosides of a nucleoside pattern set forth in nucleoside pattern V. In certain embodiments, the modified oligonucleotide comprises at least 8 linked nucleosides of a nucleoside pattern set forth in nucleoside pattern VI. In certain embodiments, the modified oligonucleotide comprises at least 8 linked nucleosides of a nucleoside pattern set forth in nucleoside pattern VII,
In certain embodiments, a modified oligonucleotide having any of the nucleoside patterns described herein comprises at least one modified intemucleoside linkage. In certain embodiments, each 5 intemucleoside linkage is a modified intemucleoside linkage. In certain embodiments, the modified intemucleoside linkage is a phosphorothioate intemucleoside linkage.
In certain embodiments, a modified oligonucleotide has a nucleobase sequence wherein at least one nucleobase is a cytosine. In certain embodiments, at least one cytosine is a 5-methyl cytosine. In certain embodiments, each cytosine is a 5-methyl cytosine. In certain embodiments, at least one nucleoside comprises a modified nucleobase.
Modified oligonucleotides may undergo cleavage by exonucleases and/or endonucleases at various positions throughout the modified oligonucleotide. The products of such cnzymatic cleavage may retain miR-21 inhibitory activity, and as such are considered active métabolites. As such, a metabolic product of a modified oligonucleotide may be used in the methods described herein.
In certain embodiments, a modified oligonucleotide targeted to miR-21 has a nucleoside pattern selected from Table 2A, where NM is a modified nucleoside that is not a bicyclic nucleoside; each NB is a bicyclic nucleoside; each is a non-bicyclic nucleoside; NY is a modified nucleoside or an unmodified nucleoside; and Nz is a modified nucleoside.
Table 2A: Metabolic Products of Nucleoside Pattern IV
5’ | 3’ | |||||||||||||||||
Nm | Nu | Nu | N^ | nb | b^ | NU | Nu | Nv | N2 | |||||||||
Nu | bP | Nu | Nb | bP | Nu | Nu | Nv | N2 | ||||||||||
Nu | N^ | Nu | b^ | N^ | N° | Nu | N^ | Nu | Nv | N2 | ||||||||
Nu | M* | N^ | Nu | N^ | N^ | Nu | Nu | Nv | N2 | |||||||||
Nu | Nu | Nu | N^ | Nu | Nv | N2 | ||||||||||||
Nu | Nu | Nu | Nv | N2 | ||||||||||||||
N^ | Nu | N^ | N^ | Nu | Nu | Nv | N2 | |||||||||||
Nu | bP | Nu | bP | Nu | Nv | N2 | ||||||||||||
Nu | N^ | Nu | Nu | Nv | N2 | |||||||||||||
b^ | Nu | N^ | Nu | Nv | N2 | |||||||||||||
Nu | b^ | b^ | Nu | Nv | N2 | |||||||||||||
Nu | Nü | Nv | N2 | |||||||||||||||
Nm | Nu | N^ | Nu | Nu | Nu | Nü | Nv | |||||||||||
“n” | Nu | N^ | Nu | n'J | Nu | bP | N8 | Nu | ||||||||||
Nu | Nu | Nu | n’J | Nu | Nu | Nv | ||||||||||||
Nu | Nu | n’J | Nu | n'J | Nu | Nu | ||||||||||||
Ny | 1^ | Nü | bP | Nu | Nu | Nu | Nv |
Nb | b^ | Nb | br | bF | br | Nb | bF | bF | bF | Nb | ||||||||
b^ | Nb | l^1 | Nb | Nb | b^ | N42 | N42 | Nb | Nv | |||||||||
Nb | ν<; | Nb | Nb | b/2 | n42 | N42 | Nb | |||||||||||
Nb | Nu | N° | Nb | ν’2 | n42 | N42 | Nb | Nv | ||||||||||
Nb | Nb | N*2 | Nb | b/2 | N42 | N42 | Nb | |||||||||||
b^ | Nb | b^ | Nb | N*2 | N42 | N42 | Nb | Nv | ||||||||||
Nb | Nb | N*2 | N42 | N42 | Nb | |||||||||||||
l^1 | Nb | Nb | N*2 | N42 | N42 | Nb | Nv | |||||||||||
Nb | b^ | N0 | Nb | N42 | N42 | N42 | Nb | |||||||||||
« | Nb | Nb | N42 | N42 | N42 | Nb | Nv | |||||||||||
Nb | 1^ | Nb | N42 | N42 | N42 | Nb | ||||||||||||
Nb | Nb | N42 | N42 | n42 | Nb | Nv | ||||||||||||
Nb | Nu | N42 | N42 | N42 | Nb | |||||||||||||
1^ | b^ | Nb | N42 | N42 | N42 | Nb | Nv | |||||||||||
Nb | N42 | N42 | N42 | Nb | ||||||||||||||
N0 | Nb | N42 | N42 | N42 | Nb | Nv |
In certain embodiments, a modified oligonucleotide targeted to miR-21 has a nucleoside pattern selected from Table 2B, where NM is a modified nucleoside that is not a bicyclic nucleoside; each NB is a bicyclic nucleoside; each N*3 is a non-bicyclic nucleoside; and Nz is a modified nucleoside.
Table 2B: Metabollc Products of Nucleoside Pattern V
5’ | 3’ | |||||||||||||||||
nm | Nb | N42 | N42 | bF | Nb | N42 | N42 | Nb | Nb | N42 | N42 | Nb | Nb | Nu | Nu | Nz | ||
Nu | N42 | N42 | Nb | Nu | N42 | N42 | Nb | Nb | N42 | N42 | Nb | N11 | Nu | Nu | Nz | |||
N42 | N42 | Nb | Nb | N42 | Nb | Nb | N42 | N42 | Nb | Nu | Nu | Nu | N2 | |||||
N42 | Nb | Nb | N42 | N42 | Nb | Nb | N42 | N42 | Nb | Nu | Nu | Nu | N2 | |||||
Nb | Nb | N42 | N42 | Nb | Nb | N42 | N42 | Nb | Nb | FF | Nu | N2 | ||||||
Nb | N42 | N42 | Nb | Nb | N42 | N42 | Nb | Nu | Nu | Nb | N2 | |||||||
N42 | N42 | Nb | Nb | N42 | N42 | Nb | Nu | Nu | Nb | N2 | ||||||||
N42 | N11 | N11 | N42 | N42 | Nb | Nu | bP | Nb | Nu | N2 | ||||||||
Nb | Nb | N42 | N42 | Nb | Nu | Nu | Nb | N2 | ||||||||||
Nb | N42 | N42 | Nb | Nu | b^ | Nu | Nb | N2 | ||||||||||
N42 | N42 | Nu | Nu | Nu | Nb | N2 | ||||||||||||
N42 | Nb | Nu | Nu | Nb | N2 | |||||||||||||
bF | Nb | N42 | N42 | Nu | Nb | N42 | N42 | Nb | Nb | N42 | N42 | Nb | Nu | Nu | Nb | |||
IF | Nb | N42 | N42 | Nu | Nb | N42 | N42 | Nu | Nu | N42 | N42 | Nb | Nu | Nu |
bF | N^ | N^ | hF | FF | N^ | N^ | FF | Nu | N®- | FF | FF | FF | FF | bF | ||||
N11 | N^ | N^ | Nu | Nu | n’J | N^ | Nu | Nu | N° | Nu | Nu | N^ | N^ | Nu | ||||
b^ | Nu | Nu | NU | Nu | N^ | N^ | Nu | Nu | N^ | Nu | Nu | |||||||
N^ | N^ | Nu | Nu | N^ | N^ | Nu | Nu | N^ | N^ | Nu | Nu | N^ | N^ | Nu | ||||
N^ | Nb | Nu | N^ | Nb | Nu | N^ | N^ | Nu | Nu | N^ | N^ | Nü | Nu | |||||
N° | Nu | Nu | N^ | Nb | Nu | N^ | N^ | Nu | Nu | N^ | b^ | Nb | ||||||
Nu | Nu | N^ | N^ | Nu | Nu | N° | N^ | Nu | Nu | N^ | N^ | Nu | Nu | |||||
Nu | Nu | N^ | N^ | Nu | Nu | N^ | N^ | Nü | Nu | bP | N^ | Nu | ||||||
Nu | N^ | N^ | Nu | Nu | N^ | N^ | Nu | Nu | N^ | b^ | Nu | Nu | ||||||
Nu | N^ | N^ | Nu | Nu | N^ | Nu | Nu | N^ | N^ | Nu | ||||||||
N^ | N^ | Nu | Nu | N^ | Nu | N11 | l^1 | N^ | Nu | Nu | ||||||||
N^ | Nü | Nu | n’J | N^ | Nu | Nu | N^ | N^ | Nu | |||||||||
N^ | Nu | Nu | N^ | N^ | Nu | Nu | N^ | N^ | Nu | Nu | ||||||||
Nu | Nu | N^ | Nu | Nu | Nu | |||||||||||||
Nu | Nu | N^ | Nb | Nu | N^ | N^ | Nü | Nu | ||||||||||
Nu | Nu | N^ | Nu | Nu | N^ | N^ | Nu | |||||||||||
NU | N^ | N^ | Nu | Nu | b^ | Nu | Nb | |||||||||||
N^ | N^ | N^ | Nu | Nu | b^ | Nu | ||||||||||||
N^ | Nu | Nu | N0 | 1^ | Nu | Nu |
In certain embodiments, a modified oligonucleotide targeted to miR-21 has a nucleoside pattern selected from Table 2C, where each NB îs a bicyclic nucleoside; and each N** îs a non-bicyclic nucleoside.
Table 2C: Metabollc Products of Nucleoside Pattern VI
5’ | 3’ | |||||||||||||
b^ | Nu | Nu | N^ | Nb | Nu | N^ | Nu | Nu | N^ | N^ | Nu | N^ | Nu | |
Nu | Nu | b^ | Nu | Nu | N^ | N^ | Nu | Nu | N^ | N^ | Nu | N^ | Nu | |
Nu | Nb | Nu | N^ | Nu | Nu | Nb | Nü | |||||||
N^ | Nu | Nu | b^ | Nu | Nu | N^ | N^ | Nu | bP | Nu | ||||
Nu | Nu | N^ | N^ | Nü | Nu | N^ | bP | Nu | Nu | |||||
Nu | N^ | N^ | Nu | Nu | N^ | N^ | Nu | N^ | Nu | |||||
N^ | N^ | Nu | Nu | N^ | N^ | Nu | N^ | Nu | ||||||
N^ | Nu | Nu | N^ | N^ | Nu | N^ | Nu | |||||||
Nu | Nu | Nu | Nu | N° | N^ | Nu | Nu | N° | Nu | N^ | ||||
N^ | Nu | Nu | N^ | Nu | Nu | Nu | Nu | N^ | N^ | Nu | ||||
Nu | Nu | N^ | Nu | Nu | Nu | Nu | N° | N^ | Nu |
7F | TF | 7F | 7F | TF | 7F | TF | FF | 7F | 7F | |||||
Nu | n’J | Nu | Nu | Nu | Nu | Nu | ||||||||
Nu | Nu | Nu | N*’ | Nu | Nu | Nu | ||||||||
Nu | Nu | Nu | Nu | Nu | ||||||||||
Nu | Nu | Nu | Nu | N0 | Nu | |||||||||
TF | TF | Nu | Nu | 1^ | Nu | |||||||||
Nu | Nu | Nü | Nu | N^ | Nb | |||||||||
Nu | Nu | Nu | Nu | |||||||||||
Nu | Nu | Nu | Nu | |||||||||||
Nu | Nu | Nü | N** |
In certain embodiments, a modified oligonucleotide targeted to miR-21 has a nucleoside pattern selected from Table 2D, where NM is a modified nucleoside that is not a bicyclic nucleoside; each NB is a bicyclic nucleoside; each N9 is a non-bicyclic nucleoside; and Nz is a modified nucleoside.
Table 2D: Metabollc Products of Nucleoside Pattern VII
5’ | 3’ | |||||||||||||||||
7F | n“ | 7F | 7F | Nu | 7F | 7F | 7F | Nu | Nu | Nu | Nu | Nz | ||||||
Nu | 7F | 7F | Nu | 7F | 7F | 7F | Nu | N° | Nu | n'J | Nu | Nu | Nz | |||||
7F | 7F | nl | 7F | 7F | 7F | Nu | Nu | b^ | Nu | Nu | Nz | |||||||
7F | Nu | 7F | 7F | 7F | Nu | N0 | Nu | Nu | Nu | Nz | ||||||||
Nu | nm | nm | nm | Nu | bP | Nu | b^ | Nu | Nu | Nz | ||||||||
7F | nm | 7F | Nu | N° | N^ | Nu | Nu | Nü | N2 | |||||||||
7F | 7F | Nu | Nu | N0 | Nb | Nu | Nz | |||||||||||
nm | Nu | Nu | bP | Nu | Nu | Nz | ||||||||||||
Nu | Nu | Nu | Nu | Nz | ||||||||||||||
Nu | Nu | Nu | Nz | |||||||||||||||
Nu | Nu | Nu | Nz | |||||||||||||||
n“ | Nu | Nb | Nz | |||||||||||||||
7F | 7F | 7F | 7F | Nu | 7F | 7F | 7F | Nu | Nu | Nu | Nu | |||||||
7F | Nu | 7F | 7F | Nu | 7F | 7F | 7F | Nu | Nü | b^ | Nu | |||||||
Nu | 7F | 7F | Nu | 7F | nm | 7F | Nü | Nu | Nu | Nu | ||||||||
Nu | 7F | 7F | Nu | 7F | 7F | 7F | Nu | Nu | Nu | |||||||||
7F | 7F | Nu | 7F | 7F | nm | Nu | Nu | Nu | Nu | |||||||||
nm | nm | Nu | nm | nm | 7F | Nu | N° | Nu | bP | Nu | ||||||||
7F | Nu | 7F | 7F | 7F | Nu | Nu | bP | Nu | Nu | |||||||||
7F | Nu | 7F | 7F | 7F | NU | Nu | Nu |
N“ | Nm | Nm | nm | Nu | N^ | N^ | Nu | NB | NU | |||||||||
Nu | FF | FF | FF | Nu | hP | Nu | N^ | Nu | ||||||||||
FF | FF | FF | Nu | N^ | N^ | Nu | n'J | Nu | Nu | |||||||||
Nw | nm | nm | Nu | N^ | Nu | N^ | Nu | |||||||||||
FF | FF | Nu | N^ | Nu | N^ | N^ | Nu | Nu | ||||||||||
FF | FF | Nu | N° | Nu | N^ | N^ | N^ | Nu | ||||||||||
FF | Nu | N^ | N^ | l^1 | Nu | N^ | N^ | N11 | Nu | |||||||||
FF | nu | Nu | N^ | NU | ||||||||||||||
n“ | Nu | n'J | l^1 | N11 | Nu | |||||||||||||
nu | 1^ | Nu | N^ | N^ | Nu | |||||||||||||
N^ | Nu | 1^* | N^ | N^ | Nu | Nu | ||||||||||||
hP | N^ | NU | N^ | hP | N^ | NU | ||||||||||||
hP | N^ | Nu | N^ | N^ | Nu | Nu |
In certain embodiments, a modified oligonucleotide targeted to mîR-21 has a nucleoside pattem and nucleobase sequence selected from Table 3A, Table 3B, Table 3C, Table 3D, Table 3D, or Table 3E. Nucleosides not followed by a subscript indicate β-D-deoxyribonucleosides. Nucleosides followed by a 5 subscript “E” indicate 2’-M0E nucleosides. Nucleosides followed by a subscript “S” indicate S-cEt nucleosides. Each intemucleoside linkage is a phosphorothioate intemucleoside linkage. Nucleobases may or may not comprise a methyl group at the 5* position.
Table 3A: Metabollc products of compound # 25221
5’ | 3’ | SEQ IDNO | |||||||||||||||||
N, | n2 | Nj | n4 | Nj | n6 | n7 | Ng | N, | Nio | Nu | NtI | N13 | Nl4 | Nl3 | Nu | Nu | N» | N,, | |
Ae | Cs | A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
Cs | A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 9 | |
A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 17 | ||
T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 18 | |||
Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 19 | ||||
A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 20 | |||||
G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 21 | ||||||
T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 22 | |||||||
Cs | T | G | A | Us | A | A | G | Cs | Us | As | 23 | ||||||||
T | G | A | Us | A | A | G | Cs | Us | As | 24 | |||||||||
G | A | Us | A | A | G | Cs | Us | As | |||||||||||
A | Us | A | A | G | Cs | Us | As |
Ae | Cs | A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | 25 | |
Ae | Cs | A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | 26 | ||
Cs | A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | 27 | ||
Cs | A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | 28 | |||
A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | 29 | |||
A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | 30 | ||||
T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | 31 | ||||
T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | 32 | |||||
Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | 33 | |||||
Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | 34 | ||||||
A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | 35 | ||||||
A | G | T | Cs | T | G | A | Us | A | A | G | Cs | 36 | |||||||
G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | 37 | |||||||
G | T | Cs | T | G | A | Us | A | A | G | Cs | 38 | ||||||||
T | Cs | T | G | A | Us | A | A | G | Cs | Us | 39 | ||||||||
T | Cs | T | G | A | Us | A | A | G | Cs | 40 | |||||||||
Cs | T | G | A | Us | A | A | G | Cs | Us | 41 | |||||||||
Cs | T | G | A | Us | A | A | G | Cs | |||||||||||
T | G | A | Us | A | A | G | Cs | Us | |||||||||||
T | G | A | Us | A | A | G | Cs | ||||||||||||
G | A | Us | A | A | G | Cs | Us |
Table 3B: Metabolic products of compound # 25220
5’ | 3’ | SEQ ID NO | |||||||||||||||||
N» | N: | Nj | N< | Nj | Ne | N, | N, | N, | Nio | N„ | Nu | Nu | Nu | Nu | Nie | Nn | N„ | N,9 | |
Ae | Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 3 |
Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 9 | |
A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 17 | ||
T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 18 | |||
Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 19 | ||||
As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 20 | |||||
G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 21 | ||||||
T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 22 | |||||||
Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 23 |
Us | G | A | Us | As | A | G | Cs | Us | Ae | 24 | |||||||||
G | A | Us | As | A | G | Cs | Us | Ae | |||||||||||
A | Us | As | A | G | Cs | Us | Ae | ||||||||||||
Ae | Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | 25 | |
Ae | Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | 26 | ||
cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | 27 | ||
Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | 28 | |||
A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | 29 | |||
A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | 30 | ||||
T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | 31 | ||||
T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | 32 | |||||
Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | 33 | |||||
Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | 34 | ||||||
As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | 35 | ||||||
As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | 36 | |||||||
G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | 37 | |||||||
G | T | Cs | Us | G | A | Us | As | A | G | Cs | 38 | ||||||||
T | Cs | Us | G | A | Us | As | A | G | Cs | Us | 39 | ||||||||
T | Cs | Us | G | A | Us | As | A | G | Cs | 40 | |||||||||
Cs | Us | G | A | Us | As | A | G | Cs | Us | 41 | |||||||||
Cs | Us | G | A | Us | As | A | G | Cs | |||||||||||
Us | G | A | Us | As | A | G | Cs | Us | |||||||||||
Us | G | A | Us | As | A | G | Cs | ||||||||||||
G | A | Us | As | A | G | Cs | Us |
Table 3C: Metabotic products of compound # 36284
5’ | 3’ | SEQID NO | |||||||||||||
N, | n2 | Nj | N< | n3 | n6 | n7 | Ng | N, | NI0 | Nn | N« | Nu | N|4 | Nu | |
“**cT | As | As | TE | Cs | Us | Ae | Ae | Us | As | AE | Ge | Cs | Te | As | 7 |
As | As | Te | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | As | 42 | |
As | Te | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | As | 43 | ||
Te | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | As | 44 | |||
Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | As | 45 | ||||
Us | Ae | Ae | Us | As | Ae | ge | Cs | Te | As | 46 | |||||
Ae | Ae | Us | As | Ae | Ge | Cs | Te | As |
Ae | Us | As | Ae | Ge | Cs | TE | As | ||||||||
m‘Ce | As | As | TE | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | 47 | |
m‘Ce | As | As | Te | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | 48 | ||
As | As | TE | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | 49 | ||
As | As | TE | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | 50 | |||
As | Te | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | 51 | |||
As | Te | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | 52 | ||||
Te | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | 53 | ||||
Te | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | 54 | |||||
Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | 55 | |||||
Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | |||||||
Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | |||||||
Us | Ae | Ae | Us | As | Ae | Ge | Cs | ||||||||
Ae | Ae | Us | As | Ae | Ge | Cs | Te |
Table 3D: Metabolic products of compound # 36039
5’ | 3’ | SEQ IDNO | |||||||||||||||||
N, | n2 | Nj | n4 | Nj | n6 | NT | Ng | N, | Nio | Nu | Nu | Nu | Nu | Nu | Nu | Nu | N« | N19 | |
Ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | As | 3 |
Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | As | 9 | |
Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | As | 17 | ||
Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | As | 18 | |||
Cs | ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | As | 19 | ||||
Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | As | 20 | |||||
Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | As | 21 | ||||||
Te | Cs | T | G | A | Us | A | A | G | Cs | T | As | 22 | |||||||
Cs | T | G | A | Us | A | A | G | Cs | T | As | 23 | ||||||||
T | G | A | Us | A | A | G | Cs | T | As | 24 | |||||||||
G | A | Us | A | A | G | Cs | T | As | |||||||||||
A | Us | A | A | G | Cs | T | As | ||||||||||||
Ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | 25 | |
Ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 26 | ||
Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | 27 | ||
Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 28 | |||
Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | 29 |
Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 30 | ||||
Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | 31 | ||||
Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 32 | |||||
Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | 33 | |||||
Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 34 | ||||||
Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | 35 | ||||||
Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 36 | |||||||
Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | T | 37 | |||||||
Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 38 | ||||||||
Te | Cs | T | G | A | Us | A | A | G | Cs | T | 39 | ||||||||
Te | Cs | T | G | A | Us | A | A | G | Cs | 40 | |||||||||
Cs | T | G | A | Us | A | A | G | Cs | T | 41 | |||||||||
Cs | T | G | A | Us | A | A | G | Cs | |||||||||||
T | G | A | Us | A | A | G | Cs | T | |||||||||||
T | G | A | Us | A | A | G | Cs | ||||||||||||
G | A | Us | A | A | G | Cs | T |
Table 3E: Metabolic products of compound # 36731
5’ | 3’ | SEQ ID NO | |||||||||||||||||
Ni | Nj | Nj | n4 | Nj | N6 | n7 | Ng | N, | Nio | Nu | Nu | N13 | N|4 | Nu | N,* | Nl7 | N,, | Ni, | |
Ae | Cs | Ae | Te | Cs | Ae | Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 9 | |
Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 17 | ||
Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 18 | |||
Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 19 | ||||
Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 20 | |||||
Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 21 | ||||||
Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 22 | |||||||
Cs | T | G | A | Us | A | A | G | Cs | Us | As | 23 | ||||||||
T | G | A | Us | A | A | G | Cs | Us | As | 24 | |||||||||
G | A | Us | A | A | G | Cs | Us | As | |||||||||||
A | Us | A | A | G | Cs | Us | As | ||||||||||||
Ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | 25 | |
Ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 26 |
Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | 27 | ||
Cs | Ae | TE | Cs | Ae | Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | 28 | |||
Ae | Te | Cs | Ae | Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | Us | 29 | |||
Ae | TE | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 30 | ||||
TE | Cs | Ae | Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | Us | 31 | ||||
TE | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 32 | |||||
Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | 33 | |||||
Cs | Ae | Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | 34 | ||||||
Ae | Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | Us | 35 | ||||||
Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 36 | |||||||
Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | Us | 37 | |||||||
Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | 38 | ||||||||
Te | Cs | T | G | A | Us | A | A | G | Cs | Us | 39 | ||||||||
TE | Cs | T | G | A | Us | A | A | G | Cs | 40 | |||||||||
Cs | T | G | A | Us | A | A | G | Cs | Us | 41 | |||||||||
Cs | T | G | A | Us | A | A | G | Cs | |||||||||||
T | G | A | Us | A | A | G | Cs | Us | |||||||||||
T | G | A | Us | A | A | G | Cs | ||||||||||||
G | A | Us | A | A | G | Cs | Us |
In certain embodiments, a modified oligonucleotide consists of greatcr than 19 linked nucleosides, and comprises a nucleoside pattern described herein. The nucleosides that are présent in addition to the nucleosides described by the nucleoside pattern are either modified or unmodified. For example, a modified oligonucleotide consisting of 21 linked nucleosides and having a nucleobase sequence complementary to miR-21 may hâve nucleoside pattern IV, V, or VII, which is 19 linked nucleosides in length, or may hâve nucleoside pattern VI, which is 15 nucleosides in length, or may hâve nucleoside pattern III, which may be 19 to 22 nucleosides in length. The additional nucleosides may be comprised of modified or unmodified sugar moieties. In certain embodiments, a modified oligonucleotide consists of
19 linked nucleosides and comprises any of the nucleoside patterns described herein. In certain embodiments, a modified oligonucleotide consists of 20 linked nucleosides and comprises any of the nucleoside patterns described herein. In certain embodiments, a modified oligonucleotide consists of 21 linked nucleosides and comprises any of the nucleoside patterns described herein. In certain embodiments, a modified oligonucleotide consists of 22 linked nucleosides and comprises any of the nucleoside patterns described herein. In certain embodiments, a modified oligonucleotide consists of 23 linked nucleosides and comprises any of the nucleoside patterns described herein. In certain embodiments, a modified oligonucleotide consists of 24 linked nucleosides and comprises any of the nucleoside patterns described herein. In certain embodiments, a modified oligonucleotide consists of 25 linked nucleosides and comprises any of the nucleoside patterns described herein.
Certain Uses of the Invention
Modulation of miR-21 Activity
The compounds provided herein are potent and spécifie inhibitors of miR-21 activity, and are thus useful for modulating miR-21 activity.
MicroRNAs bind to and repress the expression of messenger RNAs. In certain instances, inhibiting the activity of a microRNA leads to de-repression of the messenger RNA, i.e. the messenger RNA expression is increased at the level of RNA and/or protein. Provided herein are methods for modulating the expression of a miR-21-regulated transcript, comprising contacting a cell with a compound ofthe invention, wherein the compound comprises a modified oligonucleotide having a sequence complementary to a miR-21.
In certain embodiments, a miR-21-regulated transcript is YODl, and inhibition of miR-21 results in an increase in the level of YODl mRNA. In certain embodiments, a miR-21 regulated transcript is PPAR-alpha, and inhibition of miR-21 results in an increase in the level of PPAR-alpha mRNA. In certain embodiments, a miR-21-regulated transcript is RNF167.
In certain embodiments, a miR-21-regulated transcript is SPG20. In certain embodiments, inhibition of miR-21 in the liver results in an increase in the level of SPG20 mRNA.
In certain embodiments, following contacting a cell with a compound of the invention, an at least
1,5-fold increase in the mRNA level of a miR-21-regulated transcript is observed. In certain embodiments, following contacting a cell with a compound of the invention, an at least 2.0-fold increase in the mRNA level of a miR-21 -regulated transcript is observed. In certain embodiments, the mRNA level of the microRNA-regulated transcript increases at least 2.5-fold. In certain embodiments, the mRNA level ofthe microRNA-regulated transcript increases at least 3.0-fold. In certain embodiments, the mRNA level ofthe microRNA-regulated transcript increases at least 3.5-fold. In certain embodiments, the mRNA level ofthe microRNA-regulated transcript increases at least 4.0-fold. In certain embodiments, the mRNA level of the microRNA-regulated transcript increases at least 4.5-fold. In certain embodiments, the mRNA level of the microRNA-regulated transcript increases at least 5.0fold.
Certain microRNAs are known to target several messenger RNAs, in some cases hundreds of messenger RNAs. Inhibiting the activity of a single microRNA can lead to détectable changes in expression of many of the microRNAs targets. Provided herein are methods for modulating multiple miR-21 -regulated transcripts, comprising inhibiting the activity of miR-21, wherein broad gene expression changes occur.
In certain embodiments, phenotypic changes may be observed following inhibition of a miR-21 with a compound of the invention. Such phenotypic changes may occur with or without détectable changes in the expression of a miR-21 -regulated transcript.
Diseases and Disorders
A normal physiological response to damage or injury in an organ or tissue involves repair of the damaged tissue, which is a fondamental biological process necessary for survival. During the repair process, after foreign materials, bacteria, and damaged tissue are eliminated, fibroblasts migrate in to the site of injury to deposit new cxtraccllular matrix, which then becomes structurally organized as part of the tissue remodeling phase.
Fibroblasts are the most common cells found in connective tissue, and are responsible for the synthesis of reticulin and other clastic fibres which support the cxtracellular matrix and play an important part in normal wound healing (Sempowski, G.D. et al., 2002. Wound Repair Régénération. 3: 120-131). Fibroblasts are responsible for the déposition of collagen, which is necessary to repair injured tissue and restore its structure and function. During the wound-healing process, activated fibroblasts are transformed into myo fibroblasts, which are collagen-secrcting alpha-SMA+ fibroblasts. In the initial stages of the wound-healing process, myofibroblaste produce matrix métalloprotéases, which disrupt the basement membrane and permit inflammatory cells to bc efticiently recruited to the site of injury. During the later stages of injury repair, myofibroblaste promotc wound contraction, the process by which the edges of the wound migrate toward the center of the wound. Thus, fibroblast actîvity is essential to the normal healing process.
Fibroblasts that participate in the normal injury repair process may bc derived from local mesenchymal cells, recruited from the bone marrow, or derived by cpithclial-mesenchymal transition. Epithelial-mesenchymal transition (EMT) describes a sériés of rapid changes of cell phenotype (Kalluri, R. andNcilson, E.G. 2003. J. Clin. Invest. 112: 1776-1784) during which static épithelial cells losecellcell contacts, acquire mesenchymal features and manifest a migratory phenotype. Résident fibroblasts, infiltrating fibrocytes or pericyte-like cells may also participate in the injury repair process.
Under some conditions, the tissue repair process occurs in excess, resulting an excessive accumulation of cxtracellular matrix (ECM) components and substantial remodeling of the ECM, which contributc to the formation of a permanent fibrotic scar. The formation of this excess fïbrous connective tissue, a process known as fibrosis, contributes to abnormal changes in tissue architecture and interfères with normal organ function.
Fibrosis can occur in any part of the body, and can resuit from a variety of physical, metabolic, ischémie, infectious, inflammatory or immunologîcal injuries. Although the anatomical locations, origins, and clinical manifestations of fibrosis may be diverse, there are important pathological features common to all types of fibrosis. Regardless of the location in which fibrosis occurs, the fibrotic process involves the sécrétion and activation of pro fibrotic cytokines, the expansion and activation of mesenchymal cell populations, and cxtracellular matrix synthesis and organization, and ultimately Ieads to the destruction of normal tissue. Left untrcated, fibrosis can lead to a variety of conditions of the heart, lungs, kidney, liver, eye, and skin, among other tissues.
As demonstrated herein, the inhibition of miR-21 in a model of fibrosis led to decreased collagen déposition. Accordingly, provided herein are methods for treating, preventing, and/or delaying the onset of fibrosis, comprising administering a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is complementary to miR-21, to a subject. Also provided herein are compositions for treating, preventing, and/or delaying the onset of fibrosis, comprising a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is complementary to miR21, to a subject. The subject may hâve received a diagnosis of fibrosis, may be at risk for developing fibrosis, or may be suspected of having fibrosis.
In certain embodiments, a subject having fibrosis has kidney fibrosis, lung fibrosis, liver fibrosis, cardiac fibrosis, skin fibrosis, age-related fibrosis, spleen fibrosis, scleroderma, or post-transplant fibrosis.
Many diseases or abnormalities of the kidney are characterized by the presence of fibrosis. As such, the compounds provided herein are useful for treating, ameliorating, preventing, and/or delaying the onset of any kidney disease that is characterized by the presence of fibrosis. In certain embodiments, a subject having fibrosis has a kidney disease or condition. In certain embodiments, a subject at risk for developing fibrosis has a kidney disease or condition. In certain embodiments, a subject suspected of having fibrosis has a kidney discase or condition. Accordingly, provided herein are methods for treating a subject having, at risk for developing, or suspected of having fibrosis, wherein the subject has a kidney disease or condition. The kidney disease or condition may be one or more of, without limitation, glomerular disease, tubulointerstitial fibrosis, IgA nephropathy, interstitial fibrosis/tubular atrophy, glomerulosclerosis, glomerulonephritis, Alport Syndrome, diabètes mellitus, idiopathïc focal segmentai glomcrulosclerosis, membranous nephropathy, collapsingglomenilopathy, chronic récurrent kidney infection, diabètes mellitus, diabetic nephropathy, chronic récurrent kidney infection, hypertension, systemic hypertension, Întraglomerular hypertension, or end stage rénal disease.
Provided herein are methods for improving kidney function in a subject. In certain embodiments, provided herein are methods for delaying and/or preventing the onset of end stage rénal disease. In certain embodiments, provided herein are methods for delaying the need for dialysis in a subject. In certain embodiments, provided herein are methods for delaying the need for rénal transplant in a subject. In certain embodiments, provided herein are methods for delaying impaired kidney function in a subject.
Chronic kidney discase may be characterized by the presence of fibrosis. Accordingly, in certain embodiments, the kidney disease or condition is chronic kidney disease. In certain embodiments, the subject is at risk for developing chronic kidney disease. In certain embodiments, a subject having acute kidney injury is at risk for developing fibrosis and/or chronic kidney disease. Accordingly, the compositions and methods provided herein may be administered to a subject having acute kidney injury, to prevent or delay the onset of fibrosis and/or chronic kidney disease.
In certain embodiments, a subject having fibrosis has kidney fibrosis that results from acute or répétitive trauma to the kidney. The trauma may resuit from surgery, chemotherapy, radiation treatment, allograft rejection, chronic transplant rejection, and acute transplant rejection.
In certain embodiments, kidney fibrosis may resuit from exposure to any agent that may be nephrotoxîc after acute or chronic exposure. Such agents include pharmaceutical agents, including but not limited to analgésies, non-steroidal anti-inflammatory drugs, antibiotics, lithium, cyclosporine, mesalazine, contrast media, chemotherapeutic agents; occupational toxins, including but not limited to heavy metals; and environmental toxins, including but not limited to heavy metals (e.g. cadmium, mercuric chioride) or plant nephrotoxins (e.g. aristolochic acid).
Provided herein are methods for the treatment of Alport Syndrome, comprising administering to a subject having or suspected of having AJport Syndrome a modified oligonucleotide complementary to miR-21. In certain embodiments, the subject has been diagnosed as having AJport Syndrome prior to administration of the modified oligonucleotide. Diagnosis of Alport Syndrome may be achieved through évaluation of parameters including, without limitation, a subject’s family history, clinical features (including without limitation proteinuria, albuminurie, hematuria, impaired GFR, deafness and/or ocular changes) and results of tissue biopsies. Kidney biopsies may be tested for the presence or absence of the type IV collagen alpha-3, alpha-4, and alpha-5 chains. Additionally, structural changes in the glomerulus can be detected by électron microscopy of kidney biopsy material. A skin biopsy may be tested for the presence of the type IV collagen alpha-5 chain, which is normally présent in skin and is usually absent from male subjects with the X-linked form of Alport Syndrome. Diagnosis of Alport Syndrome may also include screening for mutations in one or more of the Col4a3, Col4a4, or Col4a5 genes.
In certain embodiments, levels of miR-21 are increased in the kidney of a subject having Alport Syndrome. In certain embodiments, prior to administration, a subject is determined to hâve an increased level of miR-21 in the kidney. miR-21 levels may be measured from kidney biopsy material.
Many diseases or abnormalities of the liver are characterized by the presence of fibrosis. As such, in certain embodiments, a subject having fibrosis has a liver disease or condition. In certain embodiments, a subject at risk for developing fibrosis has a liver disease or condition. In certain embodiments, a subject suspected of having fibrosis has a liver disease or condition. Accordingly, provided herein are methods for treating a subject having, at risk for developing, or suspected of having fibrosis, wherein the subject has a liver disease or condition. In certain embodiments, a liver disease or condition may be one or more of, without limitation, chronic liver injury, hepatitis virus infection (including hepatitis C virus infection and hepatitis B virus infection), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatïtis (NASH), a lcohol ic liver disease (ALD), alcoholic steatohepatitis, bridging fibrosis, or cirrhosis. In certain embodiments a liver disease or condition is associated with exposure to toxic chemicals. In certain embodiments, a liver disease or condition results from exposure to pharmaceutical agents, e.g. acctaminophen. In certain embodiments, a subject receiving chemotherapy is at risk for liver fibrosîs and/or chronic liver injury.
The presence or degree of fibrosïs may be detected by needle liver biopsy or through a noninvasive transi ent elastography method that évaluâtes the degree of liver stiffness, such as the
FibroScan® method.
Fibrosis may be présent in many diseases or abnormalities of the lung. As such, in certain embodiments, a subject having fibrosis has a lung disease or condition. In certain embodiments, a subject at risk for developing fibrosis has a lung disease or condition. In certain embodiments, a subject suspected of having fibrosis has a lung disease or condition. Accordingly, provided herein are methods for treating a subject having, at risk for developing, or suspected of having fibrosis, wherein the subject has a lung disease or condition. In certain embodiments, a lung disease or condition may be one or more of, without limitation, lung fibrosis, îdiopathic pulmonary fibrosis, or chronic obstructive lung disease. In certain embodiments, lung fibrosis may resuit from inhalation of particulate matter, such as those found in silica gel, asbestos, air pollutants or cigarette smoke.
In certain embodiments the fibrosis is cardiac fibrosis.
In certain embodiments the fibrosis is skin fibrosis. In certain embodiments the fibrosis is agerelated fibrosis. In certain embodiments the fibrosis is spleen fibrosis.
Sclcrodenna is a chronic autoimmune disease characterized by fibrosis, among other symptoms. In certain embodiments, a subject having fibrosis has sclerodenna. In certain embodiments, a subject having sclerodenna has fibrosis in internai organs, in addition to fibrosis of the skin.
Fibrosis frequently occurs in transplant ed organs, leading to loss of organ function and ultimately to chronic rejection of the transplanted organ. Prévention or treatment of fibrosis in transplanted organs may prevent or delay chronic rqection of the transplanted organ, or in other words may prolong function of the transplanted organ. Accordingly, in certain embodiments a subject has post-transplant fibrosis. In certain embodiments, the post-transplant fibrosis is kidney post-transplant fibrosis. In certain embodiments, the transplantation associated fibrosis is liver post-transplant fibrosis. In certain embodiments, a compound described herein is administered prier to transplantation. In certain embodiments, a compound described herein is administered concurrently with transplantation. In certain embodiments, a compound described herein is administered following transplantation.
Provided herein arc methods for treating a subject having a fîbroprolîferativc disorder. In certain embodiments such methods comprise administering to a subject having or suspected of having a fibroproliferativc disorder a modified oligonucleotide having a nucleobase sequence which is complementary to a miRNA or a precursor thereof. In certain embodiments, the mïRNA is miR-21.
Cancer and Metastasis
Abnormally high expression of miR-21 has been demonstrated in numerous types of cancer. Further, inhibition of miR-21 in in vitro and in vivo models has demonstrated that inhibitors of miR-21 arc useful for the inhibition of cellular processes that support cancer cell growth, as well as for the treatment of cancer.
Accordingly, in certain embodiments, the compounds provided herein arc used for treating, preventing, ameliorating, and/or delaying the onset of cancer. In certain embodiments, the cancer is liver cancer, breast cancer, bladder cancer, prostate cancer, bone cancer, colon cancer, lung cancer, brain cancer, hematological cancer, pancreatic cancer, head and neck cancer, cancer of the tongue, stomach cancer, skin cancer, thyroid cancer, neuroblastoma, csophageal cancer, mesothclioma, neuroblastoma, kidney cancer, tcsticular cancer, rectal cancer, cervical cancer, or ovarian cancer. In certain embodiments, the liver cancer is hepatocellular carcinoma. In certain embodiments, the liver cancer is duc to metastasis of cancer that originated in another part of the body, for example a cancer that is duc to metastasis of bone cancer, colon cancer or breast cancer. In certain embodiments, the brain cancer is glioblastoma multiforme, oligoastrocytoma, or oligodcndroglioma. In certain embodiments, the glîoblastoma multiforme is proncural glioblastoma multiforme, neural glioblastoma multiforme, classîcal glioblastoma multiforme, or mcscnchymal glioblastoma multiforme. In certain embodiments, In certain embodiments, the hematological cancer is acute myelogenous leukemia, acute lymphocytic leukemia, acute monocytic leukemia, multiple myeloma, chronic lymphotic leukemia, chronic myeloid leukemia, hodgkin’s lymphoma, or non-hodgkin’s lymphoma.In certain embodiments, the skin cancer is melanoma. In certain embodiments, the kidney cancer is rénal cell carcinoma. In certain embodiments, the breast cancer is ductal cell carcinoma in situ, invasive ductal cell carcinoma, triple négative breast cancer, medullary carcinoma, tubular carcinoma, and mucinous carcinoma. In certain embodiments, the cancer is résistant to chemotherapy.
In certain embodiments, in liver cancer, miR-21 is elevated and the level of one or more mîR-21regulated transcripts is reduced. In certain embodiments, the reduced miR-21-regulated transcript is SPG20.
In certain embodiments, the liver cancer is hepatocellular carcinoma (HCC). The diagnosis of hepatocellular carcinoma is typically made by liver imaging tests such as abdominal ultrasound, hclical computed tomography (CT) Scan or triple phase CT scan. Such imaging tests may be performed in conjunction with measurement of blood levels of alpha-fctoprotein and/or blood levels of des-gammacarboxyprothrombin. In certain subjects, MRI may be used in place of CT scan. The liver imaging tests allow the assessment of the tumor size, number, location, metastasis outside the liver, patency and or invasion of the arterics and vcîns of the liver by the tumor. This assessment aids the decision as to the mode of therapeutic or palliative intervention that is appropriate. The final diagnosis is typically confirmed by needle biopsy and histopathologïcal cxamînation.
Accordingly, in certain embodiments, the liver cancer is detected following a computed tomography (CT) scan that detects tumors. In certain embodiments, the liver cancer is detected following magnetic résonance imaging (MRI). In certain embodiments, HCC is characterized as a single primary tumor. In certain embodiments, HCC is characterized as multiple primary tumors. In certain embodiments, HCC is characterized as a poorly defined primary tumor with an infiltrative growth pattem. In certain embodiments, the HCC is a single primary tumor with vascular invasion. In certain embodiments, the HCC is characterized as multiple primary tumors with vascular invasion. In certain embodiments, the HCC has metastasized to one or more lymph nodes. ln certain such embodiments, the lymph nodes are régional lymph nodes. In certain embodiments, the HCC has metastasized to one or more distant tissues. ln certain embodiments, the HCC has metastasized to other régions of the liver, the portai vein, lymph nodes, adrenal glands, bone or lungs. ln certain embodiments, fibrosis is présent.
A number of Systems hâve been employed to predict the prognosis for HCC, including the TNM System, the Okuda System, the Barcelona Clinic Liver Cancer (BCLC) and the CLIP score. Each of thèse Systems incorporâtes four features that hâve been recognized as being important déterminants of survival: the severity of underlying liver disease, the size of the tumor, extension of the tumor into adjacent structures, and the presence of métastasés. The TNM System classifies HCC as stage I, Π, III, IV, or V. The BCLC classifies HCC as Stage Al, A2, A3, A4, B, C, and D, and includes considération of a ChildPugh score.
ln certain embodiments, liver cancer is classified as Stage 1, Stage 2, Stage 3A Stage 3B, Stage 3C, or Stage 4. Stage 1 is characterized by a cancer is no bigger than 2 cm in size and that has not begun to spread. At Stage 2, the cancer is affecting blood vessels in the liver, or there is more than one tumor in the liver. At Stage 3 A the cancer is bigger than 5 cm in size or has spread to the blood vessels near the liver. At Stage 3B, the cancer has spread to nearby organs, such as the bowel or the stomach, but has not spread to the lymph nodes. At Stage 3C the cancer can be of any size and has spread to nearby lymph nodes. At Stage 4 the cancer has spread to parts of the body further away from the liver, such as the lungs.
Biomarkcrs in a subjcct’s blood may be used to augment a diagnosis of liver cancer, stage a liver cancer, or develop a prognosis for survival. Such biomarkcrs include blood tumor biomarkers, such as alpha-fetoprotein and des-gamma carboxyprothrombin. In certain such embodiments, the subject has elevated blood alpha-fetoprotein. ln certain such embodiments, the subject has elevated blood desgamma carboxyprothrombin.
A subject having liver cancer may also suffer from abnormal liver fonction. Liver function may be assessed by liver fonction tests, which measure, among other things, blood levels of liver transaminases. In certain embodiments, a subject having abnormal liver function has elevated blood liver transaminases. Blood liver transaminases include alanine aminotransferase (ALT) and aspartate aminotransferase (AST). In certain embodiments, a subject having abnormal liver fonction has elevated blood bilirubin. In certain embodiments, a subject has abnormal blood albumin levels.
In certain embodiments, a subjcct’s liver fonction is assessed by the Child-Pugh classification System, which defines three classes of liver function. ln this classification System, points are assigned to measurements in one of five categories: bilirubin levels, albumin levels, prothrombin time, ascites, and encephalopathy. One point is assigned per each of the following characteristics présent: blood bilirubin of less than 2.0 mg/dl; blood albumin of greater than 3.5 mg/dl; a prothrombin time of less than 1.7 international normal ized ratio (INR); ascites is absent; or enccphalopathy is absent. Two points are assigned per each of the following characteristics présent: blood bilirubin of 2-3 mg/dl; blood bilîrubin of
3.5 to 2.8 mg/dl; prothrombin time of 1.7-2.3 INR; ascites is mild to moderate; or enccphalopathy is mild. Three points arc assigned per each of the following characteristics présent: bilirubin of greater than 3.0 mg/dl; blood albumin of less than 2.8 mg/dl; prothrombin time of greater than 2.3 INR; ascites îs severe to refractory; or enccphalopathy is severe. The scores arc added and Class A is assigned for a score of 5-6 points, Class B is assigned for a score of 7-9 points, and Class C is assigned for a score of 10-15 points,
A subject having liver cancer may hâve prcviously suffered from, or may currently suffer from, chronic hcpatitis C infection, chronic hcpatitis B infection, non-alcoholic fatty liver disease, or cirrhosis. Subjects having liver cancer accompanied by and/or resulting from hcpatitis C infection, hcpatitis B infection, non-alcoholic fatty liver disease, or cirrhosis may be treated by the methods described herein.
A subject’s response to treatment may be evaluated by tests similar to those used to diagnosîs the 15 liver cancer, induding, without limitation, CT Scan, MRI, and needie biopsy. Response to treatment may also bc assessed by measuring biomarkers in blood, for comparison to pre-treatment levels of biomarkers.
miR-21 has also been linked to the process of metastasis. While cpithelial-mesenchymal transition (EMT) occurs in normal physiological processes, EMT has been connected to the process of metastasis. The relevance of EMT in tumor progression has been explored in several studies (Greenburg, 20 G. and Hay, E. 1986. Dcv. Biol. 115: 363-379; Boyer, B. et al., 1989. J. Cell. Biol. 109:1495-1509;
Uchara, Y. et al,, 1992. J. Cell. Biol. 117: 889-894). Epithelial cells arc held together through integrins to
- an underlyîng extracellular matrix (ECM) called the basement membrane. Mesenchymal cells, on the other hand, hâve the ability to invade and move through the three-dimensional structure of the ECM. Therefore, EMT at least supcrficially resembles the transformation of normal adhèrent cells into the metastatic phenotype.
Provided herein arc methods for treating, preventing, ameliorating, and/or delayîng the onset of metastasis. The metastasis may resuit from the migration of cancer cells from any primary site of cancer to any secondary site of cancer.
Acute Kidney Iniurv
Acute kidney injury is a rapid loss of kidney function, which may be brought on by a number of causes, induding low blood volume, exposure to toxins, and urinary obstruction. Acute kidney injury may progress to fibrosis and/or chronic kidney disease. Elevated miR-21 has been observed in a model of acute kidney injury. Accordingly, in certain embodiments, the compounds provided herein are used for 35 treating, preventing, ameliorating, and/or delayîng fibrosis that occurs as a resuit of of acute kidney injury. In certain embodiments, acute kidney înjury may be the resuit of exposure to toxic substances, such as environmental toxins or cancer therapeutic agents. Acute kidney injury may arise from damage to the kidney itself, for exemple in conditions such as glomerulonephritis, acute tubular necrosis, and acute interstitiel nephritis. In certain embodiments, acute kidney injury is caused by urinary tract obstruction, such as that related to benign prostatic hyperplasia, kidney stones, obstmeted urinary cathéter, bladder stone, bladder, urétéral or rénal malignancy. In some embodiments, the compounds provided herein are administered to a subject to enhance recovery from acute kidney injury.
Cardiac Diseases
Elevated miR-21 expression has been found in human cardiac disease, and inhibition of mîR-21 in relevant animal models has demonstrated improvements in cardiac fibrosis and cardiac function. Accordingly, in certain embodiments, the compounds provided herein are used for treating, preventlng, ameliorating, and/or delaying the onset of one more cardiac diseases. In certain embodiments, a cardiac disease is cardiac fibrosis, cardiac cnlargement, cardiac hypertrophy, cardiac dilation, hypertrophie cardiomyopathy, heart failure, post-myocardïal infarction remodeling, myocardial infarction, cardiomyopathy (for example, hypertrophie cardiomyopathy, restrictive cardiomyopathy, dilated cardiomyopathy (DCM), idiopathic dilated cardiomyopathy, or dilated cardiomyopathy with arrhythmias), diastolic heart failure, chronic atrial fibrillation, primary pulmonary hypertension, acute respiratory distress syndrome, bnigada syndrome, progressive cardiac conduction disease, urémie pericarditis, anthracycline cardiomyopathy, arterial fibrosis, post-radiation lymphatic fibrosis, sarcoidosis, sclerodenna, endocardial fibroelastosis, serotonergic cxcess, cardiac valvulopathy, atrial fibrosis, atrial fibrillation, mitral valvular disease, hypertension, chronic ventricular dysfunction, pressure and volume overload, or myocardial fibrosis.
Cellular Processes
Provided herein are compositions and methods for reducing or preventing fibroblast prolifération or activation. Also provided herein are compositions and methods for inhiblting the synthesis of extracellular matrix, which includes but is not limited to the synthesis of collagen, fibronectin, collagénase, or a tissue inhibitor of metalloproteinase.
Provided herein are methods for modulating the cellular processes associated with cpithelialmesenchymal transition (EMT). Such methods comprise contacting an epithélial cell with a compound consisting of a modified oligonucleotide, wherein the modified oligonucleotide is complementary to miR-21. In certain embodiments, the contacting delays the transition of an epithélial cell to a fibroblast. In certain embodiments, the contacting prevents the transition of an épithélial cell to a fibroblast.
In certain embodiments, a compound provided herein may stop, slow, or reduce the prolifération of cancer cells. In certain embodiments, a compound provided herein may induce apoptosis in cancer cells. In certain embodiments, a compound provided herein may reduce cancer cell survival.
In certain embodiments, the épithélial cell is a cancer cell. In certain embodiments, the contacting delays the metastasis of the cancer cell. In certain embodiments, the contacting prevents metastasîs of the cancer cell.
Certain Clinical Outcomes
In certain embodiments, administration of the compounds or methods provided herein resuit in one or more clinîcally désirable outcomes in a subject. Such improvements may be used to détermine the extent to which a subject is responding to treatment.
In certain embodiments a clinîcally désirable outcome is the amelioration of fibrosis. In certain embodiments a clinîcally désirable outcome is the slowing of further progression of fibrosis. In certain embodiments a clinîcally désirable outcome is the halting of further progression of fibrosis. In certain embodiments a clinîcally désirable outcome is a réduction in fibrosis. In certain embodiments a clinîcally désirable outcome is a réduction in collagen content in the organ having fibrosis.
In certain embodiments a clinîcally désirable outcome is the amelioration of fibrosis in any organ 15 or tissue. In certain embodiments a clinîcally désirable outcome is the slowing of further progression of fibrosis. In certain embodiments a clinîcally désirable outcome is the halting of further progression of fibrosis. In certain embodiments a clinîcally désirable outcome is a réduction in fibrosis. In certain embodiments a clinîcally désirable outcome is a réduction in collagen content in the affected organ.
In certain embodiments a clinîcally désirable outcome is improved kidney function. Kidney function may be assessed by one or more known methods commonly performed in a clinical setting, including, without limitation: measuring blood urca nitrogen in the blood of the subject; measuring créatinine in the blood of the subject; measuring créatinine clearance in the subject; measuring proteinuria in the subject; measuring albuminxreatinine ratio in the subject; measuring glomcrular filtration rate in the subject; measuring urinary output in the subject; measuring înulin clearance in the urine of the subject; measuring urinary osmolarity in the subject; measuring urinary osmolality in the subject; measuring hematuria in the subject; measuring cystatin C in the blood and/or urine of the subject; measuring neutrophil gelatinase-associated lipocalin (NGAL) in the blood or urine of the subject; measuring kidney injury molécule-1 (KIM-1) mRNA levels in the urine; and/or measuring clusterin levels in the urine.
In certain embodiments, the administration improves kidney function in the subject. In certain embodiments, the administration delays time to dialysis. In certain embodiments, the administration delays time to rénal transplant. In certain embodiments, the administration improves life expectancy of the subject. In certain embodiments, the administration reduces hematuria. In certain embodiments, the administration delays the onset of hematuria. In certain embodiments, the administration reduces proteinuria. In certain embodiments, the administration delays the onset of proteinuria.
In any of the embodiments provided herein, the administration of a modified oligonucleotide targeted to miR-21 improves one or more markers of kidney function in the subject. Improvements in markers of kidney function include, without limitation: reduced blood urea nitrogen in the subject; reduced créatinine in the blood of the subject; improved créatinine clearance in the subject; reduced proteinuria in the subject; reduced albumin:creatinine ratio in the subject; improved glomerular filtration rate in the subject; improved inulin clearance in the subject; reduced ncutrophil gelatinase-associated lipocalin (NGAL) in the blood of the subject; reduced Cystatin C in the blood of the subject; and increased urinary output in the subject. In certain embodiments, the proteinuria is microalbuminuria. In certain embodiments, the proteinuria is macroalbuminurïa.
In certain embodiments, a clinically désirable outcome is improved liver function. Livcr function may be assessed by one or more known methods commonly performed in a clinical setting, including, without limitation: measuring alanine aminotransferase levels in the blood of the subject; measuring aspartate aminotransferase levels in the blood of the subject; measuring bilirubin levels in the blood of the subject; measuring aibumin levels in the blood of the subject; measuring prothrombin time in the subject; measuring ascites in the subject; and/or measuring encephalopathy in the subject.
In certain embodiments a clinically désirable outcome is improved lung function in a subject having pulmonary fibrosis. In certain embodiments the subject has idiopathic pulmonary fibrosis. Lung function may be assessed by one or more known methods commonly performed in a clinical setting, including, without limitation: measuring vital capacity in the subject; measuring forced vital capacity in the subject; measuring forced expiratory volume in one second in the subject; measuring peak expiratory flow rate in the subject; measuring forced expiratory flow in the subject; measuring maximal voluntary ventilation in the subject; determining the ratio of forced expiratory volume in one second to forced vital capacity in the subject; measuring ventilation/perfusion ratio in the subject; measuring nitrogen washout in the subject; measuring absolute volume of air in one or more lungs of a subject; and administering the 6-minute walk test.
In certain embodiments a clinically désirable outcome is improved cardiac function in a subject having cardiac fibrosis. Cardiac function may be assessed by one or more known methods commonly performed in a clinical setting, including, without limitation: measuring cardiac output in the subject; measuring stroke volume in the subject; measuring mean systolic éjection rate in the subject; measuring systolic blood pressure in the subject; measuring left ventricular éjection fraction in the subject; determining stroke index in the subject; determining cardiac index in the subject; measuring left ventricular percent fractional shortening in the subject; measuring mean velocity of circumferentiai fiber shortening in the subject; measuring left ventricular inflow velocity pattern in the subject;measuring pulmonary venous flow velocity pattern in the subject; measuring peak early diastolic velocity of the mitral annulus of the subject.
In certain embodiments a clinically désirable outcome is réduction of tumor number and/or réduction of tumor size in a subject having cancer. In certain embodiments a clinically désirable outcome is a réduction in cancer cell number in a subject having cancer. Additional clinically désirable outcomes include the extension of ovcrall survival time of the subject, and/or extension of progression-free survival time of the subject. In certain embodiments, administration of a compound provided herein prevents an increase in tumor size and/or tumor number. In certain embodiments, administration of a compound provided herein prevents metastatic progression. In certain embodiments, administration of a compound provided herein slows or stops metastatic progression. In certain embodiments, administration of a compound provided herein prevents the récurrence of tumors. In certain embodiments, administration of a compound provided herein prevents récurrence of tumor metastasis.
Certain désirable ciinical outcomes may be assessed by measurements of blood biomarkers. In certain embodiments, administration of a compound provided herein may resuit in the decrease of blood alpha-fetoprotein and/or blood des-gamma carboxyprothrombin. Administration of a compound provided herein may further resuit in the improvement of liver function, as evideneed by a réduction in blood ALT and/or AST levels.
Certain Additional Thérapies
Treatments for fibrosis or any of the conditions listed herein may comprise more than one therapy. As such, in certain embodiments provided herein are methods for treating a subject having or suspected of having fibrosis comprising administering at least one therapy in addition to administering a modified oligonucleotide having a nucleobase sequence complementary to a miR-21.
In certain embodiments, the at least one additional therapy comprises a pharmaceutical agent.
In certain embodiments, pharmaceutical agents include anti-inflammatory agents. In certain embodiments, an anti-inflammatory agent is a steroidal anti-inflammatory agent. In certain embodiments, a steroid anti-inflammatory agent is a corticosteroîd. In certain embodiments, a corticosteroid is prednisone. In certain embodiments, an anti-inflammatory agent is a non-steroidal anti-inflammatory drug. In certain embodiments, a non-steroidal anti-inflammatory agent is ibuprofen, a COX-I inhibitor, or a COX-2 inhibitor.
In certain embodiments, pharmaceutical agents include immunosuppressive agents. In certain embodiments, an immunosuppressive agent is a corticosteroid, cyclophosphamide, or mycophcnolate mofetil.
In certain embodiments, pharmaceutical agents include anti-dîabetic agents. Antidiabetic agents include, but are not limited to, biguanides, glucosidasc inhibitors, insulins, sulfonylureas, thiazolidenediones, GLP-1 analogs, and DPP-IV inhibitors.
In certain embodiments, pharmaceutical agents include angiotensin II receptor blockers (ARB). In certain embodiments, an angiotensin II receptor blocker is candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, or eprosartan.
In certain embodiments, pharmaceutical agents include angiotensin II converting enzyme (ACE) inhibitors. In certain embodiments, an ACE inhibitor is captopril, enalapril, lisinopril, bnazepril, quinapril, fosinopril, or ramipril.
In certain embodiments, an additional therapy is dialysis. In certain embodiments, an additional therapy is rénal transplant.
In certain embodiments, pharmaceutical agents include, but are not limited to, diuretics (e.g. sprionolactone, eplerenone, furosemide), inotropes (e.g. dobutamine, milrinone), dîgoxin, vasodilators,, calcium channel blockers, isosorbide dinitrate, hydralazine, nitrates (e.g. isosorbîde mononitrate, isosorbide dinitrate), hydralazine, beta-blockers (e.g. carvedilol, mctoprolol), and natriuretîc peptides (e.g. nesiritide).
In certain embodiments, pharmaceutical agents include heparinoids. In certain embodiments, a heparinoid is pentosan polysulfate.
In certain embodiments, a pharmaceutical agent is a pharmaceutical agent that blocks one or more responses to fibrogenic signais.
In certain embodiments, a pharmaceutical agent is an anti-connective tissue growth factor therapy. In certain embodiments, an anti-CTGF therapy is a monoclonal antibody against CTGF. In certain embodiments, a pharmaceutical agent is an anti-transforming growth factor β therapy. In certain embodiments, an antî-TGF-β therapy is a monoclonal antibody against TGF-β.
In certain embodiments, an additional therapy may be a pharmaceutical agent that enhances the body's immune system, including low-dose cyclophosphamide, thymostîmulin, vitamins and nutritional suppléments (e.g., antioxidants, including vitamins A, C, E, beta-carotene, zinc, sélénium, glutathione, coenzyme Q-10 and echinacea), and vaccines, e.g., the immunostimulating complex (ISCOM), which comprises a vaccine formulation that combines a multimcric présentation of antigen and an adjuvant.
In certain embodiments, the additional therapy is selected to treat or ameliorate a side effect of one or more pharmaceutical compositions ofthe présent invention. Such side effects include, without limitation, injection site reactions, liver function test abnormalities, rénal function abnormalîties, liver toxicity, rénal toxicity, central nervous system abnormalîties, and myopathies. For example, increased aminotransferase levels in sérum may indicate liver toxicity or liver function abnormality. For example, increased bilirubin may indicate liver toxicity or liver function abnormality.
Further examples of additional pharmaceutical agents include, but are not limited to, immunoglobulins, including, but not limited to intravenous immunoglobulin (IVIg); analgésies (e.g., acetaminophen); salicylates; antibiotics; antivirals; antifungal agents; adrenergic modifiers; hormones (e.g., anabolic steroids, androgen, estrogen, calcitonin, progestîn, somatostatin, and thyroid hormones); immunomodulators; muscle relaxants; antihistamines; osteoporosis agents (e.g., biphosphonates, calcitonin, and estrogens); prostaglandins, antineoplastic agents; psychotherapeutic agents; sédatives; poison oak or poison sumac products; antibodies; and vaccines.
Cancer treatments often comprise more than one therapy. As such, in certain embodiments the présent invention provides methods for reducing or preventing metastasis comprising administering to a subject a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is complementary to miR-21, and admînistering at least one additional therapy that is an anti-cancer therapy.
In certain embodiments, an anti-cancer therapy is chemotherapy. Suitable chemotherapeutic agents include docetaxel, cyclophosphamide, ifosfamide, methotrexate, Vinblastine, cisplatin, 5fluorouracil, gemcitabine, doxorubicin, mitomycin c, sorafenib, etoposide, carboplatin, epirubicin, irinotecan and oxaliplatin. An additional suitable chemotherapeutic agent includes an oligomeric compound, other than a composition targeted to miR-21 provided herein, that is used to treat cancer.
In certain embodiments, an anti-cancer therapy is radiation therapy. In certain embodiments, an anti-cancer therapy is surgical resection of a tumor. In certain embodiments, an anti-cancer therapy is a DNA damaging agent, a prolifération inhibitor, an anti-folate, a growth factor receptor inhibitor, an antiangiogenic agent, a receptor tyrosine kinase inhibitor, a kinase inhibitor, a growth factor inhibitor, or a cytotoxic agent.
In certain embodiments, a DNA damaging agent is l,3-bis(2-chlorocthyl) -1-nitrosourea, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, daunorubicin, doxorubicin, epirubicin, etoposide, idarubicîn, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan, mitomycin C, mîtoxantrone, oxaliplatin, temozolomide, or topotecan.
In certain embodiments, an anti-folate is methotrexate, aminopterin, thymidylate synthase, serine hydroxymethyltransferase, folyilpolyglutamyl synthetase, g-glutamyl hydrolase, glycinamideribonucleotide transformylase, leucovorin, amino-imidazole-carboxamide-ribonucleotide transformylase, 5-fluorouracil, or a folate transporter.
In certain embodiments, a growth factor receptor is eriotinib, or gefitinib.
In certain embodiments, an angiogenesis inhibitor is bevacizumab, thalidomide, carboxyamidotriazole, TNP-470, CM 101, IFN-α, platelet factor-4, suramin, SU5416, thrombospondin, a VEGFR antagonist, cartilage-derived angiogenesis inhibitory factor, a matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxycstradiol, tecogalan, tetrathiomolybdate, prolactin, or linomide.
In certain embodiments, a kinase inhibitor is bevacizumab, BIBW 2992, cetuximab, imatinib, trastuzumab, gefitinib, ranîbizumab, pegaptanib, sorafenib, dasatinîb, sunitinib, eriotinib, nilotinib, lapatinib, panitumumab, vandetanib, E7080, pazopanib, mubritinib, or fostamatinib.
Certain MicroRNA Nucleobase Sequences
The modified oligonucleotides having a nucleoside pattern described herein hâve a nucleobase sequence that is complementary to miR-21 (SEQ ID NO: 1), or a precursor thereof (SEQ ID NO: 2). In certain embodiments, each nucleobase of the modified oligonucleotide is capable of undergoing basepairing with a nucleobase at each corresponding position ïn the nucleobase sequence of miR-21. In certain embodiments the nucleobase sequence of a modified oligonucleotide may hâve one or more mismatched base pairs with respect to the nucleobase sequence of miR-21 or precursor sequence, and remains capable of hybridizing to its target sequence.
As the miR-21 sequence is contained within the miR-21 precursor sequence, a modified oligonucleotide having a nucleobase sequence complementary to miR-21 is also complementary to a région ofthe miR-21 precursor.
In certain embodiments, a modified oligonucleotide consists of a number of linked nucleosïdes that is equal to the length of miR-21.
In certain embodiments, the number of linked nucleosïdes of a modified oligonucleotide is less than the length of miR-21. A modified oligonucleotide having a number of linked nucleosïdes that is less than the length of miR-21, wherein each nucleobase ofthe modified oligonucleotide is complementary to 10 each nucleobase at a corresponding position of miR-21, is considered to be a modified oligonucleotide having a nucleobase sequence that is fully complementary to a région of the miR-21 sequence. For example, a modified oligonucleotide consisting of 19 linked nucleosïdes, where each nucleobase is complementary to a corresponding position of miR-21 that is 22 nucleobases in length, is fully complementary to a 19 nucleobase région of miR-21. Such a modified oligonucleotide has 100% IS complementarity to a 19 nucleobase portion of miR-21, and is considered to be 100% complementary to miR-21.
In certain embodiments, a modified oligonucleotide comprises a nucleobase sequence that is complementary to a seed sequence, i.e. a modified oligonucleotide comprises a seed-match sequence. In certain embodiments, a seed sequence is a hexamer seed sequence. In certain such embodiments, a seed 20 sequence is nucleobases 1 -6 of miR-21. In certain such embodiments, a seed sequence is nucleobases 2-7 of miR-21. In certain such embodiments, a seed sequence is nucleobases 3-8 of miR-21. In certain embodiments, a seed sequence is a heptamer seed sequence. In certain such embodiments, a heptamer seed sequence is nucleobases I -7 of miR-21. In certain such embodiments, a heptamer seed sequence is nucleobases 2-8 of miR-21. In certain embodiments, the seed sequence is an octamer seed sequence. In 25 certain such embodiments, an octamer seed sequence is nucleobases 1 -8 of miR-21. In certain embodiments, an octamer seed sequence is nucleobases 2-9 of miR-21.
In certain embodiments, a modified oligonucleotide has a nucleobase sequence having one mismatch with respect to the nucleobase sequence of miR-21, or a precursor thereof. In certain embodiments, a modified oligonucleotide has a nucleobase sequence having two mismatches with 30 respect to the nucleobase sequence of miR-21, or a precursor thereof. In certain such embodiments, a modified oligonucleotide has a nucleobase sequence having no more than two mismatches with respect to the nucleobase sequence of miR-21, or a precursor thereof. In certain such embodiments, the mismatchcd nucleobases are contiguous. In certain such embodiments, the mismatched nucleobases arc not contiguous.
In certain embodiments, the number of linked nucleosïdes of a modified oligonucleotide is greater than the length of miR-21. In certain such embodiments, the nucleobase of an additional nucleoside is complementary to a nucleobase ofthe miR-21 stem-loop sequence. In certain embodiments, the number of linked nucleosides of a modified oligonucleotide is one greater than the length of miR-21. In certain such embodiments, the additional nucleoside is at the 5’ terminus of an oligonucleotide. In certain such embodiments, the additional nucleoside is at the 3’ terminus of an oligonucleotide. In certain embodiments, the number of linked nucleosides of a modified oligonucleotide is two greater than the lengthofmiR-21. Incertain such embodiments, the two additional nucleosides are at the 5’ terminus of an oligonucleotide. In certain such embodiments, the two additional nucleosides are at the 3’ terminus of an oligonucleotide. In certain such embodiments, one additional nucleoside is located at the 5’ terminus and one additional nucleoside is located at the 3' terminus of an oligonucleotide. In certain embodiments, a région of the oligonucleotide may be fully complementary to the nucleobase sequence of miR-21, but the entire modified oligonucleotide is not fully complementary to miR-21. For example, a modified oligonucleotide consisting of 24 linked nucleosides, where the nucleobases of nucleosides 1 through 22 are each complementary to a corresponding position of miR-21 that is 22 nucleobases in length, has a 22 nucleoside portion that is fully complementary to the nucleobase sequence of miR-21 and approximately 92% overall complementarity to the nucleobase sequence of miR-21.
Certain Modified Oligonucleotides
In certain embodiments, a modified oligonucleotide consists of 8 to 30 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 12 to 30 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 15 to 30 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 12 to 25 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 15 to 25 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 12 to 19 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 15 to 19 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 12 to 16 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 15 to 16 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 19 to 24 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 21 to 24 linked nucleosides.
In certain embodiments, a modified oligonucleotide consists of 8 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 9 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 10 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 11 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 12 linked nucleosides. Incertain embodiments, a modified oligonucleotide consists of 13 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 14 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 15 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 16 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 17 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 18 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 19 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 20 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 21 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 22 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 23 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 24 linked nucleosides. In certain embodiments, a modified oligonucleotide consists of 25 linked nucleosides.
The nucleobase sequences set forth herein, including but not limited to those found in the examples and in the sequence listing, are independent of any modification to the nucleic acid. As such, nucleic acids defined by a SEQ ID NO may comprise, independently, one or more modifications to one or more sugar moieties, to onc or more intemucleoside linkages, and/or to one or more nucleobases.
Although the sequence listing accompanying this filing identifies each nucleobase sequence as either “RNA or “DNA” as required, in practice, those sequences may bc modified with any combination of chemical modifications. One of skill ïn the art will readily appreciate that such désignation as “RNA or “DNA to describe modified oligonucleotides is somewhat arbitrary. For example, a modified oligonucleotide comprising a nucleoside comprising a 2’-OH sugar moiety and a thymine base could be described as a DNA having a modified sugar (2*-OH for the naturel 2'-H of DNA) or as an RNA having a modi fîed base (thymine (methylated uracil) for naturel uracil of RNA).
Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of naturel or modified RNA and/or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of further exemple and without limitation, an oligonucleotide having the nucleobase sequence ATCGATCG” encompasses any oligonucleotide having such nucleobase sequence, whether modified or unmodifîed, including, but not limited to, such compounds comprising RNA bases, such as those having sequence “AUCGAUCG and those having some DNA bases and some RNA bases such as “AUCGATCG and oligonucleotides having other modified bases, such as “AT“CGAUCG,” wherein ”*C indicates a 5-methylcytosine. Similarly, an oligonucleotide having the nucleobase sequence “AUCGAUCG” encompasses any oligonucleotide having such nucleobase sequence, whether modified or unmodifîed, including, but not limited to, such compounds comprising DNA bases, such as those having sequence “ATCGATCG” and those having some DNA bases and some RNA bases such as AUCGATCG” and oligonucleotides having other modified bases, such as “AT™*CGAUCG,“ wherein C indicates a 5-methylcytosine.
Certain Modifications
In certain embodiments, oligonucleotides provided herein may comprise one or more modifications to a nucleobase, sugar, and/or intemucleoside linkage, and as such is a modified oligonucleotide. A modified nucleobase, sugar, and/or intemucleoside linkage may be selected over an unmodi fîed form because of désirable properties such as, for example, enhaneed cellular uptake, enhanced affînity for other oligonucleotides or nucleic acid targets and increased stability in the presence of nudeases.
In certain embodiments, a modified oligonucleotide comprises one or more modified nucleosides. In certain such embodiments, a modified nucleoside is a stabilizing nucleoside. An example of a stabilizing nucleoside is a sugar-modified nucleoside.
In certain embodiments, a modified nucleoside is a sugar-modified nucleoside. In certain such embodiments, the sugar-modified nucleosides can further comprise a naturel or modified heterocyclic base moiety and/or a naturel or modified intemucleoside linkage and may include further modifications independent from the sugar modification. In certain embodiments, a sugar modified nucleoside is a 2’modified nucleoside, wherein the sugar ring is modified at the 2’ carbon from naturel ribose or 2’-deoxyribose.
In certain embodiments, a 2’-modified nucleoside has a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety is a D sugar in the alpha configuration. In certain such embodiments, the bicyclic sugar moiety is a D sugar in the beta configuration. In certain such embodiments, the bicyclic sugar moiety is an L sugar in the alpha configuration. In certain such embodiments, the bicyclic sugar moiety is an L sugar in the beta configuration.
In certain embodiments, the bicyclic sugar moiety comprises a bridge group between the 2' and the 4'-carbon atoms. In certain such embodiments, the bridge group comprises from 1 to 8 linked biradical groups. In certain embodiments, the bicyclic sugar moiety comprises from 1 to 4 linked biradical groups. In certain embodiments, the bicyclic sugar moiety comprises 2 or 3 linked biradical groups. In certain embodiments, the bicyclic sugar moiety comprises 2 linked biradical groups. Examples of such 4’ to 2’ sugar substituents, include, but arc not limited to: -[C(R1)(R3>)]n-, -[C(R«XRb)]a-O, -C(RJW-N(R)-O- or, -CfRJW-O-NfR)-; 4'-CH2-2’, 4’-(CH2)2-2', 4'-(CH2)3-2'; 4’-(CH2)-O-2' (LNA); 4XCH2)-S-2’; 4'-(CH2)2-O-2' (ENA); 4'-CH(CH3)-O-2’ (cEt) and 4'-CH(CH2OCH3)-O-2', andanalogs thereof (see, e.g., U.S. Patent 7,399,845, issuedon July 15,2008); 4’-C(CHj)(CHj)-O-2'andanalogs thereof, (see, e.g„ W02009/006478, pubiished January 8,2009); 4'-CH2-N(OCHj)-2' and analogs thereof (see, e.g., W02008/150729, pubiished December 11,2008); 4'-CH2-O-N(CH3)-2' (see, e.g., US2004/0171570, pubiished Septcmber 2,2004 ); 4'-CH2-O-N(R)-2', and 4’-CH2-N(R)-O-2'-, wherein each Ris, independently, H, a protecting group, or Ci-Ci2 alkyl; 4'-CH2-N(R)-O-2', wherein Ris H, CtCi2 alkyl, or a protecting group (see, U.S. Patent 7,427,672, issued on September 23,2008); 4'-CH2-C(H)(CH3)-2' (see, e.g., Chattopadhyaya, étal., J. Org. CAem.,2009, 74,118-134); and 4*-CH2-C(=CH2)-2* and analogs thereof (see, pubiished PCT International Application WO 2008/154401, pubiished on December 8,2008).
In certain embodiments, such 4’ to 2* bridges independently comprise 1 or from 2 to 4 linked groups independently selected from -[C(R1)(Rb)]n-, -C(R,)=C(Rb)-, -C(R1)=N-, -C(=NR.)-, -C(=O)-, -C(=S)-, -O-, -Si(R.)2-, -S(=O)X-, and -N(R.)-;
wherein:
xisO, l,or2;
nis 1,2, 3, or 4;
each R« and Rb is, independently, H, a protecting group, hydroxyl, C1-C12 alkyl, substituted CiCiï alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, Cj-C2o aryl, substituted CJ-C20 aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, Cj-C7 alicyclic radical, substituted C5-C7 alicyclic radical, halogen, OJ|, NJiJ2, SJ|, Nj, COOJ|, acyl (C(=O)-H), substituted acyl, CN, sulfonyl (S(=O)2-J|), or sulfoxyl (S(=O)-Ji); and each Jj and J2 is, independently, H, C1-C12 alkyl, substituted C1-C12 alkyl, C2-C12 alkenyl, substituted C2-C12 alkenyl, C2-C12 alkynyl, substituted C2-C12 alkynyl, CS-C20 aryl, substituted CS-C20 aryl, acyl (C(=O)-H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, Cj-Cu aminoalkyl, substituted C1-C12 aminoalkyl, or a protecting group.
Nucleosides comprising such bicyclic sugar moieties are referred to as bicyclic nucleosides or BNAs. In certain embodiments, bicyclic nucleosides include, but are not limited to, (A) a-LMethyleneoxy (4’-CH2-O-2’) BNA; (B) β-D-Methyleneoxy (4’-CH2-O-2’) BNA; (C) Ethyleneoxy (4’(CH2)2-O-2’) BNA; (D) Aminooxy (4’-CH2-O-N(R)-2’) BNA; (E) Oxyamino (4’-CH2-N(R)-O-2’) BNA; (F) Methyl(methyleneoxy) (4’-CH(CHj)-O-2’) BNA (also referred to as constrained ethyl or cEt); (G) methylene-thio (4’-CH2-S-2’) BNA; (H) methylene-amino (4’-CH2-N(R)-2’) BNA; (I) methyl carbocyclîc (4’-CH2-CH(CH3)-2’) BNA; (J) c-MOE (4’-CH2-OMe-2’) BNA and (K) propylene carbocyclîc (4’-(CH2)j-2’) BNA as depicted below.
wherein Bx is a nucleobase moiety and R is, independently, H, a protecting group, or Cj-Cu alkyl.
In certain embodiments, a 2’-modified nucleoside comprises a 2'-substituent group selected from halo, allyl, amino, azido, SH, CN, OCN, CF3, OCFj, O-, S-, or N(Rm)-alkyl; O-, S-, or N(Rm)-alkenyl; O, S- or N(Rm)-alkynyl; O-alkyl enyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaiyl, O-aralkyl, O(CH2)2SCH3, O-iCHîh-O-NtRaJfRn) or O-CH2-C(=O)-N(Rm)(Rn), where each R™ and R„ is, independently, H, an amino protecting group or substituted or unsubstituted Ct-Cio alkyl. These 2'substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NQî). thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.
In certain embodiments, a 2’-modified nucleoside comprises a 2'-substituent group selected from F, NH2, Nj, OCFj. O-CHj, O(CH2)3NH2, CH2-CH=CH2, O-CH2-CH=CH2i OCH2CH2OCH3t O(CH2)2SCH3i O-(CH2)2-O-N(Rm)(Rn), -O(CH2)2O(CH2)2N(CH3)2, and N-substituted acctamide (O-CH2C^OÏ-NtRmïfRn) where each Rm and R„ is, independently, H, an amino protecting group or substituted or unsubstituted C|-C)o alkyl.
In certain embodiments, a 2’-modified nucleoside comprises a 2’-substituent group selected from F, OCFj. O-CH3, OCH2CH2OCH3,2'-O(CH2)2SCH3,0-(CH2)2-O-N(CH3)2, -O(CH2)2O(CH2)2N(CHj)2, and O-CH2-C(=O)-N(H)CH3.
In certain embodiments, a 2’-modified nucleoside comprises a 2'-substituent group selected from F, O-CH3, and OCH2CH2OCH3.
In certain embodiments, a sugar-modified nucleoside is a 4’-thio modified nucleoside. In certain embodiments, a sugar-modified nucleoside is a 4’-thio-2’-modified nucleoside. A 4’-thio modified nucleoside has a β-D-ribonucleoside where the 4'-O replaced with 4’-S. A 4'-thio-2'-modified nucleoside is a 4’-thio modified nucleoside having the 2’-OH replaced with a 2'-substituent group. Suitable 2’substituent groups inciude 2’-OCH3,2’-O-(CH2)2-OCH3, and 2'-F.
In certain embodiments, a modified oligonucleotide comprises one or more intemucleosîde modifications. In certain such embodiments, each intemucleoside linkage of a modified oligonucleotide is a modified intemucleoside linkage. In certain embodiments, a modified intemucleoside linkage comprises a phosphores atom.
In certain embodiments, a modified oligonucleotide comprises at least one phosphorothioate intemucleoside linkage. ln certain embodiments, each intemudeosïde linkage of a modified oligonucleotide is a phosphorothioate internucleoside linkage.
ln certain embodiments, a modified intemucleoside linkage does not comprise a phosphores atom. ln certain such embodiments, an intemucleoside linkage is formed by a short chain alkyl intemucleoside linkage. In certain such embodiments, an intemucleoside linkage is formed by a cycloalkyl intemucleoside linkages. ln certain such embodiments, an intemucleoside linkage is formed by a mixed hetero atom and alkyl intemucleoside linkage. In certain such embodiments, an intemucleoside linkage is formed by a mixed heteroatom and cycloalkyl intemucleoside linkages. In certain such embodiments, an intemucleoside linkage is formed by one or more short chain heteroatomic intemucleoside linkages. In certain such embodiments, an intemucleoside linkage is formed by one or more heterocyclic intemucleoside linkages. In certain such embodiments, an intemucleoside linkage has an amide backbone. In certain such embodiments, an intemucleoside linkage has mixed N, O, S and CH2 component parts.
In certain embodiments, a modified oligonucleotide comprises one or more modified nucleobases. In certain embodiments, a modified oligonucleotide comprises one or more 5methylcytosines. In certain embodiments, each cytosine of a modified oligonucleotide comprises a 5methylcytosine.
In certain embodiments, a modified nucleobase is selected from 5-hydroxymethyl cytosine, 720 deazaguaninc and 7-deazaadenine. In certain embodiments, a modified nucleobase is selected from 7deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. ln certain embodiments, a modified nucleobase is selected from 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2 aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
In certain embodiments, a modified nucleobase comprises a polycyclic heterocycle. In certain embodiments, a modified nucleobase comprises a tricyclic heterocycle. In certain embodiments, a modified nucleobase comprises a phenoxazine dérivative. In certain embodiments, the phenoxazine can be further modified to form a nucleobase known in the art as a G-clamp.
Certain Pharmaceutical Compositions
Provided herein are pharmaceutical compositions comprising oligonucleotides. In certain embodiments, such pharmaceutical compositions are used for the treatment of fibrosis, kidney disease, and cancer. In certain embodiments, a pharmaceutical composition provided herein comprises a compound described herein.
Suitable administration routes include, but are not limited to, oral, rectal, transmucosal, intestinal, enterai, topical, suppository, through inhalation, intrathecal, intracardiac, intraventricular, intraperitoneal, intranasal, intraocular, intratumoral, and parentéral (e.g., intravenous, intramuscular, intramedullary, and subeutaneous). In certain embodiments, pharmaceutical intrathecals are administered to achieve local rather than systemic exposures. For example, pharmaceuticai compositions may be injected directly in the area of desired effect (e.g., into the liver or kidney).
In certain embodiments, a pharmaceuticai composition is administered in the form of a dosage unit (e.g., tablet, capsule, bolus, etc.). In some embodiments, a pharmaceuticai compositions comprises a modified oligonucleotide at a dose within a range selected from 25 mg to 800 mg, 25 mg to 700 mg, 25 mg to 600 mg, 25 mg to 500 mg, 25 mg to 400 mg, 25 mg to 300 mg, 25 mg to 200 mg, 25 mg to 100 mg, 100 mg to 800 mg, 200 mg to 800 mg, 300 mg to 800 mg, 400 mg to 800 mg, 500 mg to 800 mg, 600 mg to 800 mg, 100 mg to 700 mg, 150 mg to 650 mg, 200 mg to 600 mg, 250 mg to 550 mg, 300 mg to 500 mg, 300 mg to 400 mg, and 400 mg to 600 mg. In certain embodiments, such pharmaceuticai compositions comprise a modified oligonucleotide in a dose selected from 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 270 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 305 mg, 310 mg, 315 mg, 320 mg, 325 mg, 330 mg, 335 mg, 340 mg, 345 mg, 350 mg, 355 mg, 360 mg, 365 mg, 370 mg, 375 mg, 380 mg, 385 mg, 390 mg, 395 mg, 400 mg, 405 mg, 410 mg, 415 mg, 420 mg, 425 mg, 430 mg, 435 mg, 440 mg, 445 mg, 450 mg, 455 mg, 460 mg, 465 mg, 470 mg, 475 mg, 480 mg, 485 mg, 490 mg, 495 mg, 500 mg, 505 mg, 510 mg, 515 mg, 520 mg, 525 mg, 530 mg, 535 mg, 540 mg, 545 mg, 550 mg, 555 mg, 560 mg, 565 mg, 570 mg, 575 mg, 580 mg, 585 mg, 590 mg, 595 mg, 600 mg, 605 mg, 610 mg, 615 mg, 620 mg, 625 mg, 630 mg, 635 mg, 640 mg, 645 mg, 650 mg, 655 mg, 660 mg, 665 mg, 670 mg, 675 mg, 680 mg, 685 mg, 690 mg, 695 mg, 700 mg, 705 mg, 710 mg, 715 mg, 720 mg, 725 mg, 730 mg, 735 mg, 740 mg, 745 mg, 750 mg, 755 mg, 760 mg, 765 mg, 770 mg, 775 mg, 780 mg, 785 mg, 790 mg, 795 mg, and 800 mg. In certain such embodiments, a pharmaceuticai composition of the comprises a dose of modified oligonucleotide selected from 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 500 mg, 600 mg, 700 mg, and 800mg.
In certain embodiments, a pharmaceuticai agent is stérile lyophilized modified oligonucleotide that is reconstituted with a suitable diluent, e.g., stérile water for injection or stérile saline for injection. The reconstituted product is administered as a subeutaneous injection or as an intravenous infusion after dilution into saline. The lyophilized drug product consists of a modified oligonucleotide which has been prepared in water for injection, or in saline for injection, adjusted to pH 7.0-9.0 with acid or base during préparation, and then lyophilized. The lyophilized modified oligonucleotide may be 25-800 mg of an oligonucleotide. It is understood that this encompasses 25,50,75,100,125,150,175,200,225,250, 275, 300, 325,350, 375,425,450,475, 500, 525,550, 575,600, 625, 650,675, 700, 725,750, 775, and 800 mg of modified lyophilized oligonucleotide. Further, in some embodiments, the lyophilized modified oligonucleotide is an amount of an oligonucleotide within a range selected from 25 mg to 800 mg, 25 mg to 700 mg, 25 mg to 600 mg, 25 mg to 500 mg, 25 mg to 400 mg, 25 mg to 300 mg, 25 mg to
200 mg, 25 mg to 100 mg, 100 mg to 800 mg, 200 mg to 800 mg, 300 mg to 800 mg, 400 mg to 800 mg,
500 mg to 800 mg, 600 mg to 800 mg, 100 mg to 700 mg, 150 mg to 650 mg, 200 mg to 600 mg, 250 mg to 550 mg, 300 mg to 500 mg, 300 mg to 400 mg, and 400 mg to 600 mg. The lyophilîzed drug product may be packaged in a 2 mL Type I, clear glass vial (ammonium sulfate-treated), stoppered with a bromobutyl rubber closure and sealed with an aluminum FLIP-OFF® overseal.
In certain embodiments, the pharmaceutical compositions provided herein may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their artestablished usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the présent invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfère with the biological activities of the components of the compositions of the présent invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wctting agents, emulsifiers, salts for înfluencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the oligonucleotide(s) of the formulation.
Lipid moieties hâve been used in nucleic acid thérapies in a variety of methods. In one method, the nucleic acid is introduced into preformed liposomes or lipoplexes made of mixtures of cationic lipids and neutral lipids. In another method, DNA complexes with mono- or poly-cationic lipids are formed without the presence of a neutral lipid. In certain embodiments, a lipid moiety is selected to încrease distribution of a pharmaceutical agent to a particular cell or tissue. In certain embodiments, a lipid moiety is selected to încrease distribution of a pharmaceutical agent to fat tissue. In certain embodiments, a lipid moiety is selected to incrcase distribution of a pharmaceutical agent to muscle tissue.
In certain embodiments, INTRALIPID is used to prépare a pharmaceutical composition comprising an oligonucleotide. Intralipid is fat émulsion prepared for intravenous administration. It is made up of 10% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH range is 6 to 8.9.
In certain embodiments, a pharmaceutical composition provided herein comprises a poiyamine compound or a lipid moiety complexed with a nucleic acid. In certain embodiments, such préparations comprise one or more compounds each individually having a structure defined by formula (Z) or a pharmaceutically acceptable sait thereof.
wherein each X* and Xb, for each occunence, is independently alkylene; n is 0,1,2,3,4, or 5; each R is independently H, wherein at least n + 2 of the R moieties in at least about 80% of the molécules of the compound of formula (Z) in the préparation are not H; m is 1,2,3 or 4; Y is O, NR2, or S; R1 îs alkyl, alkenyl, or alkynyl; each of which is optionally substituted with one or more substituents; and R2 is H, alkyl, alkenyl, or alkynyl; each of which is optionally substituted each of which is optionally substituted with one or more substituents; provided that, if n = 0, then at least n + 3 of the R moieties arc not H. Such préparations are described in PCT publication WQ/2008/042973, which is herein incorporated by reference in its entirety for the disdosure of lipid préparations. Certain additional préparations are described in Akïnc et al., Nature Biotechnology 26,561 - 569 (01 May 2008), which is herein incorporated by reference in its entirety for the disdosure of lipid préparations.
In certain embodiments, pharmaceutical compositions provided herein comprise one or more modified oligonucleotides and one or more excipients. In certain such embodiments, excipients are selected from water, sait solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnésium stéarate, talc, silicic acid, viscous parafïïn, hydroxymethylcellulose and polyvinylpyrrolidone.
In certain embodiments, a pharmaceutical composition provided herein is prepared using known techniques, including, but not limited to mixing, dissolving, granulating, dragee-makîng, levigating, emulsifying, encapsulating, entrapping or tableting processes.
In certain embodiments, a pharmaceutical composition provided herein is a liquid (e.g., a suspension, élixir and/or solution). In certain of such embodiments, a liquid pharmaceutical composition is prepared using ingrédients known in the art, including, but not limited to, water, glycols, oils, alcohols, flavoring agents, preservatîves, and coloring agents.
In certain embodiments, a pharmaceutical composition provided herein is a solid (e.g., a powder, tablet, and/or capsule). In certain of such embodiments, a solid pharmaceutical composition comprising one or more oligonucleotides is prepared using ingrédients known in the art, including, but not limited to, starches, sugars, diluents, granulating agents, lubricants, binders, and disintegrating agents.
In certain embodiments, a pharmaceutical composition provided herein is formulated as a depot préparation. Certain such depot préparations arc typically longer actîng than non-depot préparations. In certain embodiments, such préparations are administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. In certain embodiments, depot préparations are prepared using suitable polymeric or hydrophobie materials (for example an émulsion in an acceptable oil) or ion exchange resîns, or as sparingly soluble dérivatives, for example, as a sparingly soluble sait.
In certain embodiments, a pharmaceutical composition provided herein comprises a delivery system. Examples of delivery Systems include, but are not limited to, liposomes and émulsions. Certain delivery Systems are useful for preparing certain pharmaceutical compositions including those comprising hydrophobie compounds. In certain embodiments, certain organic solvents such as dimethylsulfoxide are used.
In certain embodiments, a pharmaceutical composition provided herein comprises one or more tissue-specific delivery molecuies desîgned to deliver the one or more pharmaceutical agents of the present invention to spécifie tissues or cell types. For example, in certain embodiments, pharmaceutical compositions include liposomes coated with a tissue-specific antibody.
In certain embodiments, a pharmaceutical composition provided herein comprises a co-solvent system. Certain of such co-solvent Systems comprise, for example, benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. In certain embodiments, such co-solvent Systems are used for hydrophobie compounds. A non-limiting example of such a co-solvent system is the VPD co-solvent system, which is a solution of absolute éthanol comprising 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™ and 65% w/v polyethylene glycol 300. The proportions of such co-solvent Systems may be varied considerably without significantly altering their solubility and toxicity charactcristics. Furthermore, the identity of co-solvent components may be varied: for example, other surfactants may be used instead of Polysorbate 80™; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.
In certain embodiments, a pharmaceutical composition provided herein comprises a sustainedrelease System. A non-limiting example of such a sustained-release System is a s emi-perméable matrix of solid hydrophobie polymers. In certain embodiments, sustained-release Systems may, depending on their chemical nature, release pharmaceutical agents over a period of hours, days, weeks or months.
In certain embodiments, a pharmaceutical composition provided herein is prepared for oral administration. In certain of such embodiments, a pharmaceutical composition is formuiated by combining one or more compounds comprising a modified oligonucleotide with one or more pharmaceutically acceptable carriers. Certain of such carriers enable pharmaceutical compositions to be formuiated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject. In certain embodiments, pharmaceutical compositions for oral use are obtained by mixing oligonucleotide and one or more soüd excipient. Suitable excipients include, but are not limited to, fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose préparations such as, for exampie, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). In certain embodiments, such a mixture is optionally ground and auxiliaries are optionally added. In certain embodiments, pharmaceutical compositions are formed to obtain tablets or dragée cores. Incertain embodiments, disintegrating agents (e.g., cross-Iinked polyvinyl pyrrolidone, agar, or alginic acid or a sait thereof, such as sodium alginate) are added.
In certain embodiments, dragee cores are provided with coatings. In certain such embodiments, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to tablets or dragee coatings.
In certain embodiments, pharmaceutical compositions for oral administration are push-fit capsules made of gelatin. Certain of such push-fit capsules comprise one or more pharmaceutical agents of the présent invention in admixture with one or more filler such as lactose, binders such as starches, and/or lubricants such as talc or magnésium stéarate and, optionally, stabîlizers. In certain embodiments, pharmaceutical compositions for oral administration are soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. In certain soft capsules, one or more pharmaceutical agents of the présent invention are be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffm, or liquid polyethylene glycols. In addition, stabîlizers may be added.
In certain embodiments, pharmaceutical compositions are prepared for buccal administration. Certain of such pharmaceutical compositions are tablets or lozenges formulated in conventional manner.
In certain embodiments, a pharmaceutical composition is prepared for administration by injection (e.g., intravenous, subeutaneous, intramuscular, etc.). In certain of such embodiments, a pharmaceutical composition comprises a carrier and is formulated in aqueous solution, such as water or physiologically compatible buffers such as Hanks's solution, Ringer’s solution, or physiological saline buffer. In certain embodiments, other ingrédients are induded (e.g., ingrédients that aîd in solubility or serve as préservât!ves). In certain embodiments, injectable suspensions are prepared using appropriate liquid carriers, suspending agents and the like. Certain pharmaceutical compositions for injection are presented in unit dosage form, e.g., in ampoules or in multi-dose containers. Certain pharmaceutical compositions for injection are suspensions, solutions or émulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Certain solvents suitable for use in pharmaceutical compositions for injection include, but are not limited to, lipophilie solvents and fatty oils, such as sesame oil, synthetic fatty acid esters, such as ethyl oleate or triglycérides, and liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, such suspensions may also contain suitable stabîlizers or agents that increase the solubility of the pharmaceutical agents to allow for the préparation of highly concentrated solutions.
In certain embodiments, a pharmaceutical composition is prepared for transmucosal administration. In certain of such embodiments pénétrants appropriate to the barrier to be permeated are used in the formulation. Such pénétrants are generally known in the art.
In certain embodiments, a pharmaceutical composition is prepared for administration by inhalation. Certain of such pharmaceutical compositions for inhalation are prepared in the form of an aérosol spray in a pressurized pack or a nebulizer. Certain of such pharmaceutical compositions comprise a propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In certain embodiments using a pressurized aérosol, the dosage unit may be determined with a valve that delivers a metered amount. In certain embodiments, capsules and cartridges for use in an inhaler or insufïlator may be formulated. Certain of such formulations comprise a powder mixture of a pharmaceutical agent of the invention and a suitable powder base such as lactose or starch.
In certain embodiments, a pharmaceutical composition is prepared for rectal administration, such as a suppositories or rétention enema. Certain of such pharmaceutical compositions comprise known ingrédients, such as cocoa butter and/or other glycerides.
In certain embodiments, a pharmaceutical composition is prepared for topical administration. Certain of such pharmaceutical compositions comprise bland moisturizing bases, such as ointments or creams. Exemplary suitable ointment bases include, but are not limited to, petrolatum, petrolatum plus volatile silicones, and lanolin and water in oil émulsions. Exemplary suitable cream bases include, but are not limited to, cold cream and hydrophllic ointment.
In certain embodiments, a pharmaceutical composition provided herein comprises a modified oligonucleotide in a therapeutlcally effective amount. In certain embodiments, the therapeutlcally effective amount is suffirent to prevent, alleviate or ameliorate symptoms of a disease or to prolong the survival of the subject being treated. Détermination of a therapeutlcally effective amount is well within the capability of those skilled in the art.
In certain embodiments, one or more modified oligonucleotides provided herein is formulated as a prodrug. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutlcally more active form of an oligonucleotide. In certain embodiments, prodrugs are useful because they are casier to admînister than the corresponding active form. For example, in certain instances, a prodrug may be more bioavailable (e.g., through oral administration) than is the corresponding active form. In certain instances, a prodrug may hâve improved solubility compared to the corresponding active form. In certain embodiments, prodrugs are less water soluble than the corresponding active form. In certain instances, such prodrugs possess superior transmittal across cell membranes, where water solubility is detrimental to mobility. In certain embodiments, a prodrug is an ester. In certain such embodiments, the ester is metabolically hydrolyzcd to carboxylic acid upon administration. In certain instances the carboxylic acid containing compound is the corresponding active form. In certain embodiments, a prodrug comprises a short peptide (polyaminoacid) bound to an acid group. In certain of such embodiments, the peptide is cleaved upon administration to form the corresponding active form.
In certain embodiments, a prodrug is produced by modifying a pharmaceutically active compound such that the active compound will be regenerated upon in vivo administration. The prodrug can be designed to aller the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacodynamie processes and drug metabolism in vivo, those of skîll in this art, once a pharmaceutically active compound is known, can design prodrugs of the compound (see, e.g., Nogrady (1985) Médicinal Chemistry A Biochemical Approach, Oxford Univcrsity Press, New York, pages 388-392),
Certain Routes of Administration
In certain embodiments, administering to a subject comprises parentéral administration. In certain embodiments, administering to a subject comprises intravenous administration. In certain embodiments, administering to a subject comprises subcutaneous administration.
In certain embodiments, administering to a subject comprises intraarterial administration. In certain embodiments, administering to a subject comprises intracardial administration. Suitable means for intracardia] administration include the use of a cathéter, or administration during open heart surgery. In certain embodiments, administration comprises use of a stent.
In certain embodiments, administration indudes pulmonary administration. In certain embodiments, pulmonary administration comprises delivery of aerosolized oligonucleotide to the lung of a subject by inhalation. Following inhalation by a subject of aerosolized oligonucleotide, oligonucleotide distributes to cells of both normal and inflamed lung tissue, including alveolar macrophages, eosinophils, epithelium, blood vessei endothélium, and bronchiolar epithelium. A suitable device for the delivery of a pharmaceutical composition comprising a modified oligonucleotide indudes, but is not limited to, a standard nebulizer device. Formulations and methods for modulating the size of droplets using nebulizer devices to target spécifie portions of the respiratory tract and lungs are well known to those skilled in the art. Additional suitable devices indude dry powder inhalera or metered dose inhalera.
In certain embodiments, pharmaceutical compositions are administered to achieve local rather than systemic exposures. For exampie, pulmonary administration delivera a pharmaceutical composition to the lung, with minimal systemic exposure.
Additional suitable administration routes indude, but are not limited to, oral, rectal, transmucosal, intestinal, enterai, topical, transdermal, suppository, intrathecal, intraventricular, intraperitoneal, intranasal, intraocular, intramuscular, intramedullary, and intratumoral.
Certain Compounds
Provided herein are compounds comprising a modified oligonucleotide having certain nucleoside patterns, and uses of these compounds to modulate the activity, level or expression of a target nucleic acid. In certain embodiments, the compound comprises an oligonucleotide. In certain such embodiments, the compound consists of an oligonucleotide. In certain embodiments, the oligonucleotide is a modified oligonucleotide. In certain embodiments, a modified oligonucleotide is complementary to a small non-coding RNA. In certain embodiments, the small non-coding RNA is miR-21.
In certain such embodiments, the compound comprises a modified oligonucleotide hybridized to a complementary strand, i.e. the compound comprises a double-stranded olîgomeric compound. In certain embodiments, the hybridization of a modified oligonucleotide to a complementary strand forms at least one blunt end. In certain such embodiments, the hybridization of a modified oligonucleotide to a complementary strand forms a blunt end at each terminus of the double-stranded olîgomeric compound. In certain embodiments, a terminus of a modified oligonucleotide comprises one or more additional linked nucleosides relative to the number of linked nucleosides ofthe complementary strand. In certain embodiments, the one or more additional nucleosides are at the 5’ terminus of an oligonucleotide. In certain embodiments, the one or more additional nucleosides are at the 3' terminus of an oligonucleotide. In certain embodiments, at least one nucleobase of a nucleoside of the one or more additional nucleosides is complementary to the target RNA. In certain embodiments, each nucleobase of each one or more additional nucleosides is complementary to the target RNA. In certain embodiments, a terminus of the complementary strand comprises one or more additional linked nucleosides relative to the number of linked nucleosides of an oligonucleotide. In certain embodiments, the one or more additional linked nucleosides are at the 3’ terminus of the complementary strand. In certain embodiments, the one or more additional linked nucleosides are at the 5’ terminus ofthe complementary strand. In certain embodiments, two additional linked nucleosides are linked to a terminus. In certain embodiments, one additional nucleoside is linked to a terminus.
In certain embodiments, the compound comprises a modified oligonucleotide conjugated to one or more moieties which enhance the activity, cellular distribution or cellular uptake of the resulting antisense oligonucleotides. In certain such embodiments, the moiety is a cholestérol moiety. In certain embodiments, the moiety is a lipid moiety. Additional moieties for conjugation include carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. In certain embodiments, a conjugate group is attached directly to an oligonucleotide. In certain embodiments, a conjugate group is attached to a modified oligonucleotide by a linking moiety selected from amino, hydroxyl, carboxylic acid, thiol, unsaturations (e.g., double or triple bonds), 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1carboxylate (SMCC), 6-aminohexanoic acid(AHEX or AHA), substituted CI-CIO alkyl, substituted or unsubstituted C2-C10 alkenyl, and substituted or unsubstituted C2-C10 alkynyl. In certain such embodiments, a substituent group is selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.
In certain such embodiments, the compound comprises a modified oligonucleotide having one or more stabilizing groups that are attached to one or both termini of a modified oligonucleotide to enhance properties such as, for example, nuclease stability. Included in stabilizing groups are cap structures. These terminal modifications protect a modified oligonucleotide from exonuclease dégradation, and can help in delivery and/or localization within a cell. The cap can be présent at the 5’terminus (5’-cap), or at the 3'-terminus (3’-cap), or can be présent on both termini. Cap structures include, for example, inverted deoxy abasic caps,
Suitable cap structures indude a 4*,5*-methylene nucléotide, a l-(beta-D-erythiOfuranosy!) nucléotide, a 4’-thio nucléotide, a carbocyclic nucléotide, a 1,5-anhydrohexitol nucléotide, an Lnucleotide, an alpha-nucleotidc, a modified base nucléotide, a phosphorodithioate linkage, a threopentofuranosyl nucléotide, anacyclic 3',4'-seco nucléotide, an acyclic 3,4-dihydroxybutyl nucléotide, an acyclic 3,5-<lihydroxypentyl nucléotide, a 3’-3'-inverted nucléotide moiety, a 3’-3'-inverted abasic moiety, a 3'-2'-inverted nucléotide moiety, a 3'-2'-inverted abasic moiety, a 1,4-butanediol phosphate, a 3'phosphoramidate, a hexy (phosphate, an aminohexyl phosphate, a 3'-phosphate, a 3-phosphorothioate, a phosphorodithioate, a bridging methylphosphonate moiety, and a non-bridging methylphosphonate moiety 5'-amino-alkyl phosphate, a 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate, a 6aminohexyl phosphate, a 1,2-aminododecyl phosphate, a hydroxypropyl phosphate, a 5'-5’-inverted nucléotide moiety, a 5*-5 '-invert ed abasic moiety, a 5’-phosphoramidate, a 5’-phosphorothioate, a 5’amino, a bridging and/or non-bridging 5'-phosphoramidate, a phosphorothioate, and a 5'-mercapto moiety.
Certain Kits
The présent invention also provides kits. In some embodiments, the kits comprise one or more compounds of the invention comprising a modified oligonucleotide, wherein the nucleobase sequence of the oligonucleotide is complementary to the nucleobase sequence of miR-21. The compounds complementary to miR-21 can hâve any of the nucleoside patterns described herein. In some embodiments, the compounds complementary to miR-21 can be présent within a vial. A plurality of vials, such as 10, can be présent in, for example, dispensing packs. In some embodiments, the vial is manufactured so as to be accessible wîth a syringe. The kit can also contain instructions for using the compounds complementary to miR-21.
In some embodiments, the kits may be used for administration of the compound complementary to miR-21 to a subject. In such instances, in addition to compounds complementary to miR-21, the kit can further comprise one or more ofthe following: syringe, alcohol swab, cotton bail, and/or gauze pad. In some embodiments, the compounds complementary to miR-21 can be présent in a pre-filled syringe (such as a single-dose syringes with, for example, a 27 gauge, A inch needle with a needle gnard), rather than in a vial. A plurality of pre-filled syringes, such as 10, can be présent in, for example, dispensing packs. The kit can also contain instructions for administering the compounds complementary to miR-21.
Certain Experimental Models
In certain embodiments, the présent invention provides methods of using and/or testing modified oligonucleotides of the présent invention in an experimental model. Those having skill in the art are able to select and modify the protocols for such experimental models to évaluât e a pharmaceutical agent of the invention.
Generally, modified oligonucleotides are first tested in cultured cells. Suitable cell types include those that are related to the cell type to which delivery of a modified oligonucleotide is desired in vivo. For example, suitable cell types for the study of the methods described herein include primary or cultured cells.
In certain embodiments, the extent to which a modified oligonucleotide interfères with the activity of miR-21 îs assessed in cultured cells. In certain embodiments, inhibition of microRNA activity may be assessed by measuring the levels of the microRNA. Altematively, the level of a predicted or validated microRNA-regulated transcript may be measured. An inhibition of microRNA activity may resuit in the increase in the miR-21 -regulated transcript, and/or the protein encoded by miR-21 -regulated transcript. Further, in certain embodiments, certain phenotypic outcomes may be measured.
Several animal models are available to the skilled artisan for the study of miR-21 in models of human disease. For example, inhibitors of miR-21 may be studied in models of cancer, such as orthotopic xenograft models, toxin-induced cancer models, or genetically-induced cancer models. In such cancer models, the studios may be performed to evaluate the effects of inhibitors of miR-21 on tumor size, tumor number, overall survival and/or progression-free survival.
The effects of inhibitors of miR-21 on cardiac function and fibrosis may be studied in models of transaortic banding or myocardial infarction, each of which induces abnormal cardiac function and fibrosis. Models of kidney fibrosis include unilatéral urétéral obstruction and ischcmia/reperfusion injury. During early time points, the kidney ischemia reperfusion injury model may be used as a model for acute kidney injury, while later time points serve as a model for kidney fibrosis. An additional model of kidney fibrosis is aristolochic acid-induced fibrosis model. Liver fibrosis models are induced by, for example, carbon tetrachloride intoxication or bile duct ligation. Liver fibrosis may also be induced by a méthionine and choline déficient diet, which results in steatotic liver with associated fibrosis. The effects of miR-21 on lung fibrosis may be studied, for example, in a model of bleomycin-induced pulmonary fibrosis or in mice that overexpress TGF-β in the lung. Wound healing models are also available to the skilled artisan, for example the C57Bl/KsJ-db/db mice, which exhibit several characteristics of adult onset diabètes, such as markedly delayed wound closure.
An additional animal model includes a mouse or canine Alport Syndrome model. An example of a mouse model of Alport Syndrome is the Col4a3 knockout mouse.
Certain Quantitation Assays
The effects of antisense inhibition of miR-21 following the administration of modified oligonucleotides may be assessed by a variety of methods known in the art. In certain embodiments, these methods are be used to quantitate microRNA levels in cells or tissues in vitro or in vivo. In certain embodiments, changes in microRNA levels are measured by microarray analysis. In certain embodiments, changes in microRNA levels are measured by one of several commercially available PCR assays, such as the TaqMan® MicroRNA Assay (Applied Biosystcms). In certain embodiments, antisense inhibition of miR-21 is assessed by measuring the mRNA and/or protein level of a target of miR-21. Antisense inhibition of miR-21 generally results in the increase in the level of mRNA and/or protein of a target of the microRNA.
Target Engagement Assay
Modulation of microRNA activity with an anti-miR or microRNA mimic may bc assessed by measuring target engagement. In certain embodiments, target engagement is measured by microarray profiling of mRNAs. The sequences of the mRNAs that arc modulated (either increased or decrcased) by 5 the anti-miR or microRNA mimic are searched for microRNA seed sequences, to compare modulation of mRNAs that are targets of the microRNA to modulation of mRNAs that are not targets of the microRNA. In this manner, the interaction of the anti-miR with miR-21, or miR-21 mimic with its targets, can be evaluated. In the case of an anti-miR, mRNAs whose expression levels are increased are screened for the mRNA sequences that comprise a seed match to the microRNA to which the anti-miR is complementary.
EXAMPLES
The following examples are presented in order to more fully illustra te some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope ofthe invention. Those of ordinary skill in the art will readily adopt the underlying principies of this discovery to design 15 various compounds without departing from the spirit ofthe current invention.
Example 1: Anti-miR-21 compounds
Various anti-miRs targeted to miR-21 and comprising cEt nucleosides were designed with variations in length and complementarity to miR-21, as well as in the number, type and placement of modified sugar moieties. The compounds were evaluated for their inhibitory effects on miR-21 activity in 20 an in vitro luciferasc assay.
Luciferase Assay
The compounds were assessed for miR-21 inhibitory activity in a luciferase assay. A microRNA luciferasc sensor construct was engineered using pGL3-MCS2 (Promega). The construct was introduced 25 into Hela cells to test the ability of anti-miR compounds to inhibit activity of miR-21. In this assay, miR21 présent in the Hela cells binds to its cognate sitefs) in the luciferase sensor construct, and suppresses luciferasc expression. When the appropriate anti-miR is introduced into the cells, it binds to miR-21 and relicves suppression of luciferase expression. Thus, in this assay anti-miRs that are effective inhibitors of miR-21 expression will cause an increase in luciferase expression.
Davl : Hela cells (ATCC), stably transfccted with a luciferasc construct engineered to contain a sequence complementary of miR-2i, were seeded inT-170 flasks (BD Falcon) at 3.5 *10* cells/flask Hela cells were grown in Dulbecco’s Modified Eaglc Medium with High Glucose (Invitrogen).
Day 2: Each flask ofHela cells was transfected with 0.5ug ofa phRL sensor plasmîd (Promega) expressing Renilla to be used in normalization. Hela cells were transfected using 20ul Lipofectamine 35 2000/flask (Invitrogen). After 4 hours of transfection, cells were washed with PBS and trypsinized. Hela cells were plated at 40k/well in 24 well plates (BD Falcon) and left ovemight.
Pav 3: Hela cells were transfected with anti-miRs using Lipofectin (Invîtrogen) at 2.5ul
Lipofectin/lOOnM ASO/ml Opti-MEM I Reduced Sérum Medium (Invîtrogen) for 4 hours. After ASO transfection, Hela cells were refed with Dulbecco’s Modified Eagle Medium with High Glucose (Invîtrogen).
Pav 4: Hela cells are passively lysed and luciferase actîvity measured using the Pual-Luciferase Reporter Assay System (Promega).
Luciferase actîvity in anti-miR-21 -treated cells was compared to a ‘mode* treatment, în which cells received no anti-miR treatment.
Certain of the active compounds are shown in Table A. Nucleoside modifications are indicated as follows: nucleosides not followed by a subscript indicate β-Ρ-deoxyribonucleosides; nucleosides followed by a subscript “F’ indicate 2’-MOE nucleosides; nucleosides followed by a subscript “S” indicate S-cEt nucleosides. Each intemucleoside linkage is a phosphorothioate intemucleoside linkage. Superscript “Me” indicates a 5-methyl group on the base ofthe nucleoside.
Table A: Anti-miR-21 Compounds
Compound | Sequence and Chemistry (shading indicates S-cEt nucleoside) | SEQID NO | ||||||||||||||
36328 | Mcz^ | As | Gs | TE | Cs | Us | Ge | Ae | Us | As | Ae | Ge | Cs | TE | As | 5 |
36232 | C | As | Gs | T | Cs | Us | G | A | Us | As | A | G | Cs | T | As | 5 |
36234 | c | As | Gs | T | Cs | Us | G | A | Us | A | As | Gs | C | T | As | 5 |
36235 | c | As | Gs | T | Cs | Us | G | A | Us | A | As | G | Cs | T | As | 5 |
36237 | c | As | Gs | T | Cs | Us | G | A | Us | A | A | Gs | Cs | T | As | 5 |
Table B: Inhibitory actîvity of anti-miR-21 compounds
Treatment | Concentration of Oligonucleotide (uM) | |||||
50 | 16.7 | 5.6 | 1.9 | 0.6 | 0.2 | |
36328 | 1.1 | 4.36 | 1.05 | 0.93 | 0.94 | 0.98 |
36232 | 1.1 | 4.2 | 5.22 | 2.37 | 0.9 | 0.76 |
36234 | 1.02 | 4.4 | 4.96 | 1.67 | 1.03 | 0.79 |
36235 | 2 | 6.17 | 7.57 | 3.01 | 1.1 | 1.01 |
36237 | 1.49 | 6.2 | 4.35 | 1.14 | 0.93 | 0.99 |
As shown in Table B, the anti-miR-21 compounds of Table A inhibited miR-21 actîvity in vitro in the luciferase assay. These active compounds were selected for further testing in an in vivo model of kidney fibrosis.
UUO Model of Fibrosis
Unilatéral urétéral obstruction (UUO) is a well-cstablished experimental model of rénal injury leading to interstitial fibrosis, and thus is used as an experimental model that is reflective of human kidney disease. UUO is induced by surgically ligating a single ureter. As fibrosis is characterized by an increase in collagen, the présence and extent of kidney fibrosis may be determined by measuring collagen content. Both collagen 1A1 (Col 1A1) and collagen 3A1 (Col 3A1) are measured to assess collagen content. An additional indicator of fibrosis is the percentage of kidney tissue that exhibits collagen expression following the UUO procedure. This ‘collagen area fraction’ is measured histologically through quantitative image processing of the area of kidney tissue that is stained red by the pîcrosirius red stain; the percent detected as red is normal ized by the area of kidney section. Kidney fibrosis may also be observed by measuring the amount of hydroxyproline, which îs a major component of collagen, in a sample.
The cEt-containing anti-miR-21 compounds 36232,36234,36235,36237, and 36328 were tested in the UUO model of kidney fibrosis. Groups of animais were treated as follows: UUO only (n=4), UUO with PBS (n=8), or UUO with anti-miR-21 compound (n=7 to 8). Relative to the day of the UUO procedure, PBS or anti-miR-21 compound was administered at days -4, -2,0, and +3. Anti-miR-21 compounds were administered at a dose of 20 mg/kg. As the anti-miR compounds were administered prior to the UUO procedure, this dosing regimen is considered a prophylactic treatment. At day 11, animais were sacrificed and kidney was isolated for measurement of collagen expression. Collagen expression was measured by real-time PCR and normalized first to GAPDH and then to the sham control animais. Statistical significance was determined according to a 1 -way ANOVA test. As shown in Figure l, treatment with 36232 and 36328 reduced the expression of collagen l Al (Figure 1 A) and collagen 3Al (Figure IB) in a statistically significant manner, relative to sham-treated animais. Although they were active inhibitors of miR-21 in vitro, the compounds 36234,36235, and 36237 did not resuit in statistically significant réductions in collagen expression in vivo.
These results demonstrate that 36328 and 36232 are candidate agents for the treatment or prévention of fibrosis, including kidney fibrosis.
Although compounds 36328 and 36232 hâve identical S-cEt nucleosîde placement and inhibit miR-21 in vitro and in vivo, they exhibit markcdly different viscosities in solution. 36328 is a highly viscous in a saline solution, where as 36232 is not. A highly viscous solution may not be suitable for administration, for example, via a subeutaneous injection, as a larger volume of administration would be required to accommodatc the required amount of anti-miR, and larger volumes are more dîftîcult to administer subcutaneously. A lower viscosity solution may bc désirable in order to facilitate administration of an agent. In an effort to alter the viscosity of 36328, variations were designed as shown în Table C. Each compound was tested for activity in the luciferase assay, viscosity in water, and activity in the UUO model.
Table C: 36328 and related compounds
Compound # | Sequence and Chemistry (shading indicates cEt sugar, underscore indicates mismatch) | SEQ ID NO | ||||||||||||||
36328 | MeCE | As | Gs | TE | Cs | Us | Ge | Ae | Us | As | Ae | Ge | Cs | Te | As | 5 |
36282 | As | Gs | Te | As | Us | Ge | Ae | Us | As | Ae | Ge | Cs | Te | As | 11 | |
36283 | MeCE | As | Gs | Te | As | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | As | 12 |
36284 | ^CÎ | As | As | Te | Cs | Us | Ae | Ae | Us | As | Ae | Ge | Cs | Te | As | 7 |
36285 | MCf'i | As | As | Te | Cs | As | Ae | Ae | Us | As | Ae | Ge | Cs | Te | As | 13 |
Results from the luciferase assay are shown in Table D and are shown as fold increase in luciferase activity, relative to mock transfection. As shown in Table D, 36283,36284 and 36328 inhibited miR-21 activity. 36282 and 36285 were not effective inhibitors of miR-21 in vitro. Inhibitory activity of 36328 from a separate experiment (above) is shown for comparison.
Table D: anti-miR-21 activity in vitro
Treatment | Concentration of Oligonucleotide (uM) | ||||
50 | 16.7 | 5.6 | 1.9 | 0.6 | |
36282 | 1.67 | 1.33 | 1.10 | 1.13 | 0.77 |
36283 | 5.90 | 5.50 | 3.57 | 2.30 | 0.60 |
36284 | 5.00 | 5.03 | 3.67 | 2.13 | 1.10 |
36285 | 1.27 | 0,90 | 0.97 | 1.03 | 0.87 |
36328 | 1.1 | 4.36 | 1.05 | 0.93 | 0.94 |
Compounds were dissolved in water. Using routing methods, oligonucleotide concentration was calculated gravimetrically (mg/g) and viscosity (cP) was measured using a viscometer. Results are shown în Table E.
Table E: An tl-miR-21 compound viscosity
Compound # | Viscosity cP | Concentration mg/g |
36282 | 178 | 156 |
36283 | 147 | 165 |
36284 | 25 | 184 |
36285 | 13 | 174 |
36328 | 212 | 141 |
lntroducing a single mismatch into compound #36382 reduced viscosity only slightly, and significantly reduced miR-21 inhibitory activity in the luciferase assay. lntroducing three mismatches into compound #36285 significantly reduced viscosity, but resulted in very weak miR-21 inhibitory activity in the luciferase assay. Compounds 36283 and 36284 each inhibîted miR-21 in the luciferase assay but exhibited very different viscosities. Compound 36284 has one mismatch at nucleobase position 3 and one mismatch at nucleobase position 7 and exhibited a very low viscosity. Compound 36283 has one mismatch at nucleobase position 3 and one mismatch at nucleobase position 5 and was found to hâve a high viscosity.
To evaluate in vivo activity, each of the compounds was tested in the UUO model. Groups of animais were treated as follows: sham surgery (n=4), UUO with PBS (n=8), or UUO with anti-miR-21 compound (n=7 to 8). Relative to the day of the UUO procedure, PBS or anti-miR-21 compound was administered at days -3, -I, and +5. Anti-miR-21 compounds were administered at a dose of 20 mg/kg. As the anti-miR compounds were administered prior to the UUO procedure, this dosing regimen is considered a prophylactic treatment. At day 11, animais were sacrifîced and ladney was isolated for measurement of collagen expression. Collagen expression was measured by real-tîme PCR and normalized first to GAPDH and then to the sham control animais. Statistical significance was determined according to a 1-way ANOVA test. As shown in Figure 2, treatment with 36283 and 36284 reduced the expression of collagen I Al (Figure 2A) and collagen 3Al (Figure 2B) in a statistically signîficant manner, relative to sham-treated animais. The compounds 36282 and 36285 dîd not resuit in statistically signîficant réductions in collagen expression in vivo.
These results demonstrate that 36284 significantly reduced the expression of both Coll Al and Coll A3 and exhibited a low viscosity in solution.
Example 2: Metabolic stability of antl-mlR-21 compound
It has been found that certain anti-miR-21 compounds are particularly susceptible to metabolism by endonucléase and/or exonuclease activity. To faciîitate anti-miR distribution and prolong half-life, increased stability in the presence of nucleascs in vivo may be a désirable property of an anti-miR-21 compound and as such, compounds of varying structure were tested for metabolic stability. The compounds tested included 25923, which was found to be susceptible to nuclease activity, and structural variants 25220 and 25221. The structure of each compound is shown in Table F. Nucleoside modifications are indicated as follows: nucleosides not followed by a subscript indicate β-Ddeoxyribonucleosidcs; nucleosides followed by a subscript “E” indicate 2’-M0E nucleosides;
nucleosides followed by a subscript “S” indicate S<Et nucleosides. Each intemucleosïde linkage is a phosphorothioate intemucleosïde linkage.
Table F: Anti-miR-21 compounds
Compound # | Sequence and Chemistry (5’ to 3’) | SEQ ID NO | ||||||||||||||||||
25923 | Ae | Cs | A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | T | As | 3 |
25220 | Ae | Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Ae | 3 |
2522! | Ae | Cs | A | T | Cs | A | G | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
In an ex vivo assay, 5 μΜ of oligonucleotide was incubated in liver homogenatc (50 mg tissue per ml) for 24 hours at 37 ’C. Foliowing this incubation, oligonucleotide was extracted by Liquid-Liquid Extraction (LLE) followed by Solid-Phase Extraction (SPE). Oligonucleotide lengths and amounts were measure by high-performance liquid chromatography time-of-flight mass spectrometry (HPLC-TOF MS). Nuclease activity in the liver tissue homogenatc was confirmed by using reference oligonucleotides, which included a compound with known résistance to nuclease activity, a compound susceptible to 3*-exonuclease activity, and a compound susceptible to endonuclease activity. An internai standard compound was used to control for extraction efficiency. For testing of metabolic stability in vivo, compounds were administered to mice, kidney tissue was isolated, and the extraction and détection of compound was performed as for the ex vivo assay. Table G shows the structures for the compounds 25923,25220 and 25221, and the results of the stability measurements.
Table G: 25923,25220 and 25221 ex vivo and in vivo stability
Compound | SEQ ID NO | Structure | ex vivo (liver) | in vivo (kidney) | |||
—► s | S5 £ | % Endo | £ | N-l (%) | |||
25923 | 3 | AeCsATCsAGTCsTGAUsAAGCsTAs | 17 | 13 | 2-3 | 58±3 | 14±5 |
25220 | 3 | AeCsATCsAsGTCsUsGAUsAsAGCsUsAe | 3 | 0 | 3 | 67±I6 | 16±6 |
25221 | 3 | AeCsATCsAGTCsTGAUsAAGCsUsAs | 3 | 0 | 3 | 76±4 | 4±1 |
As shown in Table G, compounds 25220 and 25221 exhibited increased résistance to nuclease activity in both the ex vivo and in vivo assays.
To evaluate the effects of the compounds on fibrosis, compounds 25220 and 25221, as well as 25923, were tested in the UUO model. Groups of 8 animais each were treated as follows: sham surgery, UUO with PBS, UUO with 25220, UUO with 25221, or UUO with 25923. Relative to the day of the UUO procedure, PBS or anti-miR-21 compound was administered at days -5, -3, and +3. Anti-miR-21 compounds were administered at a dose of 20 mg/kg. As the anti-miR compounds were administered prior to the UUO procedure, this dosing regimen is considered a prophylactic treatment. At day 10, animais were sacrificed and kidney was isolated for measurement of collagen expression. Collagen expression was measured by rcal-time PCR and normalized to GAPDH.
The results of that experiment are shown in Figure 3. Collagen 1 Al and collagen 3 Al expression are shown in Figure 3A and 3B, respectively. Administration of compound 25220 or 25221 reduced collagen 1 Al and collagen 3A1 expression by a stastically significant amount (* = p < 0.05; ** = P < 0.01; *** = p < 0.001), as did administration of compound 25923.
These results demonstratc that 25220 and 25221 significantly reduce both Coll Al and Col3Al expression and exhibit résistance to metabolism by nuclcases.
The metabolic stability of 25284 was also tested. In an ex vivo assay, only full-length compound was detected. In vivo, 96% of the compound detected was full-length compound. These results dcmonstrate that 25284 is highly résistant to nuclease activity.
Example 3: Inhibition of miR-21 ln model of Ischemia/reperfusion injury
The unilatéral ischemia reperfusion injury (IRI) model is a well-characterized model of kidney injury that results in progressive interstitial fibrosis. The injury is created in the mouse through the clamping of a rénal artery for a short period of time, followed by restoration of blood flow. The reperfusion results in severe injury to the kidney, which is followed by chronic injury with fibrosis. IRI leading to chronic injury is often observed in humans, thus the mouse IRI model may be used to test candidate agents for the treatment and/or prévention of fibrosis in the context of kidney injury.
Anti-miR-21 compounds were tested in the unilatéral IRI model. Unilatéral IRI was indueed for a period of 30 minutes (Day 0). Treatment groups were as follows: sham IRI procedure; IRI with PBS administered subcutaneously; IRI with anti-miR-21 compound administered intraperitoneally at a dose of 20 mg/kg. PBS or anti-miR compound was administered on days 5, 6, and 7 following IRI, and animais were sacrificed on Day 13. As anti-miR compound is administered 5 days following the injury to the kidney, or later, when fibrosis has already occurred to some extent, this treatment regimen is considered a therapeutic regimen, rather than a prophylactic regimen.
Kidney tissue was coliected for analysis of collagen 1 AI and collagen 3A1 expression, and collagen area fraction (as described in the previous example). Statistical signtficance was determined by a 1 -way ANOVA test. The results are shown in Figure 4. In this study, anti-miR-21 treatment with 36328 or 36232 produced a statistically significant réduction in Collai expression (Figure 4A; * = p < 0.05) and in collagen area fraction (Figure 4C; *** = p < 0.0001). Compound 36232 reduced Col3al expression in a statistically significant manner (Figure 4B). Compound 36328 reduced Col3al expression, however the réduction was not statistically significant (Figure 4B).
These studies demonstrate a réduction in collagen content following inhibition of miR-21 in a model of acute kidney injury. Thus, the anti-miR-21 compounds 36232 and 36328 are therapeutic agents for the treatment of fibrosis in the context of acute kidney injury. For example, preventing or delaying the onset of fibrosis following acute kidney injury may prevent or delay the onset of fibrosis and chronic kidney disease.
Example 4: Inhibition of mlR-21 in an ischemia reperfusion injury / nephrectomy model
An ischemia reperfusion injury/nephrectomy (IR/Nx) model is created in the mouse through temporary unilatéral clamping of an artery in one kidney, which leads to tubule damage, inflammation, and fibrosis, followed by removal of the second kidney at a later timepoint. In this model, the acute kidney dysfunctîon phase is useful to test candidate agents for the treatment of acute kidney injury (i.e. up to about the first 5 days), and the later phases of kidney dysfunctîon are useful to model chronic fibrosis (i.e. after about the first 5 days).
Anti-miR-21 compounds were tested in the IR/Nx model. 25109, a 6-base mismatch to miR-21, was used as a control compound (AeAsATCsTGTCsTCAUsAATAsAAe; SEQ ID NO: 14; where nucleosides not followed by a subscript indicate β-deoxynucleosides; nucleosides followed by a subscript “E” indicate 2’-MOE nucleosides; nucleosides followed by a subscript “S” indicate S-cEt nucleosides; and ail întemucleoside linkages are phosphorothioate intemucleoside linkages).
Unilatéral IR was induced for a period of 30 minutes. Treatment groups were as follows: sham IR procedure (n=8); IR with PBS administered subcutaneously (n=16); IR with mismatched control 25109 administered subcutaneously at a dose of 20 mg/kg (n=l 6); and IR with anti-miR-21 compound 36328 administered subcutaneously at a dose of 20 mg/kg (n=l 6). PBS or anti-miR was administered on days 2,3,4, and 8 following IR. On day 8, the healthy kidney was removed by nephrectomy from each animal, and animais were sacrifîced on day 9. Just prior to sacrifice, urine was collect cd by direct bladder puncture.
To assess albuminuria, urinary aibumin to créatinine ratio was measured in the urine from each mouse. The results of that experiment are shown in Figure 5A. In this study, 36328 produced a statistically significant réduction in urinary aibumin to créatinine ratio (Figure 5A). The géométrie mean of the aibumin to créatinine ratio in each group of mice was 16 pgAlb/mgCr (nephrectomy-only control), 127 pgAlb/mgCr (IR/Nx, PBS control), 140 pgAlb/mgCr (IR/Nx, 25109 control), and 30 pgAlb/mgCr (IR/Nx, 36328). Blood urea nitrogen and sérum créatinine levels were similar across ail IR/Nx mice, and were elevated relative to nephrectomy-only control mice (data not shown).
In a similarly designed experiment, the compound 36284 was also tested in the IR/Nx mode!. Unilatéral IR was induced for a period of 30 minutes. Treatment groups were as foliows: sham IR procedure (n=7) ; IR with PBS administered subcutaneously (n=l 3); and IR with anti-miR-21 compound 36284 administered subcutaneously at a dose of 20 mg/kg (n=l9). PBS or anti-miR was administered on days 2, 3,4, and 8 following IR. On day 8, the healthy kidney was removed by nephrcctomy from each animal, and animais were sacrificed on day 9. Just prior to sacrifice, urine was collected by direct bladder puncture. To assess albuminuria, urinary albumin to créatinine ratio was measured in the urine from each mouse. The results of that experiment are shown in Figure 5B. In this study, 36284 produced a statistîcally sïgnificant réduction in urinary albumin to créatinine ratio.
Compound 25220 was also tested in the IR/Nx model. Unilatéral IR was induced for a period of 30 minutes. Treatment groups were as foliows: sham IR procedure (n=7) ; IR with PBS administered subcutaneously (n=l 3); and IR with anti-miR-21 compound 25220 administered subcutaneously at a dose of 20 mg/kg (n= 19). PBS or anti-miR was administered on days 2, 3,4, and 8 following IR. On day 8, the healthy kidney was removed by ncphrectomy from each animal, and animais were sacrificed on day
9. Just prior to sacrifice, urine was collected by direct bladder puncture. To assess albuminuria, urinary albumin to créatinine ratio was measured in the urine from each mouse. The results of that experiment are shown in Figure 5C. In this study, 25220 produced a statistîcally sïgnificant réduction in urinary albumin to créatinine ratio.
Example 5: Survival of IR/Nx model mice following administration of anti-miR-21 compounds
The survival rate of IR/Nx model mice two days after ncphrectomy was determined across six different experiments to détermine if administration of anti-miR-21 compounds increases survival. In the first three experiments, anti-miR-21 compound was administered on days 5,6, and 7 after ischemia reperfusion injury, and ncphrectomy occurrcd on day 10 or day 11. In the second three experiments, anti-miR-21 compound was administered on days 2, 3, and 4, and ncphrccromy occurrcd on day 7. The rates of survival of the IR/Nx mice in each experiment are shown in Table H.
Table II: 36328 Increases survival rate of IR/Nx mice two days after nephrectomy.
DayofNx | Survival rate 2 days after Nx | Anti-miR-21 dose | |
PBS | 36328 | ||
Day 10 | 50% | 75% | 20 mg/kg |
Day 7 | 66.7% | 91.7% | 20 mg/kg |
In the first experiment, in which nephrectomy occurrcd on day 10, the survival rate of PBStreated mice was 55%, while the survival rate of 36328-treatcd mice was 75% (P=0.02 using a 1-sided Fisher’s Exact Test). In the second experiment, in which ncphrectomy occurrcd on day 7, the survival rateof PBS-treated mice was 52%, while the survival rateof 36328-treated mice was 69% (P=0.11 using a l-sîded Fisher’s Exact Test).
Exampie 6: Antl-miR-21 compounds
Additional anti-miRs targeted to miR-21 and comprising S-cEt nucleosides were designed with variations in length, as well as in the number, type and placement of modified sugar moieties. These anti5 miRs are shown in Table I. Nucleoside patterns ΠΙ, IV, V and VII are shown in the first three rows of Table I. Nucleoside modifications are indicated as follows: nucleosides not followed by a subscript indicate β-D-deoxyribonuclcosides; nucleosides followed by a subscript “E” indicate 2’-M0E nucleosides; nucleosides followed by a subscript “M” indicate 2’-O-methyl nucleosides; nucleosides followed by a subscript “S” indicate S*cEt nucleosides. Each intemucleoside linkage is a phosphorothioate intemucleoside linkage.
Table I: Anti-miR-21 compounds
Compound # | Nucleoside Pattern | Sequence and chemistry (shadtng indicates bicyclic nucleoside, such as S-cEt nucleoside) | SEQ ID NO | ||||||||||||||||||
III | R | NU | îx | Nu | br | br | br | Nu | br | br | br | Nb | br | br | br | Nb | NY | Nz | |||
IV | Nm | Nu | Nb | Nu | NU | Nu | Nv | N2 | |||||||||||||
V | Nm | Nu | Nu | Nu | Nü | NU | nb | Nu | Nu | Nb | N2 | ||||||||||
vn | nm | NU | “n”- | Nm | NB | “FF | IF | ÏF | Nu | N0 | nb | N^ | NU | Nb | N2 | ||||||
36039 | III, IV | Ae | Cs | Ae | Te | Cs | Ae | Ce | Te | Cs | T | G | A | Us | A | A | G | Cs | T | As | 3 |
36731 | III, IV, VII | ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
36843 | ιπ,ιν,νπ | Ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | Gm | A | Us | A | Gm | G | Cs | Us | As | 3 |
36844 | III, IV, VII | Ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | Gm | A | Us | A | Am | G | Cs | Us | Te | 8 |
36845 | III, IV, VII | Ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | Am | Us | Am | A | G | Cs | Uj | As | 3 |
36846 | ΙΠ, IV, vn | Ae | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | Am | Us | Am | A | G | Cs | Us | Te | 8 |
36847 | V | Ae | Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | Te | 8 |
36842 | Ae | Cs | Ae | TE | Cs | Ae | Ge | Te | Cs | T | Gs | A | Us | A | As | G | Cs | Us | As | 3 | |
36000 | III, IV | Ae | Cs | A | T | Cs | Ae | Ge | Te | Cs | T | G | Ae | Us | Ae | A | G | Cs | Us | As | 3 |
36001 | III, IV | Ae | Cs | A | T | Cs | A | Ge | Te | Cs | T | G | Ae | Us | Ae | A | G | Cs | Us | As | 3 |
36002 | III, IV | Ae | Cs | A | T | Cs | A | G | Te | Cs | T | G | Ae | Us | Ae | A | G | Cs | Us | As | 3 |
36003 | III, IV | Ae | Cs | A | T | Cs | A | G | T | Cs | T | G | Ae | Us | Ae | A | G | Cs | Us | As | 3 |
36004 | III, IV | Ae | Cs | A | TE | Cs | Ae | Ge | TE | Cs | T | G | Ae | Us | Ae | A | G | Cs | Us | Te | 8 |
36005 | III, IV | Ae | Cs | A | T | Cs | Ae | Ge | Te | Cs | T | G | Ae | Us | Ae | A | G | Cs | Us | Te | 8 |
36006 | III, IV | Ae | Cs | A | T | Cs | A | Ge | Te | Cs | T | G | Ae | Us | Ae | A | G | Cs | Us | Te | 8 |
36007 | III, IV | Αε | Cs | A | T | Cs | A | G | Te | Cs | T | G | Ae | Us | Ae | A | G | Cs | Us | Te | 8 |
36008 | III, IV | Αε | Cs | A | T | Cs | A | G | T | Cs | T | G | Ae | Us | Ae | A | G | Cs | Us | Te | 8 |
36009 | III, IV, νπ | Αε | Cs | Ae | TE | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | 10 | |
36010 | Ιΐϊ,ΐν,νπ | Αε | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | Am | A | G | Cs | Us | 10 | |
36011 | III, IV, νπ | Αε | cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | Am | Us | A | A | G | Cs | Us | 10 | |
36012 | III, IV, VII | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 9 | |
36016 | III, IV | Αε | Cs | Ae | Te | Cs | Ae | Ge | T | Cs | T | G | Am | Us | A | A | G | Cs | Us | As | 3 |
36017 | III, IV | Αε | Cs | Ae | T | Cs | Ae | Ge | T | Cs | T | G | Am | Us | A | A | G | Cs | Us | As | 3 |
36018 | III, IV | Αε | Cs | Ae | TE | Cs | Ae | Ge | T | Cs | T | G | A | Us | Am | A | G | Cs | Us | As | 3 |
36019 | ιπ,ιν | Αε | Cs | Ae | T | Cs | Ae | Ge | T | Cs | T | G | A | Us | Am | A | G | Cs | Us | As | 3 |
36020 | III, IV | Αε | Cs | Ae | Te | Cs | Ae | Ge | TE | Cs | T | G | Am | Us | Am | A | G | Cs | UM | As | 3 |
36021 | III, IV | Αε | Cs | Ae | Te | Cs | Ae | Ge | Te | Cs | T | G | Am | Us | A | A | G | Cs | Um | As | 3 |
36022 | III, IV | Αε | Cs | Aï | Te | Cs | Ae | Ge | T | Cs | T | G | Am | Us | A | A | G | Cs | Um | As | 3 |
36023 | III, IV | Αϊ | Cs | Ae | T | Cs | Ae | Ge | T | Cs | T | G | Am | Us | A | A | G | Cs | Um | As | 3 |
36024 | ιπ,ιν | Αε | Cs | Ae | TE | Cs | Ae | Ge | Te | Cs | T | G | A | Us | Am | A | G | Cs | Um | As | 3 |
36025 | III, IV | Αε | Cs | Ae | Te | Cs | Ae | Ge | T | Cs | T | G | A | Us | Am | A | G | Cs | Um | As | 3 |
36026 | ΙΠ, IV | Αε | Cs | Ae | T | Cs | Ae | Ge | T | Cs | T | G | A | Us | Am | A | G | Cs | Um | As | 3 |
36027 | III, IV | Αε | Cs | Ae | TE | Cs | Ae | Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | Um | As | 3 |
36028 | ΙΙΙ,ΐν | Αε | Cs | Ae | Te | Cs | Ae | Ge | T | Cs | T | G | A | Us | A | A | G | Cs | Um | As | 3 |
36029 | ιπ,ιν | Αε | Cs | Ae | T | Cs | Ae | Ge | T | Cs | T | G | A | Us | A | A | G | Cs | Um | As | 3 |
36030 | III, IV | Αε | Cs | Ae | TE | Cs | Ae | Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | Um | TE | 8 |
36031 | III, IV | Αε | Cs | Ae | Te | Cs | Ae | Ge | T | Cs | T | G | A | Us | A | A | G | Cs | Um | Te | 8 |
36032 | ΙΙΙ,ΐν | Αε | Cs | Ae | T | Cs | Ae | Ge | T | Cs | T | G | A | us | A | A | G | Cs | Um | Te | 8 |
36033 | Αε | Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | Am | A | G | Cs | Us | As | 3 | |
36034 | Αε | Cs | A | T | Cs | As | G | T | Cs | UM | G | A | Us | Am | A | G | Cs | Us | As | 3 | |
36035 | III, IV | Αε | Cs | A | T | Cs | A« | G | T | Cs | Um | G | A | Us | Am | A | G | Cs | Us | As | 3 |
36040 | Αε | Cs | A | T | Cs | As | G | T | Cs | Te | G | A | Us | Ae | A | G | Cs | Us | As | 3 | |
36041 | III, IV | Αε | Cs | A | T | Cs | Ae | G | T | Cs | Te | G | A | Us | Ae | A | G | Cs | Us | As | 3 |
36045 | III, IV | Αε | Cs | A | Te | Cs | Ae | Ge | TE | Cs | T | G | Am | Us | Am | A | G | Cs | Us | Te | 8 |
36046 | III, IV | Αε | Cs | A | T | Cs | Ae | Ge | Te | Cs | T | G | Am | Us | Am | A | G | Cs | Us | Te | 8 |
36047 | III, IV | Αε | Cs | A | T | Cs | A | Ge | Te | Cs | T | G | Am | Us | Am | A | G | Cs | Us | Te | 8 |
36048 | III, IV | Αε | Cs | A | T | Cs | A | G | Te | Cs | T | G | Am | Us | Am | A | G | Cs | Us | Te | 8 |
36049 | Αε | Cs | A | T | Cs | As | G | T | Cs | US | G | A | Us | Am | A | G | Cs | Us | Te | 8 | |
36050 | Αε | Cs | A | T | Cs | As | G | T | Cs | UM | G | A | Us | Am | A | G | Cs | Us | Te | 8 | |
36051 | ιπ,ιν | Αε | Cs | A | T | Cs | Am | G | T | Cs | UM | G | A | Us | Am | A | G | Cs | Us | Te | 8 |
36055 | V | Αε | Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | As | A | G | Cs | Us | 11 | |
36239 | Αε | Cs | A | T | Cs | As | G | T | Cs | Us | G | A | Us | Ae | A | G | Cs | Us | As | 3 | |
36968 | III, IV | Αε | Cs | Ae | Te | Cs | Ae | Ge | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
36969 | III, IV | Αε | Cs | Ae | T | Cs | Ae | Ge | T | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
36970 | III, IV, VII | Αε | Cs | Ae | Te | Cs | Ae | Ge | TE | Cs | T | G | A | Us | A | A | G | Cs | US | Te | 8 |
36971 | III, IV | Αε | Cs | Ae | Te | Cs | Ae | Ge | T | Cs | T | G | A | Us | A | A | G | Cs | Us | Te | 8 |
36972 | III, IV | Αε | Cs | Ae | T | Cs | Ae | Ge | T | Cs | T | G | A | Us | A | A | G | Cs | Us | Te | 8 |
36973 | III, IV | Αε | Cs | A | TE | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
36974 | III, IV | Αε | Cs | Ae | T | Cs | Ae | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
36975 | III, IV | Αε | Cs | Ae | TE | Cs | A | Ge | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
36976 | 111,1V | Αε | Cs | Ae | Te | Cs | Ae | G | Te | Cs | T | G | A | Us | A | A | G | Cs | Us | As | 3 |
m | m | m | m | m | m | m | m | m | m | m | m | m | m | m | m | m | m | m | m |
< | <Λ < | <Λ < | Ut < | <Λ < | <Λ < | <Λ < | ΙΛ < | (Λ < | <Λ < | <Λ < | <Λ < | ΙΛ < | ΙΛ < | <Λ < | ΙΛ < | «Λ < | «Λ < | <Λ < | <Λ < |
$ | £ | •3 | dS | rf | H | <Λ □ | rf | rf | rf | <Λ Ο | rf | <Λ O | rf | rf | rf | M O | rf | rf | rf |
$ | U | rf | rf | rf | v> Q | Μ U | Μ υ | (Λ υ | Q | rf | V) Q | V» Q | <4 Q | rf | rf | rf | rf | rf | rf |
o | o | o | o | o | o | ω Ο | ο | ο | ο | ο | ο | o | o | o | o | o | o | o | o |
< | < | < | < | < | < | < | U < | < | < | < | < | < | < | < | < | < | < | < | < |
< | < | « | « | < | < | < | tu < | < | < | < | X < | « | X < | -? | |||||
dS | •zS | zS | rf | rf | M □ | <Λ □ | rf | rf | rf | rf | rf | rf | rf | rf | rf | rf | rf | rf | rf |
< | < | < | < | < | « | < | « | « | tU < | « | < | < | 4 | I < | $ | $ | x < | ||
a | o | o | o | o | o | ο | ο | ο | ο | eu ο | ο | O | o | o | o | o | O | o | o |
H | H | H | H | H | H | Η | Η | Η | Η | Η | H | H | H | H | H | H | H | H | |
rf | rf | <Λ U | rf | ΙΛ U | U | <Λ Q | rf | rf | rf | rf | tft U | rf | rf | rf | «rt U | trt U | v> U | M Q | «0 U |
H | H | H | Η | £ | £ | IU H | «al H | H | H | H | H | H | |||||||
tu o | O | O | ttl D | □ | U o | IU Ο | tU Ο | IU Ο | ttl ο | tu ο | ω O | tu O | tu o | U) o | tu o | tu □ | o | o | la) O |
« | tu < | « | « | <? | 4? | «? | -? | <? | 4? | 4? | 4? | 4? | «? | U < | < | < | « | <“ | |
«A U | M Q | v> U | rf | M Q | (Λ U | <Λ υ | (Λ υ | rf | (Λ υ | rf | V) U | </} Q | rf | rf | rf | rf | Vt U | g | rf |
H | H | H | H | H | μ? | Η | tai Η | Η | £ | H | H | H | H | H | |||||
< | lU < | lU < | « | < | tu < | 4? | 4? | 4? | 4? | 4? | «? | U < | tu < | < | < | « | « | < | < |
rf | M Q | rf | rf | t/i Q | U | rf | <Λ Q | Vt υ | V) Q | ΙΛ υ | M U | v> U | rf | V3 U | «rt Q | «rt Q | t/i Q | M Q | rf |
«? | 4? | «? | ttl < | <“ | -? | 4? | IU < | IU < | 4? | 4? | tu < | tu < | w < | 4? | tu < | tu < | U < | «al < | 4? |
III, IV | III, IV | ιπ,ιν | £: -j M | AI *111 | III, IV, vn | III, IV, VII | £ U* Μ | III, IV, VII | III, IV, VII | III, IV, VII | III, IV, VII | III, IV, VII | III, IV, VII | III, IV | III, IV | AlTll | III, IV | > M » M M | £: -j M |
36977 | 36978 | Os r* ©s «© d | e oo ©s so n | M w O-. so n | M w ©s ό en | 36984 | Ι/Ί οο Os Ό Π | « οο Os sO ί*1 | 36988 | es « Os *Ο | 36990 | 36992 | 36993 | 36994 | S669C | 36996 | 36997 | «e e* Os SO r» | i |
Γ*
Compounds selected from Table I were evaluated for their inhibitory effects on miR-21 activity in an in vitro luciferase assay. The assay was performed as described herein, and the results are shown in
Table J and Figure 6A.
Table J: Anti-miR-21 compound luciferase data
Anti-miR concentration nM | 36731 | 36842 | 36843 | 36844 | 36845 | 36846 | 36847 | 36039 |
300 | 7.63 | 5.34 | 6.43 | 26.07 | 21.90 | 13.64 | 8.08 | 28.53 |
100 | 9.72 | 10.87 | 5.71 | 19.33 | 13.36 | 26.13 | 39.10 | 28.85 |
3333 | 10.76 | 4.50 | 6.52 | 22.11 | 16.35 | 20.54 | 19.46 | 23.44 |
11.11 | 9.38 | 5.06 | 5.21 | 25.46 | 25.83 | 21.08 | 27.84 | 28.51 |
3.7 | 8.53 | 2.45 | 5.62 | 18.61 | 27.05 | 29.88 | 18.21 | 15.93 |
1.23 | 4.49 | 1.20 | 2.84 | 9.28 | 20.86 | 17.41 | 22.11 | 16.05 |
0.41 | 3.51 | 0.75 | 1.41 | 5.04 | 9.64 | 12.64 | 3.44 | 15.12 |
0.14 | 2.60 | 0.65 | 6.50 | 3.24 | 6.89 | 5.69 | 3.71 | 7.46 |
0.05 | 1.52 | 0.67 | 0.90 | 2.66 | 7.18 | 5.33 | 1.74 | 4.66 |
0 | 0.33 | 0.36 | 4.34 | 1.21 | 1.07 | 1.19 | 0.85 | 0.90 |
Based on the data in Table J and data from repeat expérimente, it was observed that compounds 36731, 36039,36846 and 36847 consistcntly inhîbited miR-21 in the luciferase assay.
Certain anti-miR-21 compounds were additionally tested for their effects on cell prolifération in an in vitro assay. Two mismatch control anti-miRs were used (36965 GeGsAeAeUs^ÇiTeTeAsACTAsGACUsAsCs,SEQ ID NO: 15; 36967 GeAsAeTeAsAeTeAeUsAACCsCCTGsGsUs, SEQ ID NO: 16). The human adenocarcinoma cell line SKHepl was used in this experiment. SK-Hcpl were plated onto collagcn-coated 96 well plates at a density of 500 cells per well. The following day, cells were treated with anti-miR at a concentration ranging from 50 nM to 20 uM (n = 6 wells for each treatment). No transfection reagent was used. Cell viabilîty was measured using the CellTiter-Glo® Luminescent Cell Viabîlity Assay. Results were calculated as percent of viable cells relative to untreated control. As shown in Table K and Figure 6B, compounds 36731, 36846, 36847 and 25220 reduced cell viabîlity in a conccntration-depcndcnt manner.
Table K: Anti-proliferative effects of antl-mlR-21 compounds
Anti-miR Concentration | |||||||||
Compound # | 50nM | lOOnM | 250nM | 500nM | luM | 2uM | 5uM | lOuM | 20uM |
36965 | 103.87 | 97.48 | 97.64 | 81.87 | 38.01 | 0 | 0 | 0 | 0 |
36967 | 98.50 | 97.10 | 95.93 | 94.11 | 84.90 | 47.72 | 0 | 0 | 0 |
36731 | 96.92 | 95.53 | 51.74 | 0 | 0 | 0 | 0 | 0 | 0 |
36846 | 96.95 | 90.07 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
25220 | 95.54 | 91.35 | 21.37 | 0 | 0 | 0 | 0 | 0 | 0 |
36847 | 93.61 | 93.98 | 4.41 | 0 | 0 | 0 | 0 | 0 | 0 |
Compounds that reduce cell viability are candidate therapeutic agents for the treatment of cancer. To evaluate in vivo activity in a fibrosis model, certain compounds was tested in the UUO model. Groups of animais were treated as follows: sham surgery (n=4), UUO with PBS (n=8), or UUO with antimiR-21 compound (n=8). Relative to the day of the UUO procedure, PBS or anti-miR-21 compound was administered at days -5, -3, and +3. Anti-miR-21 compounds were administered at a dose of 20 mg/kg. As the anti-miR compounds were administered prior to the UUO procedure, this dosing regimen is considered a prophylactic treatment. At day 10 following the UUO procedure, animais were sacrifîced and kidney was isolated for measurement of collagen expression. Collagen expression was measured by rcal-time PCR and normalized first to GAPDH and then to the sham control animais. Statistical signifîcance was determined according to a 1 -way ANOVA test. As shown in Figure 7, treatment with 36731 and 36055 reduced the expression of collagen 1 Al (Figure 7Α) and collagen 3 Al (Figure 7B) in a statistically significant manner, relative to sham-treated animais (* = p < 0.05; ♦♦ p < 0.01). Compounds 36847 reduced collagen 1 Al and collagen 3Α1 expression, although not in a statistically significant manner in this study.
Viscosity of certain compounds was also determined. Compounds were dissolved in water. Using routing methods, oligonucleotide concentration was calculated gravimetrically (mg/g) and viscosity (cP) was measured using a viscometer. Results are shown in Table L.
Table L: An tl-miR-21 compound viscosity
Compound | Viscosity | Concentration |
# | cP | mg/g |
36731 | 81 | 153 |
36847 | 128 | 130 |
36846 | 66 | 150 |
Compounds 36731 and 36846 exhibited relatively low viscosity, compared to 36847 and other compounds described herein.
The metabolic stability of certain compounds was determined. In an ex vivo assay, performed as described above, approximately 89% of full-lcngth 36731 compound was detected at the end of the assay. Thus, 36731 is a highly stable compound in the presence of nucleases.
Example 7: Xenograft models
Human xenograft models are often used to measure the ïn vivo efficacy of potential cancer thérapies.
Cell-line based xenograft models arc prepared by injecting human cancer cells into immunodeficient mice. The injected cells form tumors, and the effects of potential anti-cancer agents can be evaluated for effects on parameters including tumor size, tumor number, tumor architecture and metastatic potential. Cells arc grown in culture, and then harvested for injection into a mouse. The cells are from a cancer cell line (e.g. SK-Hepl, Huh7, HeLa293, Hcp3B, SNU). To initiate tumor growth, approximately 5 x 106 cells are injected subcutaneously into the flank of an immunodeficient mouse (e.g. a SCID mouse or an athymie nude mouse). The cells are allowed to form tumors of an average volume of up to 75 mm1.
Patient-derived tumor tissue xenograft models (patient-derived xenograft or PDX models) are established by transplanting an expiant of a human tumor into an immunodeficient mouse. To preserve as many of the original tumor characteristics as possible, the expiant may be propagated from one mouse to another, but is generally not propagated in cell culture.
Anti-miR-21 compounds are tested for their anti-cancer effects in a human xenograft model. When tumors arc of the appropriate size, mice arc treated as follows: PB S (n=5 to 10); anti-miR-21 (n=5 to 10); or anti-miR-21 mismatch (optional; n=5to 10). Treatments arc administered subcutaneously, up to 3 times per week for up to 12 weeks.
Tumor size is measured one to two times per week, using calipers, for example. Body weight is measured two to three times per week. Blood is collected weekly and at the end of the study. Tumor and other tissues are collected at the end of the study.
A réduction in tumor size in tumor size is observed in anti-miR-21 -treated mice, relative to PBStreated mice, suggestîng that anti-miR-21 is a therapeutic agent that can be used for the treatment of cancer.
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference (including, but not limited to, journal articles, U.S. and non-U.S. patents, patent application publications, international patent application publications, GENBANK® accession numbers, and the like) cited in the présent application is specifically incorporated herein by reference in its entîrety.
Claims (15)
1. A compound comprising a modified oligonucleotide complementary to miR-21 (SEQ ID NO: 1) and wherein the modified oligonucleotide:
a. consists of 8 to 19 linked nucleosides, and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattern VII in the 5’ to 3’ orientation:
Nu-(Ne-NM-NM)rNM-(NB-NQ-NQ-NQ)rNB-Ne-Nz wherein each NM is a modified nucleoside that is not a bicyclic nucleoside;
each N9 is a bicyclic nucleoside;
each N° Is a non-bicyciic nucleoside; and Nz is a modified nucleoside; or
b. consists of 8 to 22 iinked nucleosides, and wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the foilowing nucleoside pattern
III ln the 5’ to 3’ orientation:
(Rïx-N^hP-N^N^^-N^N^^Jj-N^N2 wherein each R is a non-blcyclic nucleoside; X is from 1 to 4;
each N9 is a bicyclic nucleoside;
each N° Is a non-bicyclic nucleoside;
NY is a bicyclic nucleoside; and each N2 is a modified nucleoside; or
c. consists of 8 to 19 linked nucleosides, wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattern
IV in the 5' to 3’ orientation:
NU-N9-NQ-NQ-NB-(NQ-NQ-NQ-N9)3-NY-NZ wherein NM is a modified nucleoside that is not a bicyclic nucleoside; each NB is a bicyclic nucleoside;
each N° Is a non-bicyclic nucleoside;
NY is a bicyclic nucleoside; and
Nz is a modified nucleoside; or
d. consists of 8 to 19 linked nucleosides, wherein the modified oligonucleotide comprises atleast 8 contiguous nucleosides ofthe following nucleoside pattern
V in the 5' to 3’ orientation:
Nm-Nb-(Nq-Nq-Nb-Nb)4-Nz wherein NM ls a modified nucleoside that is not a bicyclic nucleoside;
each Nb is a bicyclic nucleoside;
each N° is a non-bicyciic nucleoside; and
Nz is a modified nucleoside; or
e. consiste of 8 to 15 linked nucleosides, wherein the modified oligonucleotide comprises at least 8 contiguous nucleosides of the following nucleoside pattern VI in the 5' to 3’ orientation:
NQ-NB-NB-NQ-(NB-NB-NQ-NQ)2-NB-NQ-NB wherein each N° is a non-bicyciic nucleoside; and each Nb is a bicyclic nucleoside.
2. The compound of any one of the preceding claims, wherein each bicyclic nucleoside is independently selected from an LNA nucleoside, a cEt nucleoside, and an ENA nucleoside.
3. The compound of any one of the preceding claims, wherein each non-bicyciic nucleoside is independently selected from a β-D-deoxyribonucleoside, a 2’-O-methyl, and a 2'-0-methoxyethyl nucleoside.
4. The compound of claim 1 wherein:
a. the modified oligonucleotide is a modified oligonucleotide of claim 1 (a), wherein: i. each NMisa 2-0-methoxyethyl nucleoside;
each Nb is an S-cEt nucleoside;
each NQ is independently selected from a 2’-O-methyl nucleoside and a p-Ddeoxyribonucleoslde; and
Nz ls selected from an S-cEt nucleoside and a 2’-0-methoxyethyl nucleoside; or
II. each NMls a 2-0-methoxyethyl nucleoside;
each Nb Is an S-cEt nucleoside;
each N° is a β-D-deoxyribonucleoside; and
Nz is an S-cEt nucleoside; or iii. each NM is a 2-0-methoxyethyl nucleoside;
each Nb ls an S-cEt nucleoside;
each N° ls independently selected from a 2*-O-methyl nucleoside and a β-Ddeoxyribonucleoside; and
Nz Is an S-cEt nucleoside; or iv. each NM Is a 2-O-methoxyethyl nucleoside;
each Nb Is an S-cEt nucleoside;
each N° is Independently selected from a 2’-O-methyl nucleoside and a β-Ddeoxyribonucleoside; and
N2 is a 2'-O-methoxyethyl nucleoside; or
b. the modified oligonucleotide Is a modified oligonucleotide of claim 1 (b), whereln:
i. each R is a 2’-0-methoxyethyl nucleoside; X Is 1 ;
each Nb is an S-cEt nucleoside;
each N° is a β-D-deoxyribonucieoside;
NY Is an S-cEt nucleoside; and
Nz Is an S-cEt nucleoside; or il. each R is a 2’-O-methoxyethyl nucleoside; X is 1 ;
each Nb Is an S-cEt nucleoside;
each Nq is independently selected from a β-D-deoxyribonucleoside and a 2'O-methoxyethyl nucleoside;
NY Is an S-cEt nucleoside; and
Nz is an S-cEt nucleoside; or
c. the modified oligonucleotide Is a modified oligonucleotide of claim 1 (c), wherein: I. Nm Is a 2'-O-methoxyethyl nucleoside;
each Nb Is an S-cEt nucleoside;
each Nq is a β-D-deoxyribonucleoside;
NY is an S-cEt nucleoside; and
N2 is an S-cEt nucleoside; or li. Nm Is a 2’-0-methoxyethyl nucleoside;
each Nb Is an S-cEt nucleoside;
each Nq Is Independently selected from a β-D-deoxyribonucleoside and a 2’O-methoxyethyl nucleoside;
NY is an S-cEt nucleoside; and
N2 Is an S-cEt nucleoside; or
d. the modified oligonucleotide is a modified oligonucleotide of claim 1(d), wherein:
Nm is a 2’-O-methoxyethyl nucleoside;
each NBls an S-cEt nucleoside;
each N° Is a β-D-deoxyribonucleoside; and
Nzls a 2’-O-methoxyethyl nucleoside; or
e. the modified oligonucleotide Is a modified oligonucleotide of claim 1(e), wherein:
5 I. each NB Is an S-cEt nucleoside; and each Nq Is a 2-O-methoxyethyl nucleoside; or li. each NB is an S-cEt nucleoside; and each Nq Is a β-D-deoxyribonucieoslde.
5. The compound of daims 1, having the structure:
10 AeCsAeTeCsAeGeTeCsTGAUsAAGCsUsAs (SEQ ID NO: 3);
AeCsAeTeCsAeGeTeCsTGAUsAAGCsTAs (SEQ ID NO: 3); AeCsATCsAsGTCsUsGAUsAsAGCsUsAe (SEQ ID NO: 8); ^CeAsAsTeCsUsAeAeUsAsAeGeCsTeAs (SEQ ID NO: 7);
wherein nucleosldes not followed by a subscript are β-D-deoxyribonucleosldes; nucleosldes IS followed by a subscript ’E’ are 2'-MOE nucleosldes; nucleosldes followed by a subscript “S are S-cEt nucleosldes; and “’C Is 5-methyl cytosine.
6. The compound of any one of the preceding daims, wherein the nucleobase sequence of the modified oligonucleotide Is at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at ieast 97%, at ieast 98%, at least 99%, or 100%
20 complementary to the nucleobase sequence of miR-21 (SEQ ID NO: 1 ).
7. The compound of any one of the preceding daims, wherein the modified oligonucleotide comprises or consists of 8, 9,10,11,12,13,14,15,16,17,18,19,20,21, or 22 linked nucleosldes of nucleoside pattern III, IV, V, VI, or VII.
8. The compound of any one of the preceding daims, wherein at least one Intemucleoside
25 linkage Is a modified intemucleoside linkage, or wherein each Intemucleoside linkage Is a modified Intemucleoside linkage, and wherein the modified intemucleoside linkage Is optionally a phosphorothioate Intemucleoside linkage.
9. The compound of any one of the preceding daims, wherein at least one cytosine Is a 5methyl cytosine, or wherein each cytosine Is a 5-methylcytosine.
30
10. The compound of any one of the preceding daims, wherein the nucleobase sequence of the modified oligonucleotide Is selected from SEQ ID NOs: 3 to 10, wherein each T is independently selected from T and U.
11. A compound comprising a modified oligonucleotide consisting of 8 to 22 linked nucleosides, wherein the modified oligonucleotide comprises at ieast 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least
17, at least 18, or at least 19 contiguous nucleosldes of a structure selected from the structures in Table 1.
12. A method of treating, preventing or delaying the onset of a disease associated with mlR21 comprising administering to a subject having a disease associated with miR-21 a compound of any of clalms 1 to 11, wherein the subject is preferably human.
13. The method of claim 12, wherein the disease is selected from kldney fibrosis, lung fibrosis, liver fibrosls, cardiac fibrosis, skin fibrosls, age-related fibrosis, spleen fibrosls, scleroderma, post-transplant fibrosis, and cancer.
14. The method of claim 13, wherein:
a. the kidney fibrosis is présent in a subject having a disease selected from glomeruloscierosis, tubulointerstitial fibrosis, IgA nephropathy, interstitial fibrosis/tubular atrophy; chronic kidney damage, glomerular disease, glomerulonephritis, Alport Syndrome, diabètes mellitus, idiopathy focal segmenta! glomeruloscierosis, membranous nephropathy, collapsing glomerulopathy, chronic récurrent kidney infection, and end stage rénal disease:
b. the kidney fibrosis results from acute or répétitive trauma to the kidney;
c. the liver fibrosis is présent in a subject having a disease selected from chronic liver injury, hepatitis infection, non-alcoholic steatohepatitis, and cirrhosis; the pulmonary fibrosis is Idiopathic pulmonary fibrosis;
d. the subject has chronic obstructive pulmonary disease; and/or
e. the cancer ls liver cancer, breast cancer, bladder cancer, prostate cancer, colon cancer, lung cancer, brain cancer, hematological cancer, pancreatic cancer, head and neck cancer, cancer of the longue, stomach cancer, skin cancer, or thyroid cancer.
15. The method of any one of clalms 12 to 14 comprising administering at least one therapeutic agent selected from an anti-inflammatory agent, an immunosuppressive agent, an anti-dlabetlc agent, digoxln, a vasodilator, an anglotensln II converting enzyme (ACE) Inhibitors, an anglotensln il receptor blockers (ARB), a calcium channel blocker, an isosorbide dinitrate, a hydralazine, a nitrate, a hydralazine, a beta-blocker, a natriuretic peptides, a heparinoid, a connective tissue growth factor inhibitor, and an anti-cancer therapy.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/741,783 | 2012-04-25 | ||
US61/717,927 | 2012-10-24 | ||
US61/779,913 | 2013-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17147A true OA17147A (en) | 2016-03-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9970009B2 (en) | MicroRNA compounds and methods for modulating miR-21 activity | |
US20220098583A1 (en) | MicroRNA Compounds and Methods for Modulating MIR-21 Activity | |
EP3060664A1 (en) | Microrna compounds and methods for modulating mir-21 activity | |
OA17147A (en) | Microrna compounds and methods for modulating MIR-21 activity | |
NZ616748B2 (en) | Microrna compounds and methods for modulating mir-21 activity |